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Abstract  
A commonly used approach for the improvement of dissolution and disintegration is to 
render a poorly soluble drug into its amorphous or disordered form. However, such 
amorphous materials are physically unstable and are difficult to formulate into oral 
dosage forms due to their sensitivity to the physical and thermal processes that are 
involved in production. The first aim of work presented here was to produce the 
amorphous form of a drug in-situ within a capsule. The second aim was to develop a 
predominantly amorphous freeze-dried buccal tablet for the rapid delivery of 
emergency medicine. Nifedipine and naloxone were used as the test compounds to 
achieve aims 1 and 2 respectively. 
Nifedipine and polyvinylpyrrolidone K10 (PVP) were dissolved in tert-butanol at 37 oC 
to provide a range of drug to polymer ratios. These solutions were dispensed into 
gelatin capsules, freeze-dried, sealed and packaged in amber vials under nitrogen. The 
nifedipine content was maintained at 10 mg per capsule, but the PVP concentration 
was increased from 0 to 90% w/w. Differential scanning calorimetry, infra-red 
spectroscopy, polarization light microscopy and USP in vitro dissolution were used to 
optimise and characterise drug-polymer interactions in the freeze-dried formulations. 
The optimised in-situ freeze-dried capsule formulation (10% w/w nifedipine in PVP) 
formed a predominantly amorphous and porous formulation, with 3 months shelf life 
at 40 oC, stabilised by drug-polymer hydrogen bond intermolecular interactions. Drug 
released in vitro dissolution by optimized formulation reached 80% in < 6 min, 
approximately half the time required by the marketed nifedipine formulation.  
Excipients and naloxone HCl were dissolved in aqueous solution and dispensed into 
aluminium blisters to be freeze-dried. The optimised tablet composition (mannitol 24% 
w/v, gelatin 65% w/v, sodium bicarbonate 11% w/v and naloxone 800 µg) formed 
stable predominantly amorphous tablets. Sodium bicarbonate was found to be 
essential in preventing mannitol from recrystallizing in freeze concentrates, while high 
gelatin to mannitol ratio ensured the stability of amorphous mannitol during and after 
freeze-drying. A novel disintegration assay was developed to represent conditions in 
the buccal cavity: i.e. temperature 33-37 oC, dissolution volumes (0.1-0.7mL), mucin 
containing disintegration medium. The amorphous tablet has shown to disintegrate in 
less than 10 s. The disintegration assay was discriminatory for quality control purposes 
and has potential for future development as an assay to predict in vivo performance.  
In conclusion, rapidly dissolving tablets have been developed which are suitable for 
proof-of-concept clinical trial in humans to determine the pharmacokinetics of 
naloxone delivered via the buccal route. 
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Chapter 1. General introduction 
The oral route, from the patient’s perspective, is the most familiar and convenient 
form of consuming medication, the assistance of trained medical staff in the 
administration process is not usually needed, and therefore a greater patient 
compliance is seen when administering oral formulations (Sugawara et al., 2005, Youn 
et al., 2006). Medications delivered through the oral route are most commonly 
presented as a solid dosage form, such as capsules and tablets, or as liquid dosage 
forms such as solutions and suspensions (Strickley et al., 2008). While liquid oral 
formulations are easier to swallow, the bitter taste of some active pharmaceutical 
ingredients (API) can sometimes be challenging to overcome with taste masking 
excipients, and may therefore reduce the compliance of patients (Jin et al., 2008, 
Venables et al., 2015). Solid dosage forms on the other hand overcomes the taste 
barrier by encapsulating the active pharmaceutical ingredient (API) or by coating it, 
thus preventing its direct contact with taste buds on the tongue (Jin et al., 2008). 
Moreover, solid dosage forms eliminate the patient’s responsibility to measure the 
appropriate volume of medication as generally observed with liquid oral formulations 
(Marwaha et al., 2010). Economically, the pharmaceutical industry is more attracted to 
formulating a drug into a solid dosage form due to its low cost in production and 
transportation (Marwaha et al., 2010). Solid dosage forms are also a safer investment 
for community pharmacies, as they tend to have a long shelf-life, 4 - 5 years (FDA, 
2008) in comparison to 1 - 2 years for liquid dosage forms. Moreover, solid dosage 
forms may be stored at 40 oC or below, which in some climates falls under room 
temperature (WHO, 2009, ICH, 2006).  
Solid oral formulations have a long history of development, and therefore a wide range 
of materials have been explored for their role as excipients, providing the formulator 
with a large library of generally regarded as safe (GRAS) excipients (Marwaha et al., 
2010). A good understanding of the underpinning science behind the design, 
manufacture and packaging of solid oral dosage forms has developed over time (Zhang 
et al., 2004), this has led to the development of accurate methods for measuring 
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quality in performance of solid oral dosage forms, e.g. British Pharmacopeia (MHRA, 
2014b). Organizations such as the medicine and health care regulatory agency (MHRA) 
have in place thorough guidelines and regulations to help develop new and safe solid 
oral dosage formulations (MHRA, 2014a).  
Due to these advantages, pharmaceutical companies strive to formulate new chemical 
entities (NCE) into solid dosage forms that provide desirable and reproducible drug 
plasma concentration (Ikegami et al., 2006). A problem that is frequently encountered, 
is that most NCEs have low water solubility, and despite the high permeability of some 
of them, their absorbance into the circulatory system and hence their bioavailability is 
dependent on their dissolution into the aqueous gastrointestinal fluid (Kaur et al., 
2012, Vasconcelos et al., 2007, Streubel et al., 2006, Gardner et al., 1997). Drug 
research teams were reported, by Thomas et al. (2006), to rottenly target a solubility 
of > 60 µg/mL for new developable drugs, as this solubility is believed to usually lead to 
a satisfactory absorption provided the drug has average permeability (Figure ‎1.1) 
However, it can be misleading to assume a single solubility limit for all drugs as 
potency and metabolism can vary considerably from one drug to another, and thus the 
amount of drug, or dose, that must dissolve to achieve a satisfactory effect is the 
dominant factor in evaluating drug solubility.    
Fick’s first law illustrates that drug absorption is a product of drug solubility and 
permeability (Flynn et al., 1974): 
 𝐽𝑤𝑎𝑙𝑙  =  𝐶𝑖𝑛𝑡  .  𝑃𝑤𝑎𝑙𝑙  Equation ‎1.1 
Where 𝐽𝑤𝑎𝑙𝑙  is the drug flux across a homogeneous intestinal membrane measured in 
mass unit often µg, for a specific cross sectional area and a period of time, such as 
µgcm-2h-1 (Brodin et al., 2010). 𝐶𝑖𝑛𝑡 is the drug concentration in the luminal fluid, often 
measured in µg/mL, and 𝑃𝑤𝑎𝑙𝑙  is the effective permeability measured in Darcy units 
(D), named after Henry Darcy (Simmons, 2008). The most promising NCEs are generally 
limited to absorption in the upper small intestine, which therefore narrows the 
window of absorption (Gardner et al., 1997, Streubel et al., 2006). This dilemma 
presents the pharmaceutical industry with one of its most challenging objectives; to 
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design formulations that would enable poorly water-soluble drugs (PWSD) to dissolve 
rapidly into the aqueous gastrointestinal fluid (Vippagunta et al., 2007, Tanaka et al., 
2006, Ohara et al., 2005). If this objective was successfully fulfilled, such formulation 
design would be expected to have improved dissolution rate for the PWSD, and thus  
enhanced bioavailability and minimised gastrointestinal side effects for the active 
pharmaceutical ingredient (API) (Streubel et al., 2006, Tanaka et al., 2006, Leuner and 
Dressman, 2000, Majerik et al., 2007, Prabhu et al., 2005).  
The biopharmaceutical classification system (BCS) helps classify drugs in accordance to 
their solubility and permeability (Leucuta, 2014), which are the dominating factors in 
influencing oral bioavailability of drugs (Flynn et al., 1974, Pouton, 2006).  
 
Figure ‎1.1 The biopharmaceutical classification system (Pouton, 2006), with indications of how the 
solubility and permeability of drugs in Class II-IV may be enhanced to match drugs in class I.  
Class I of the BCS classification system includes drug molecules with high solubility 
(Thomas et al., 2006) and permeability. Class II, most common in currently used active 
pharmaceutical ingredients (Patil et al., 2015), include drugs with high permeability but 
low solubility, caused by a large molecular weight or the presence of hydrophobic 
groups, such as benzene rings, or in some cases due to a planer molecular geometry 
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that encourages strong π-π intermolecular bonding (Chowdary and Pavan Kumar, 
2013, Leucuta, 2014). Due to solubility limitations, absorption of a class II drug is 
hindered, this however may be markedly improved if the drug is maintained in a 
solubilized state while in the lumen of the gut, this may be achieved through 
formulation strategies (Pouton, 2006, Chowdary and Pavan Kumar, 2013). The 
absorption of class III and class IV drugs on the other hand are very difficult to improve, 
as both suffer from low permeability, which requires structural optimisation to bypass 
(Leucuta, 2014).      
1.1. Solid dosage forms and the solid state 
In order to understand the behaviour of solid dosage forms and thus allow for the 
enhancement of favoured properties, it is important to understand the properties of 
the solid-state. Unlike gases or liquids, solids retain their shapes unless a compressive 
force is applied (Milanovic et al., 1998). This indicates that the molecules of a solid 
state material are held up in close proximity to one another through strong non-
covalent intermolecular forces such as hydrogen bond or van der Waals forces (George 
Burton, 2000). The type, strength and frequency of intermolecular forces in addition to 
the presence of an order in which they occur are all of a great impact on the 
physicochemical properties of the resulting solid (Florence and Attwood, 1988). These 
factors in return are influenced by the content and structure of the individual 
molecules, hydrogen bonding for example occurs between a hydrogen atom from one 
molecule and an electronegative atom from another, or from the same 
macromolecule, given that the two atoms are within close proximity (Stone and Editor, 
1996).   
1.1.1. Crystalline state 
Molecules in a crystalline material are packed in a defined and repeated order, held in 
place by intermolecular forces such as van der Waals forces to form a crystal lattice. 
The strength of these intermolecular forces determines the energy of the lattice and 
vice versa. (Vippagunta et al., 2001, Mullin, 2001). A melting point is a characteristic 
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property of crystalline material, it indicates the temperature at which the individual 
molecules of a lattice have gained sufficient energy to overcome the intermolecular 
forces holding the lattice together, and therefore the temperature at which the crystal 
lattice converts to liquid (Vippagunta et al., 2001). A high melting temperature is 
indicative of a high energy crystal lattice which as a result indicates that strong 
intermolecular forces such as hydrogen bonding are holding the molecules together. 
Low melting temperatures on the other hand indicate the presence of only weak 
intermolecular forces in the lattice, such as van der Waals (George Burton, 2000).  The 
shape of the molecule has a great effect on the energy of the lattice, as molecules with 
planer geometry such as nifedipine are easily packed very closely, allowing stronger π-
π intermolecular bonding, therefore resulting in higher lattice energy and thus a higher 
melting temperature. (Ahmed et al., 1996, Allen et al., 1978, Aulton, 2007, Briggner et 
al., 1994, Royall et al., 2001). 
1.1.2. Amorphous state  
A solid material is said to be in an amorphous state when it lacks the long-range order 
characteristic of a crystal (Kaushal et al., 2004, Santivarangkna et al., 2011, Craig et al., 
1999). In other words, the arrangement of its molecules, and the interactions between 
them, resemble that of a liquid form while maintaining a solid like viscosity (Raudonus 
et al., 2000, Paterson et al., 2015). When heating an amorphous material a noticeable 
change in viscosity and molecular mobility takes place at a temperature specific to the 
material, this transition is known as the glass transition (Paterson et al., 2015), and the 
temperature at which it takes place is referred to as the glass transition temperature 
(Tg) (Paterson et al., 2015). Despite the change in viscosity, intermolecular interactions 
before and after the glass transitions remain approximately the same, as a result no 
endothermic melting peak appears in thermal analysis of such materials (Craig et al., 
1999).        
1.1.3. Physical stability of amorphous material 
When storing an amorphous material below its glass transition it appears brittle, 
sometimes described as being in the glassy state (Santivarangkna et al., 2011), and 
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very viscous, approximately  ≥ 1.1 x 1014Pa (Craig et al., 1999), and therefore its 
molecules lack mobility (Paterson et al., 2015). Molecular mobility is represented by 
the average relaxation time (τ), which may be described as the average time taken for 
a molecular motion to occur (Hancock et al., 1995). The specific type of motion really 
depends on the analytical method employed for their characterisation (Roudaut et al., 
2004). For example, if viscosity is used to measure relaxation behaviour, this is relative 
to intermolecular translational diffusion (Roudaut et al., 2004), whereas if IR or NMR 
are used to determine relaxation times, these will relate to motion within specific parts 
of the molecules and theirs environment (Roudaut et al., 2004). Therefore, its overall 
magnitudes behind different relaxation times within glass will be similar, but the 
specific values may change depending on the analytical technique used. 
Molecular mobility, and relaxation time, is directly influenced by storage temperature; 
at high temperatures the mean relaxation times, of amorphous materials, is very rapid 
(≤ 10 h) compared to the speed of transition molecular motion at temperatures below 
the glass transition (> 1000 h for PVP and > 1x105 h for indomethacin at approximately 
50 oC below Tg) as measured by Hancock et al. (1995). Short relaxation times (< 1h) for 
amorphous products, above their Tg, may be determined via conventional solid state 
nuclear magnetic resonance and thermal techniques (Hancock et al., 1995), while 
determining long relaxation times requires aging experiments as described by Struik 
(1977) and applied by Guo (1994) and (Hancock et al., 1995). Glassy material 
experiences gradual losses in enthalpy (∆H) and volume (∆V) when stored, under Tg 
(Hancock et al., 1995), due to molecular motion towards the more thermodynamically 
stable crystalline structure (Hancock et al., 1995). Measuring endothermic relaxation 
using differential scanning calorimetry (Hancock et al., 1995), before and after various 
lengths of controlled aging at specific temperatures permits the determination of 
molecular mobility in the non-equilibrium amorphous sample (Hancock et al., 1995). 
However the impact of extended periods of relatively high temperature aging on the 
chemical stability of the amorphous material understudy is rarely reported, and this 
casts a general concern over such approaches. 
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If amorphous materials are stored above their glass transition, they appear, less 
viscous and thus molecules are more mobile and are able to diffuse (White and 
Cakebread, 1966). This quickly leads to crystal nucleation and therefore crystallization, 
a process where the amorphous matter reverts back to the more stable ordered 
crystal structure. Crystallization is difficult to avoid but maybe slowed down by limiting 
molecular mobility, which is the dominating factor in the kinetics of recrystallization. 
As temperature directly influences molecular mobility, the Tg is commonly used as a 
marker for the process of recrystallization. (Kaushal et al., 2004, Royall et al., 1998, 
Hancock and Zografi, 1997, Yoshihashi et al., 2006, Aso et al., 2004). Despite the 
reduction in molecular mobility below Tg, this is found to have a profound influence 
over the life-time of an amorphous pharmaceutical product, which is usually in the 
order of a few years (Hancock et al., 1995). Zografi’s rule states that recrystallization of 
an amorphous material may be slowed down by storing the product 50 oC below its Tg 
(Hancock and Zografi, 1997).  
The glass transition temperature of an amorphous solid material is mainly influenced 
by the physiochemical properties of the material, such as intrinsic properties that 
directly influence molecular mobility and macroscopic fluidity (Craig et al., 1999). 
These include molecular structure, weight, size and shape. For example polymers with 
high molecular weight and long chains are less mobile than small organic molecules 
which form a large proportion of drugs. As a result polymers tend to show a higher Tg 
than amorphous small organic molecules (Meng et al., 2015). Polymers with stiff 
backbones tend to have higher Tg values than those with a more flexible, and therefore 
mobile, backbone; mobile backbones are composed of bond sequences that can easily 
rotate (e.g. –CH2CH2– or –CH2OCH2–). The mobile flexibility of a polymer may be 
hindered by bulky side groups. In addition, the purity of an amorphous material can 
also influence the Tg, for example the Tg of a pure organic material may be increased 
by the addition of high Tg long chain polymer (Raudonus et al., 2000), or decreased by 
the addition of smaller molecules with lower Tg, a process known as plasticisation 
(Craig et al., 1999). One of the most commonly dealt with plasticizers is water (with a 
Tg at 135K), and as water is present in ambient air (Craig et al., 1999) it is therefore 
important to keep amorphous material sealed and protected to avoid adsorption of 
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water molecules; a process that can eventually lead to accelerating recrystallization 
and therefore shortening the life-time of amorphous pharmaceutical products (Royall 
et al., 1999). It may therefore be concluded that the rate of crystallisation of 
amorphous drugs will vary depending on two major factors, the environmental storage 
conditions and the physicochemical properties of drug.  
In the field of investigating the stability of amorphous products, it is useful to look at 
the kinetics of crystallization, as it would allow better estimation and understanding of 
the shelf-life of amorphous pharmaceutical products. Crystallization kinetic data, 
expressed as an extent of conversion or relative crystallinity (θt) as a function of time 
(Kaushal et al., 2004, Gaisford et al., 2009), maybe fitted to different models at each 
temperature. The model that best fits the data is then selected and assumed to 
represent the mechanism at hand. One of the commonly used models is the Avrami 
model: 
 
𝜃𝑡 = 1 − exp [−(𝑘𝑎𝑡)
𝑛𝑎] Equation ‎1.2 
Where ka is the Avrami rate constant, which gives a quantitative parameter for the 
stability of the system, and na is the Avrami exponent, which provides information of 
the mechanism of nucleation and crystal growth (Gaisford et al., 2009).  
1.2. Solubility 
The thermodynamic solubility of a solid drug in an aqueous phase is defined as the 
concentration of the drug in a solution when in equilibrium with its pure solid form at a 
constant temperature and pressure, following scheme given below equation 1.4 where 
[Drug]s is the concentration of drug in solid state and [Drug]aq is the concentration of 
drug in the saturated aqueous solution (Johnson and Zheng, 2006).  
 
[𝐷𝑟𝑢𝑔]𝑠 ⇌  [𝐷𝑟𝑢𝑔]𝑎𝑞  Equation ‎1.3 
Thermodynamic solubility for a drug at a specific temperature and pressure is typically 
measured by adding an excess amount of solute to a vessel containing the solvent, 
which is then sealed and kept at constant conditions (a temperature and pressure of 
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interests). Enough time is then given to allow equilibrium to be reached between drug 
in the solid state and drug dissolved within an aqueous solution (typically 5 days). Once 
the duration is completed, the concentration of drug in solution is noted to be the 
aqueous solubility of the drug under the specified temperature and pressure 
(Soltanpour et al., 2014).   
Typically the driving force for the formation of a solution from the starting point of a 
pure solute and solvent is the increase in disorder, which may be expressed as the 
change in entropy (∆𝑆), which is a result of the increase in the random arrangements 
of the solute molecules in the solvent upon formation of a saturated solution (Liu, 
2008). The change in enthalpy (∆𝐻) is also an important factor that determines the 
likelihood for the formation of a solution. There are several steps which contribute to 
this enthalpy change: Firstly the change in enthalpy associated with the endothermic 
process of breaking non-covalent intermolecular forces which are present between 
solute molecules as well as the solvent molecules. Secondly the exothermic process of 
non-covalent bond formation between solute and solvent molecules. Thus heat flow is 
typically observed when a solution, or saturated solution, is formed. Such heat flow 
usually indicates an overall endothermic process for the dissolution of crystalline 
materials. Gibbs free energy (𝐺) is a function that is derived from the entropy and 
enthalpy of a closed system under constant temperature and pressure. For a process 
to favour the product, the change in free energy or ∆𝐺 must be negative (Florence and 
Attwood, 1988).  
 ∆𝐺 =  ∆𝐻 − 𝑇∆𝑆 Equation ‎1.4 
From equation 1.5 it can be seen that the main limitation of achieving a large negative 
change in ∆𝐺 is the presence of a large positive ∆𝐻 value. Therefore, solutes with 
strong intermolecular forces are less likely to be soluble, with the exception of solutes 
that have a high tendency to interact with the solvent molecules to form strong solute-
solvent interactions, such as ionic materials, electrolytes and salts, for example NaCl. In 
such cases the exothermic reaction of bond formation between solute and solvent 
molecules outweighs the endothermic breakage of solute-solute interactions as well as 
solvent-solvent interactions.    
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Applying a thermodynamic approach to the formation of a saturated solution, to 
determine the solubility in thermodynamic terms, the following equation has been 
derived and reported by many authors for example (Liu, 2008, Smith, 1982):  
 






) −  ln γ2  Equation ‎1.5 
Were 𝑋2 is the solubility concentration expressed as the mole fraction of solute within 
the solution, calculated by dividing the number of moles of solute by the total number 
of moles of solute and solvent present in solution. ∆𝐻𝑓 is the change in enthalpy of 
fusion. 𝑅 is the gas constant (8.314Jk-1mol-1), 𝑇𝑚 is the melting temperature of the 
solute, 𝑇 is the temperature of solution in Kelvin, and finally γ2 is the activity or 
effective coefficient (Smith, 1982). From the middle term (
𝑇𝑚−𝑇
𝑇
) the melting 
temperature of the solute can have an inverse effect on the solute’s solubility.  The 
later part of the equation ( ln γ2 ) accounts for the activity and interactions of the 
solute with the solvent in a non-ideal solution. Also an important factor which can 
influence solubility is the heat of fusion, as an increase in ∆𝐻𝑓 causes a lowering of 
solubility (Smith, 1982, Liu, 2008). It is difficult to apply the above equation to solid 
amorphous materials where the molecules are present in a disordered manner as they 
are far from equilibrium. In these systems the interactions or non-covalent bonding 
between molecules is reduced relative to the analogous crystalline form. However 
extrapolating equation 1.5 to highly viscous or slow to reach equilibrium amorphous 
systems may be useful as it can be seen that due to a lowering of the interactions 
between the molecules, because of the disordered structure, a higher apparent 
solubility would be observed (Leuner and Dressman, 2000).  
An alternative to measuring solubility using thermodynamic methods i.e. measuring 
the concentration of a saturated solution above the solid once equilibrium is reached, 
the kinetic solubility has been proposed.  This is considered to be the more favourable 
method at drug discovery stage, as it requires virtually no equilibrium time and 
relatively low amounts of the  sample (Dehring et al., 2004, Thomas et al., 2006). 
Kinetic solubility is the measurement of the solute solubility where it is pre-dissolved in 
dimethyl sulfoxide (DMSO), then titrated with an aqueous medium to precipitation 
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point (Thomas et al., 2006, Dehring et al., 2004). This method is very useful for 
obtaining an apparent solubility but if the system were allowed to equilibrate over 
many hours the values for the solubility measured at equilibrium can be expected to 
differ when compared to the kinetic or apparent solubility. For drugs in the amorphous 
state, this is more than likely as over time they have a well-reported tendency to 
crystallise in the presence of solvents especially water (Thomas et al., 2006). Verma 
and Rudraraju have shown in a recent study, that presenting cilostazol in its 
amorphous form can enhance its apparent solubility to be > 80.0 µg/mL, while its 
thermodynamic solubility was reported to equal 2.63 µg/mL. However, the 
supersaturated solutions of cilostazol lead to the recrystallization and precipitation of 
drug (Verma and Rudraraju, 2015). 
Kinetics is concerned with rates of reactions and in order for a product to form (e.g. 
solute in the aqueous form) the reactant molecules must interact with one another 
(Laidler, 1987). Therefore mobility and concentration are two of the factors that 
govern the rate of reaction (Laidler, 1987, Varma et al., 2004). Furthermore, the 
reactant molecules must carry enough energy to overcome an energy barrier known as 
the activation energy (Ea). If the reactant molecules do not hold enough energy, the 
reaction and therefore the product will not be formed (Figure ‎1.2). Arrhenius equation 
below summarises the relation between 𝑘, 𝑇and 𝐸𝑎 were (𝐴) is the pre-exponential 




𝑅𝑇⁄ ) Equation ‎1.6 
Arrhenius equation implies that 𝑇 has a positive effect on 𝑘 i.e. the rate of reaction 
increases with temperature, while 𝐸𝑎, the activation energy, acts as a barrier to the 
rate of a reaction (Laidler, 1987). As sketched in Figure ‎1.2, changes in the physical 
form of a solid material will also alter the activation energy and if solution formation is 
being considered then the rate of solution will be affected by the solid form of the 
solute i.e. whether it is presented in either the amorphous or crystalline form (Ozaki et 
al., 2012). 
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Figure ‎1.2 Comparing activation energy (Ea) between the amorphous and the crystalline state.   
1.3. Dissolution  
Dissolution can be defined as the process or rate by which a solid substance or a solute 
dissolves in a solvent. The rate of such process is measured as the mass of drug that 
goes into solution per unit time under defined conditions of temperature, pressure, 
solid/liquid interface and the composition of the solvent (Aulton, 2007). The Noyes-
Whitney equation (Noyes and Whitney, 1897) below describes the factors affecting the 










 is the rate of dissolution, 𝐴 is the surface area, 𝐶 is the concentration of the 
solid in the bulk dissolution medium, 𝐶𝑠 is the solubility of the compound in the 
dissolution medium, 𝐷 is the diffusion coefficient and 𝐿 is the diffusion layer thickness 
(Leuner and Dressman, 2000).  Equation ‎1.7 implies that the surface area has a direct 
effect on the rate of dissolution, while 𝐿 has an inverse effect on the rate of 
dissolution. Reduction of particle size and optimisation of wetting characteristics of 
solute surface, thus reducing the value of 𝐿, may therefore have a considerable 
positive effect on the rate of dissolution (Leuner and Dressman, 2000). Equation ‎1.7 
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also implies that 𝐶𝑠 has a direct effect on the dissolution rate, thus improving the 
apparent solubility of a solute can enhance dissolution rate and thus in the case of 
drugs, it may enhance bioavailability (Leuner and Dressman, 2000, Vasconcelos et al., 
2007).  
It is important to understand that enhancing the dissolution rate would not improve 
the final solubility of a solute (Florence and Attwood, 1988). Such concentration is 
achieved when equilibrium is reached between the rate of solute dissolving into 
solution and solute recrystallizing and precipitating out of solution. It is however 
possible to produce a supersaturated solution by increasing the apparent or kinetic 
solubility to be greater than the equilibrium concentration (Aulton, 2007, Brouwers et 
al., 2009). However as solutes do not precipitate out of solution as amorphous solid 
but as the crystalline form (Verma and Rudraraju, 2015), it is misleading to believe that 
the thermodynamic solubility of the amorphous form of a drug can be measured. 
 𝐷𝑟𝑢𝑔 (𝐴𝑚𝑜𝑟𝑝ℎ𝑜𝑢𝑠 𝑠𝑜𝑙𝑖𝑑) → 𝐷𝑟𝑢𝑔 (𝑎𝑞) ⇌ 𝐷𝑟𝑢𝑔 (Crystalline) Equation ‎1.8 
Dissolution profile of a drug, and hence the rate of reaching drug solubility, can be 
greatly influenced by external factors, namely: temperature, volume, pH & 
composition of dissolution medium and physical agitation of the system such as speed 
and shape of peddle rotation (Ghayas et al., 2013). The solubility of the test drug can 
be influenced by the temperature, pH & composition of dissolution medium and thus 
in return can influence the dissolution rate as described by the Noyes-Whitney 
equation (Noyes and Whitney, 1897). Wu et al. has shown the speed of peddle 
rotation to negatively influence the thickness of diffusion layer (L) in the dissolution of 
naproxen tables (Wu et al., 2004). As a result, increasing speed of peddle rotation 
caused a faster drug release, as predicted by the Noyes-Whitney equation (Noyes and 
Whitney, 1897). Furthermore, assuming sink conditions are not met, the volume of 
dissolution can have a great effect on the rate of dissolution. Due to the great effect 
external parameters have on a dissolution profile, a standard method of monitoring 
dissolution for conventional oral solid dosage forms has been designed to allow 
comparison of different formulations (MHRA, 2014b). This method was adjusted to 
simulate conditions of the gastric luminal fluid and thus to improve correlation 
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between in vitro and in vivo. For an oral medicine to be marketed, its dissolution is 
legally required to be measured using a pharmacopeia method, appropriate to the 
formulation type (MHRA, 2014b). The conventional oral tablets and capsules are 
required to be tested using the United States Pharmacopeia (USP) Apparatus 2, also 
known as paddle apparatus (MHRA, 2014b) in which the formulation is dropped in a 
dissolution bath of a specific shape containing a large but exact volume of dissolution 
medium to ensure sink conditions, and at a controlled temperature, to simulate gastric 
conditions. The solution is continuously stirred by a paddle with a specific shape and 
size, a controlled speed of rotation and a fixed position to ensure equal diffusion of 
released drug. Content, and hence rate, of drug released is monitored by measuring 
the concentration at various time intervals (MHRA, 2014b). 
1.4. Dissolution and apparent solubility enhancement 
techniques 
Dissolution rate enhancement techniques have been developed on the basis of the 
governing factors suggested by the Noyes-Whitney equation (Vasconcelos et al., 2007, 
Leuner and Dressman, 2000, Kaur et al., 2012). Increasing the surface area by reducing 
particle size is usually achieved by physical techniques such as spray drying or milling. 
However such techniques exert physical and thermal stress on drug particles and 
therefore are unsuitable for thermally sensitive drugs such as nifedipine (Kumar et al., 
2011, Chaumeil, 1998, Vogt et al., 2008, Ali, 1989) . Furthermore, it has been argued 
that the micronized powder, if stored incorrectly, tends to agglomerate, thereby 
negating the micronization procedure (Leuner and Dressman, 2000). Nano-suspension 
is another potential candidate for efficient delivery of PWSD, as a sharp increase in the 
surface area is associated with the reduction in drug particle size from micro to nano 
(Muller et al., 2000, Patravale et al., 2004). Nevertheless, many fundamental 
challenges such as the physical stability and shelf life are yet to be overcome (Agarwal 
and Bajpai, 2013), in addition carrier toxicity presents a limitation to the number of 
carriers suitable for nanosuspentions.  
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The dissolution rate of a PWSD may also be enhanced through modification of crystal 
habit and the use of polymorphs (Horter and Dressman, 1997), this technique is 
however limited to the ability of the drug to exist in more than one crystal habit 
(Brittain et al., 2009). A classic example of the effect of using the right polymorph on 
drug kinetic solubility is that of chloramphenicol palmitate suspensions. It was shown 
by Aguiar Aguiar et al. (1967) that when using the stable α-polymorph of 
chloramphenicol palmitate in an oral formulation produces low serum levels when 
compared to the same dose of the unstable β-polymorph . Due to the large differences 
in the physiochemical properties of the different polymorphic forms of the same drug, 
it is essential for the manufacturers to ensure that the same appropriate polymorphic 
form is produced every time (FDA, 2007). Moreover it is also important to ensure the 
physical stability of the more water soluble polymorphic form, as it may convert to the 
more stable polymorphic form during the shelf life of the product, resulting in a 
reduction of the expected bioavailability (Savjani et al., 2012).  
Poor aqueous solubility may also be overcome by the use of complexing agents, one of 
the commonly employed class of complexing agents is the cyclodextrin (CD) family 
(Loftsson and Brewster, 1996). CD are enzymatically modified starches composed of 
specific number of glucopyranose units that form a, controlled size, ring shaped 
molecules with a hydrophilic outer surface and a lipophilic inner cavity (Savjani et al., 
2012). PWSD’s can fit into the lipophilic cavity to form soluble inclusion complexes 
(Loftsson and Brewster, 1996, Savjani et al., 2012). The antifungal miconazole is one 
example of the PWSD’s that showed enhanced water solubility, and hence a higher 
oral bioavailability, in the presence of a seven unit ring cyclodextrin (β-cyclodextrin) 
(Tenjarla et al., 1998). Despite the solubility advantages of including cyclodextrin in 
oral formulations, limitations to the amount of cyclodextrin used can arise due to 
toxicity limits as well as costs and production capacities (Loftsson, 1998). 
Although particle size reduction can lead to dissolution rate enhancement, poor 
solubility of a drug may act as a limit to the amount of drug that dissolves into the 
dissolution medium, therefore limiting the drug influx and thus the bioavailability of 
the drug (Noyes and Whitney, 1897, Flynn et al., 1974). The enhancement of drug 
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solubility is therefore also very important. One of the most common technique of 
enhancing aqueous solubility of PWSD’s is a process known as hydrotrophy (Savjani et 
al., 2012), where a second solute, referred to as hydrotrope or hydrotropic agent 
(Savjani et al., 2012), is added to the aqueous dissolution medium, as a result the 
solubility of the primary solute (i.e. the drug) increases (Savjani et al., 2012). The 
mechanism behind this process is based on complexation involving weak interactions 
between the hydrotropic agents such as sodium acetate, sodium benzoate or sodium 
alginate and the PWSD (Savjani et al., 2012). Advantages of this technique include the 
absence for the need of chemical modification of the PWSD, the use of organic solvent 
or the preparation of emulsion systems. This approach is very beneficial for in vitro 
tests of water insoluble drugs; nevertheless, it may be impractical for the delivery of 
solid oral dosage forms as a large amount of hydrotropic agent maybe needed per 
dosage unit (Savjani et al., 2012). 
A widely known technique that is seen to improve both the dissolution rate and 
apparent solubility of PWSD’s is the use of solid dispersions; where by PWSD’s are fully 
dispersed into a water soluble carrier (Leuner and Dressman, 2000, Kaushal et al., 
2004, Vasconcelos et al., 2007), therefore reducing the drug’s particle size to the 
absolute minimum (Bates, 1969). As a result the dissolution rate of the drug is 
determined by the dissolution rate of the soluble carrier (Goldberg et al., 1966, Leuner 
and Dressman, 2000). To enhance the dissolution rate even further an amorphous 
solid dispersion, otherwise known as a solid solution, can be developed, where the 
drug is dispersed molecularly within the amorphous carrier which acts as a solvent 
(Leuner and Dressman, 2000, Ozaki et al., 2012, Brouwers et al., 2009, Chiou and 
Riegelma.S, 1969). This was reported to enhance drug dissolution by 5 to 11 times 
when compared to micronized drug depending on the drug/polymer ratio 
(Mayersoh.M and Gibaldi, 1966). 
1.5. Solid dispersions 
The term solid dispersions (SD) signifies a range of pharmaceutical products containing 
one or a number of drugs homogeneously dispersed within a matrix of carrier(s), 
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traditionally prepared by heat melt or solvent evaporation methods. The methods of 
preparing SD and the effect of each method will be discussed in more detail in later 
sections of this chapter. 
1.5.1. First generation solid dispersions 
It was first noted by Sekiguchi and Obi in 1961 that formulations of eutectic mixtures 
improves the rate of drug release and, consequently, the bioavailability of drugs with 
poor aqueous solubility (Sekiguchi et al., 1964). Eutectic mixtures consist of a fine 
dispersion of crystals of two different components, in this case the PWSD’s and the 
carrier, the melting point of the drug and polymer mixture presented as a fine 
dispersion is lower when compared to pure drug and polymer. Reduction in melting 
point, as presented by Equation ‎1.5 in section 1.2, enhances the solubility of the water 
PWSD, given all other variables in Equation ‎1.5 are maintained constant.  
Urea was one of the first highly water soluble carriers used formulating PWSD’s such 
as sulfathiazole (Sekiguchi and Obi, 1961) and chloramphenicol (Sekiguchi et al., 1964) 
into SD. The observed increase in rate of drug release and bioavailability were 
attributed to the decrease in drug particle size and better wettability (Vasconcelos et 
al., 2007). (Levy, 1963) & (Kanig, 1964) later developed molecularly dispersed solid 
systems using mannitol as a faster dissolving carrier, which has proved to increase the 
rate of drug release further. Nevertheless these SD, sometimes referred to as first 
generation SD (Vasconcelos et al., 2007), have the disadvantage of using crystalline 
carriers, such as urea (Goldberg et al., 1966, Sekiguchi and Obi, 1961, Sekiguchi et al., 
1964) and sugars (Kanig, 1964) rather than amorphous carriers. This allows the 
formation of crystalline solid dispersions which are thermodynamically stable. 
Crystalline solid dispersions do not release drugs as fast as amorphous carriers which 
makes them less attractive as a formulation platform for water PWSD’s (Vasconcelos et 
al., 2007). 
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1.5.2. Second generation solid dispersions  
In the late sixties it was first observed that maintaining the drug in its less 
thermodynamically stable state, the amorphous form, rather than the crystalline state, 
a faster drug release was achieved (Simonelli et al., 1969, Vippagunta et al., 2007, 
Urbanetz, 2006, Chiou and Riegelma.S, 1969). Therefore creating a second generation 
of SD (Vasconcelos et al., 2007), whereby PWSDs are molecularly dispersed in a 
solubilizing carrier (Kaushal et al., 2004).  
Second generation SD can be further categorised in accordance to the drug-carrier 
interactions (van Drooge et al., 2006). When the drug is completely miscible and 
soluble in the carrier, homogeneous molecular interactions between the drug and 
carrier are frequent, such interactions include hydrogen bonding and van der Waals 
interactions, which when very high result in a true one phase solution (Leuner and 
Dressman, 2000) as the affinity of the drug for the carrier outweighs the drug’s affinity 
for itself. The use of a high molecular weight, amorphous stabilizing, polymer such as 
PVP (Kaushal et al., 2004) to act as a carrier for such systems, creates a one phase 
molecularly homogenous glassy product where by the PWSD is fully dissolved in the 
polymer (van Drooge et al., 2006, van den Mooter et al., 2006).  
In some cases the solubility of the drug, usually drugs with very high melting points 
and thus low solubility (Chiou and Riegelman, 1971), in the carrier maybe very limited, 
resulting in a two phase amorphous solid system otherwise known as a solid 
suspension (Vasconcelos et al., 2007) where regions of amorphous drug and 
amorphous carrier are separated by a boundary, such as 50% w/w iopanoic acid in 
polyvinylpyrrolidone (Chiou and Riegelman, 1971). Although the obtained dispersions 
are molecularly nonhomogeneous, small drug particles, when dispersed in polymeric 
carriers, are able to provide an amorphous final product (van Drooge et al., 2006, 
Goldberg et al., 1966). Finally some systems are a mixture of both solid solutions and 
solid suspensions, where by the drug is both dissolved and suspended in the carrier. 
Such heterogeneous systems show mixed characteristics of solid solutions and solid 
suspensions (van Drooge et al., 2006, Goldberg et al., 1966).  
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1.5.3. Factors to consider when choosing carriers for a solid solution 
For a polymer to be utilised as a carrier and thus to be included in a medicinal product 
that is a solid solution, it must always be chemically stable, compatible with the drug 
and generally regarded as safe (GRAS). Furthermore, in order to develop efficient solid 
solutions, carriers are chosen with relation to the following three factors:    
1.5.3.1. Drug-polymer miscibility  
For a polymer to act as an efficient carrier, it must firstly be miscible with the drug, this 
would allow molecular dispersion of the drug with in the polymer and may also 
encourage drug-polymer interactions. Several mathematical models have been 
constructed to allow estimation of drug-polymer thermodynamic miscibility and 
interactions. The Flory-Huggins (FH) interaction theory (Flory, 1942), is one that uses 
melting point depression to predict the interaction parameter, 𝑥, using Equation ‎1.9 
below. It accounts for the entropy and enthalpy of mixing between molecules with a 
















) ∅𝑝𝑜𝑙𝑦𝑚𝑒𝑟 + 𝑥∅𝑝𝑜𝑙𝑦𝑚𝑒𝑟
2 ] Equation ‎1.9 
Where 𝑇𝑚
𝑝𝑢𝑟𝑒 and ∆𝐻𝑓𝑢𝑠  are the pure drug’s melting point and enthalpy of fusion 
respectively;  𝑇𝑚
𝑚𝑖𝑥 is the melting point of the drug when mixed with the polymer; 𝑚 is 
the molecular volume ratio of a polymer molecule to a drug molecule;  ∅𝑝𝑜𝑙𝑦𝑚𝑒𝑟 and 
∅𝑑𝑟𝑢𝑔 are the volume fractions of the polymer and drug respectively (Marsac et al., 
2009, Marsac et al., 2006). 
Another approach of predicting the drug-polymer miscibility is by calculating the 
Hansen solubility parameter, 𝛿, from their chemical structures. This may be achieved 
by using the van Krevelen and Hoftyzer method according to equation 1.10 and 1.11 
below. 
 𝛿2 = 𝛿𝑑
2 + 𝛿𝑝
2 + 𝛿ℎ
2 Equation ‎1.10 
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Where the total solubility parameter (𝛿2) is determined from the interactions 
between the dispersion forces (𝛿𝑑
2) and the polar interactions (𝛿𝑝
2), and hydrogen 
bonding (𝛿ℎ
2) of the functional group of the parent molecule divided by the molar 


















 Equation ‎1.11 
Where (𝐹𝑑𝑖), (𝐹𝑝𝑖
2 ) and (𝐸ℎ𝑖) are the group contribution for different components 
(dispersion forces, polar interactions and hydrogen bonding respectively) of structural 
groups that are reported in the literature at 25 oC. The drug-polymer interaction 
parameter (𝑥) may then be calculated from the difference in the solubility parameters 






2 Equation ‎1.12 
Where (𝑉0) is the volume of the lattice site, (𝑅) is the gas constant, and (𝑇) is the 
absolute temperature. 
1.5.3.2. Solubilization effect 
The choice of carrier also depends on its suitability to act as a solubilizing agent. 
Although all of the most explored carriers in the past 3 decades (table 1.1) have been 
frequently reported to have drug solubilizing properties, there is a clear difference in 
the degree of solubilization between carriers that are high molecular weight polymers 
and low molecular weight carriers such as sugars. (Kaushal et al., 2004). Polyethylene 
glycol (PEG) and polyvinyl(pyrrolidone) (PVP) are 2 of the most successful solubilizing 
polymers (Kaushal et al., 2004) due to their inherent drug solubilization capacity which 
is built on their ability to interact with drug molecules via electrostatic bonds such as 
van der Waals and hydrogen bridges forming soluble drug-polymer complexes. 
However, drug-polymer interactions can vary depending on the chemical structures 
and the physiochemical properties of the drug and polymer, as well as the method of 
preparing the solid solution.  
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Table ‎1.1 Most successful solubilizing carriers explored in the past three decades in development of SD, 
PEG: poly(ethylene glycol), PVP: poly(vinyl pyrrolidone), FUR: furosemide, NSAIDs: non-steroidal anti-
inflammatory drugs, CEL: celecoxib, PVP/VA: poly(vinyl pyrrolidone/vinyl acetate), HPMC: hydroxyl 
propyl methylcellulose, PVM/MA: poly(vinyl methyl ether/maleic anhydride) (Kaushal et al., 2004, 
Papadimitriou et al., 2012).  
Solubilizing carrier Drug 
PEG Griseofulvin, phenytoin, prednisolone, nortriptyline HCl, piroxicam, 
oxazepam, fenofi brate, ketoprofen, glyburide, nifedipine, 
carbamazepine, ibuprofen, zolpidem. 
PVP Griseofulvin, sulfathiazole, hydrochlorothiazide, carbamazepine, FUR, 
NSAIDs, mefenamic acid, azapropazone, glafenin, flotafenin, 
oxodipine, etoposide, benidipine HCl, atenolol, piroxicam, 
clofazimine, lonidamine, CEL. 
PVP/VA Carbamazepine, atenolol 
HPMC Benidipine, nilvadipine, albendazole 
PVM/MA Griseofulvin, clofazimine 
Crospovidone FUR 






Gelita Collagel* Oxazepam 
Egg albumin Mefenamic acid 
*Gelita Collagel is an enzymatically synthesised collagen hydrolysate (Jachowicz and Nürnberg, 
1997). 
1.5.3.3. Stabilization 
Choice of carrier can also, greatly influence the shelf-life of a solid solution product by 
acting as a stabilizer (Khougaz and Clas, 2000, Kaushal et al., 2004). Using long chain, 
and high Tg, polymers such as PVP as carriers, can increase the Tg value of an 
amorphous drug to be substantially higher (by ≥ 50 oC) than storage temperature (25 
oC) (Kaushal et al., 2004, Ikegami et al., 2006, Khougaz and Clas, 2000, Raudonus et al., 
2000, Shamblin et al., 1996, Zeng et al., 2001). This in return gives more confidence in 
the physical stability of the product when stored at room temperature (Hancock and 
Zografi, 1997).  In addition to increasing Tg values, PVP, unlike PEG, has repeatedly 
shown the ability to further stabilize amorphous drug by limiting their molecular 
mobility (Kaushal et al., 2004, Yoshioka et al., 1995, Matsumoto and Zografi, 1999a, 
Crowley and Zografi, 2003, Shamblin et al., 1996, Shamblin and Zografi, 1999, Zeng et 
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al., 2001, Miyazaki et al., 2004, Broman et al., 2001, Khougaz and Clas, 2000, Karavas 
et al., 2006b, Yuan et al., 2014, Hosono et al., 1980, Aso and Yoshioka, 2006, 
Matsumoto and Zografi, 1999b). This is done by forming strong and very specific drug-
polymer interactions, such as hydrogen bonding and dipole induced dipole forces 
(Table 1.2) (Hosono et al., 1980). As a result mobility of molecularly dispersed 
molecules is decreased and thus recrystallization is discouraged (Miyazaki et al., 2004, 
Kaushal et al., 2004, Broman et al., 2001, Khougaz and Clas, 2000, Hosono et al., 1980). 
A number of studies have even shown that the addition of a low content of PVP can 
substantially reduce the molecular mobility of nifedipine (Aso et al., 2004), 
phenobarbital (Aso et al., 2004), acetaminophen (Miyazaki et al., 2004) and 
Indomethacin (Matsumoto and Zografi, 1999b)  thus inhibiting recrystallization. This 
makes PVP a very desirable carrier as stabilizing the drug in its amorphous form has 
substantial effects on apparent solubility and the rate of dissolution (Kaushal et al., 
2004). Table 1.2 lists a number of published specific drug-carrier interactions for 
stabilization of amorphous drugs observed between PVP and a number of drugs.    
Furthermore, one of the important factors to consider when choosing a polymer to use 
as a carrier is the molecular weight (Zeng et al., 2001). An increase in molecular weight 
usually causes an increase in Tg of the polymer and therefore making it a more 
appropriate polymer to use for stabilizing drug in the amorphous form (Zeng et al., 
2001). On the other hand it is also important to note that the molecular weight is 
directly related to the intrinsic viscosity (Kaushal et al., 2004), which has a great 
influence on the rate of drug release. A very high molecular weight polymer can 
introduce a high viscosity diffusion boundary layer around the solid dispersion particles 
containing the drug, and thus the release of drug would be diffusion controlled. A 
correlation was found between a reduction in the aqueous solubility of PVP and the 
increase in chain length. Therefore when choosing the molecular weight of PVP to use 
in the development of a solid solution, it is important to balance the need for 
stabilization and solubilization.  PVP MW 10,000 for example, has shown to have a high 
aqueous solubility and dissolution rate as well as high stabilizing properties (Kaushal et 
al., 2004). 
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Table ‎1.2 Drug-polymer interactions between PVP and a range of drugs. It is well known that PVP can 




Ajmaline-PVP k15 -OH----O=C- 
A dipole-induced dipole of a drug-polymer 
complex was formed, which enhanced the 
solubility of ajmaline (Hosono et al., 1980). 
Nabilone-PVP OH----O=C- 
Hydrogen bonding forming between nabilone and 
the chains of PVP stabilized the amorphous form 
of nabilone for 2 years (at 25 oC) (Thakkar et al., 
1977). 
Indomethacin-PVP 
(K12, 17, 30, 90) 
OH----O=C- 
Hydrogen bonding forming between amorphous 
indomethacin and polymer chains, inhibited drug 
recrystallization at 30 oC for 20 weeks, using 5% 






Ion-dipole interaction resulted in higher Tg values 
than those predicted by Gordon-Taylor equation 
(Khougaz and Clas, 2000). 
Probucol-PVP K30 OH----O=C- 
Hydrogen bond complex formed between 
probucol and polymer, resulting in stabilization of 
the amorphous drug (Broman et al., 2001). 
Nifedipine-PVP k40 -NH----O=C 
Hydrogen bonding between nifedipine and PVP 
helped in stabilizing the amorphous form of 




Hydrogen bonding between drug and PVP 
prevented molecular mobility and hence limited 
crystallization (Miyazaki et al., 2004). 
 
1.5.4. Barriers to using solid solutions as pharmaceutical products  
Despite the extensive research performed on solid solutions over the past decades and 
despite their much needed ability in enhancing the oral bioavailability of PWSDs, they 
are not broadly used in commercial products. Table 1.4 below includes some of the 
amorphous or partially amorphous products that have made it to the market. The lack 
of their usage as pharmaceutical products can be related to the following challenges: 
1.5.4.1. Low physical stability 
Physical stability referred to here, is the stability of the physical state at which the 
organic drug is intended to be dispensed in, for the life time of the product which is 
typically in the range of 2-3 years (Trasi et al., 2014). Solid solutions are designed to 
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provide the drug in its amorphous state; therefore their physical stability is defined by 
the absence of the crystalline state of the drug (Craig et al., 1999). Nevertheless, 
amorphous organic drugs are thermodynamically metastable, when compared to the 
crystal state (Craig et al., 1999), and can revert back to the crystalline form when 
maintained in a temperature range where nucleation is thermodynamically and 
kinetically favourable (Trasi et al., 2014, Baird et al., 2010). This poses a problem, as 
the physicochemical properties of the crystalline form of a drug may be very different 
from the amorphous form (Baird et al., 2010). Undergoing crystallization may 
therefore take away the enhancement of intrinsic solubility and dissolution rate seen 
with the amorphous state. As a result the medicinal product may no longer meet the 
required specifications of drug delivery. As described in earlier sections (1.1.3), 
crystallisation is greatly influenced by environmental conditions, such as temperature 
and humidity. This makes manufacturing, processing, packaging and storage to be 
steps with high risk of drug crystallisation, as it would be difficult to control and 
implement anti-crystallization environmental conditions, especially with large scale 
production (Kaushal et al., 2004, Craig et al., 1999, Vasconcelos et al., 2007). In 
addition unit operations in manufacturing, such as size reduction, drying, dry and wet 
granulation and compression may induce mechanical, thermal or solvent related stress 
that may also lead to increasing the rate of crystallisation (Kaushal et al., 2004).  The 
high sensitivity of amorphous formulations to environmental conditions, the risk of 
high rate recrystallisation taking place and the effect it has on the shelf-life of 
amorphous pharmaceutical products makes them less attractive to pharmaceutical 
companies (Kaushal et al., 2004).  
The sensitivity of amorphous formulations to crystallisation does not stop at the 
manufacturing and storage stages, but also extends to the administration of the 
medicine, such as the duration of exposing the medicine to the ambient air once 
outside its packaging. For example, it is a common practice in many countries for 
pharmacies to repackage solid dosage form medicines, such as tablets and capsules, 
from their original blisters, and into an easily accessible compliance packages for 
geriatric patients (Gerber et al., 2008, Gilmartin et al., 2013, Tan and Kwan, 2014). 
Such packages do not provide environmentally controlled conditions, and therefore 
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increasing the risk of recrystallizing the drug. Physical stability is also at risk after 
ingesting the amorphous drug, as it was observed with many amorphous organic 
drugs, when solid solutions disperse in an aqueous solution, such as the luminal 
content, drug recrystallisation and precipitation may occur, therefore reducing the 
expected oral bioavailability of drug in the amorphous state. The physical stability of 
amorphous drugs is therefore undoubtedly the greatest barrier to using solid solutions 
as platforms for PWSD as marketable pharmaceutical products.   
1.5.4.2. Chemical stability  
The rate of chemical degradation of drugs is reported to be higher in the amorphous 
state than when in the crystalline state (Yu, 2001, Bhugra and Pikal, 2008). This has 
been attributed to the increase in surface area and the enhanced level of molecular 
mobility, which reduces the activation energy for solid-state chemical reactions. 
Furthermore the higher hygroscopicity of amorphous material in comparison to the 
crystalline form enhances the rate of degradation by mediating the drug and indirectly 
by increasing molecular mobility through the plasticising effects.  The chemical stability 
of the amorphous form of quinapril HCL was determined to be lower than the 
crystalline form, in addition, it was found to correlate with increased molecular 
mobility at high temperatures (Kaushal et al., 2004).    
In addition, the chemical instability of amorphous drugs can further lead to 
undesirable drug-excipient interactions promoting instability. Although drug-polymer 
interactions are generally described as a favoured interaction, however in certain cases 
may come as a disadvantage, as strong binding and interaction between a PWSD and a 
polymer can retard the dissolution rate of the polymer through polymer swelling 
(Kaushal et al., 2004). Studies with PVP, PEG, RenexTM and β-cyclodextrin showed a 
decrease in the dissolution rate of the polymer due to strong drug-polymer 
interactions (Singh et al., 1966, Gibaldi and Weintrau.H, 1968).       
1.5.4.3. Lack of characterization tools 
Although amorphous systems are not new to the pharmaceutical field, there is a lack 
of analytical tools that allow the quantification of amorphous content rather than 
crystalline content (Kaushal et al., 2004, Shah et al., 2006). The current analytical tools 
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that are typically used are designed to measure the amount of amorphous material in 
an otherwise crystalline sample, rather than the amount of crystalline in an otherwise 
amorphous material (Kaushal et al., 2004, Shah et al., 2006). This as a result can 
introduce a difficulty when undertaking quality control procedures on amorphous 
pharmaceutical products. Furthermore, the Tg value, which is one of the key 
characteristics of amorphous materials (Shah et al., 2006), may differ depending on 
the analytical method used and the parameters implemented within the method 
(Tropin et al., 2011). For example determining the Tg value using a diffraction scanning 
calorimetry can vary depending on the rate of heating and cooling (Tropin et al., 2011, 
Kerc and Srcic, 1995).                
1.5.5. Evaluation of solid solutions using model drugs 
Novel solid solutions are evaluated for efficiency of physical stability and the 
enhancement of intrinsic solubility and dissolution rate, of water insoluble drugs, as 
part of research and development. To allow accurate evaluation, suitable model drugs 
must be used. Table 1.2 shows a wide range of model drugs that have been used to 
evaluate and determine the mechanism behind novel solid solutions. A suitable model 
drug must have a low water solubility (< 60 µg/mL), but preferably has an acceptable 
permeability (BCS class II), in which case an enhancement in solubility and dissolution 
rate would improve the drug’s bioavailability. As 50% of currently used API’s are 
categorised as class II of the BCS (Patil et al., 2015), it is ideal for the model drug to be 
of this popular group.  
In addition to water insolubility, there are a number of other physicochemical and 
chemical properties that, if present in the model drug, can allow a better evaluation of 
the solid solution. These include low physical and chemical stability, which will allow 
the stabilization by the solid solution platform to be more apparent. Similarly the drug 
should have low wettability, which as a result would also make the enhancement in 
dissolution rate more apparent. Using a model drug with a published UV and 
chromatographic analysis can also help in adapting analytical methods for the novel 
solid solution. Furthermore a model drug should be relatively cheap and easily 
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accessible for academic research, and has approved marketed formulation to allow 
novel formulations to be compared with the conventional marketed formulations.               
1.6. Manufacturing solid solutions 
Traditionally solid solutions were prepared using hot-melt extrusion (HME) processing, 
a technology that was first utilised in the plastic, rubber and food industry, but was 
quickly found to have great potential in the pharmaceutical industry in early 1970s 
(Patil et al., 2015). In the pharmaceutical industry HME was applied as a continued 
process of a mechanical pressure on mixtures of polymeric materials and API’s with a 
rotating screw. The temperature of the mixtures is raised above the Tg and/or melting 
temperatures of its components. In some systems, the mixtures are also passed 
through a high-pressure homogenizer, to achieve molecular dispersion of API in 
polymer (Patil et al., 2015). The final products are solid solutions with uniform density 
and shape (Patil et al., 2015), which may then be milled to reduce the overall particle 
size (Leuner and Dressman, 2000). HME, once established, was found to be less time 
consuming and more efficient than conventional pharmaceutical manufacturing 
processes, and thus was used as an alternative platform technology for manufacturing 
pharmaceutical dosage forms, such as tablets and capsules (Patil et al., 2015). 
However, HME process was found to be limited to thermostable compounds with 
acceptable chemical and physical stability to the high temperatures, and in some cases 
high pressures, experienced during HME processes (Patil et al., 2015).       
As the HME process is limited to thermally stable drugs, a solvent evaporation method 
was adapted (Tachibana and Nakamura, 1965), where the polymer and the drug were 
dissolved in a common volatile solvent such as chloroform (Vasconcelos et al., 2007, 
Hasegawa et al., 2005, Lloyd et al., 1999); The solvent was then removed by an 
evaporation process usually including vacuum drying (Karavas et al., 2006a, Yoshihashi 
et al., 2006, Wang et al., 2005), moderate heating via the use of hot plate (Desai et al., 
2006), slow evaporation at low temperatures (Lloyd et al., 1999, Yoshihashi et al., 
2006), using a rotator evaporator, a stream of nitrogen, spray-drying, freeze-drying 
and the use of supercritical fluids (Vasconcelos et al., 2007).     
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1.6.1. Freeze-drying  
Freeze-drying, also known as lyophilisation, has been widely used as a process to 
transform pharmaceutical injectable formulations into stable solid systems with long-
term, unrefrigerated-storage stability (Craig et al., 1999). The process has found 
considerable applications in the formulation of biological pharmaceutical products, as 
the stability of freeze-dried solid formulations is usually higher than the equivalent 
aqueous solution based formulation (McPhillips et al., 1999, Tang and Pikal, 2004). In 
addition freeze-dried formulations have the advantage of ease of handling when it 
comes to shipping and storage (Pikal, 1993, Pikal, 1994). Nevertheless freeze-drying 
can be a costly process, and may require periods of many days to complete if the cycle 
is not optimised (Tsinontides et al., 2004, Tang and Pikal, 2004). Furthermore, freeze-
drying has been of high interest in the development of rapidly dissolving oral solid-
dispersion formulations as it can results in amorphous solids which can enhance the 
intrinsic solubility and dissolution rate of water insoluble drugs  (van Drooge et al., 
2006, McPhillips et al., 1999, Vasconcelos et al., 2007, Corveleyn and Remon, 1997). 
These factors therefore make freeze-drying an ideal method to manufacture stable 
solid solutions. 
1.6.1.1. Stages of freeze-drying 
Freeze-drying consists of 3 stages: Firstly the freezing stage where by the majority of 
water present in the formulation crystallises at temperatures below 0 ºC typically in 
the range of -20 oC to -50 oC (Tang and Pikal, 2004). This then is followed by a primary 
drying stage where the ice present is removed by sublimation, this is performed under 
vacuum pressure which can vary from 0.06 mbar-0.26 mbar (Pikal et al., 1984), and at 
a temperature range, known as the temperature safety margin, 2-5 ºC below the 
macroscopic collapse temperature (Tc) of the formulation (Tang and Pikal, 2004). Tc is 
the temperature above which the freeze-dried product loses macroscopic structure 
and therefore collapses during freeze-drying. Tc is estimated to be 2 
oC higher than the 
primary glass transition temperature (T’g) of the freeze concentrated amorphous 
matrix (Mackenzie, 1966). Finally the secondary drying stage, whereby water is 
desorbed from the sample, it is usually performed at elevated temperature and low 
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pressure (Tang and Pikal, 2004). There are many excellent papers covering the freeze-
drying of pharmaceuticals (Pikal, 1993, Pikal, 1994, Pikal et al., 1984, Pikal and Shah, 
1990, Pikal and Shah, 1997, Tang and Pikal, 2004, Tsinontides et al., 2004). A review of 
these papers informed the development of the freeze-drying cycles reported later in 
the thesis. This stage by stage review is given below:  
1.6.1.1.1 Freezing 
Freezing is an efficient desiccation step where by most of the water, ≥ 99% v/v, is 
separated from the solutes, which in this case are drug and excipients, and leaving 
behind a very concentrated solutions termed “freeze concentrate” (Tang and Pikal, 
2004). The typical average water content of freeze concentrate is ≤ 20% w/w (Tang 
and Pikal, 2004), which is equivalent to ≤ 1% v/v of the total water that was present in 
the feed solution. Freeze concentration of the remaining solution is a crucial factor to 
consider when dealing with biological formulations, as this often induces destabilizing 
stresses such as pH shifts and aggregations. Therefore, the optimal choice of buffer 
and or surfactants is essential (Tang and Pikal, 2004). The temperature at which the 
system undergoes a primary glass transition (T’g) is essential to note, as the product 
must be kept below this temperature for the whole duration of the primary drying 
stage.  Furthermore the rate of cooling is also an important factor to control, as slow 
cooling rate (typically > 0.5 oC/min) can result in the growth of large ice crystals, while 
this would increase the rate of sublimation in the primary drying stage, it has the 
potential to increase destabilizing stress, as it prolongs the freezing time, where 
solutes exists in freeze concentrate (Heller et al., 1999b, Heller et al., 1999a, Tang and 
Pikal, 2004). Furthermore, this can lead to phase separation and thus crystallisation of 
amorphous solute, therefore in particular cases defeats the purpose of using freeze-
drying to produce an amorphous material (Izutsu et al., 1997, Tang and Pikal, 2004). 
Rapid cooling using a pre-cooled shelf of -80 oC or cooling with liquid nitrogen results 
in small ice crystals, it requires longer periods to sublime and is uneconomical (Jiang 
and Nail, 1998). A moderate cooling rate of 1 oC/min has been reported to be a good 
compromise (Tang and Pikal, 2004). It was reported that once the sample has reached 
the required temperature, it must be kept for a sufficient length of time (typically 1h 
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per 1cm depth fill) to allow for all the solution to transform into solid (Tang and Pikal, 
2004).  
1.6.1.1.2 Primary drying 
Primary drying requires the longest period out of all three stages and so it is the most 
important parameter to optimise. The rate of mass removal is increased by altering the 
chamber pressure (𝑃𝑐) which impacts both the temperature and mass transfer (Tang 










 is the rate of sublimation (g/h per vial if applicable), 𝑃𝑖𝑐𝑒is the equilibrium 
vapour pressure of ice at the sublimation interface temperature (measured in units of 
Torr), 𝑅𝑝 and 𝑅𝑠 are the dry layer and the stopper resistance, respectively, to the ice 
vapour transporting from the sublimation interface (Torr∙ h/g) (Pikal et al., 1983, Tang 
and Pikal, 2004). Choosing the right 𝑃𝑐  is critical as it impacts on the products 
temperature (Tp), thus a compromise between high sublimation rate and 
homogenous heat transfer, to provide sublimation with the required energy is needed. 
Equation ‎1.14 below may be used to choose the optimal chamber pressure (Tang and 
Pikal, 2004, Pikal et al., 1984). 
 𝑃𝑐 = 0.29 ∙ 10
(0.019∙Tp) Equation ‎1.14 
Where 𝑃𝑐  is in Torr and  𝑇𝑝 in ºC Furthermore, rate of sublimation can be related to 
heat transfer (𝑑𝑄/𝑑𝑡) using Equation ‎1.15, where ∆𝐻𝑠 is the heat of ice sublimation 
(cal/g).  
 






 Equation ‎1.15 
Tang and Pikal (2004) reported Equation ‎1.15 as a tool to estimate the duration of the 
primary drying stage (Tang and Pikal, 2004). In addition to the theoretical approach, 
the endpoint of primary drying is typically indicated by the absence of water vapour in 
the freeze-drying chamber in addition to Tp reaching the shelf temperature (Pikal et 
al., 1984, Tang and Pikal, 2004). 
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1.6.1.1.3 Secondary drying 
Removing residual water from an amorphous product (typically 5-20% w/w depending 
on the formulation (Tang and Pikal, 2004)) by desorption requires elevation in 
temperature. It is crucial to do so at a slow rate (typically 0.1 or 0.15 oC/min), as a fast 
temperature ramp might cause the collapse of the amorphous product. It is vital to 
stay below the gradually rising Tg value of the product, but also to maintain a steady 
ramp to reach a relatively high temperature (typically 40 oC) and to maintain at such a 
temperature for a period of 3-6h (Tang and Pikal, 2004). Higher temperatures induce 
faster rate of water desorption. Therefore, gradually raising the temperature, while 
avoiding the product’s temperature rising above its Tg, can reduce the duration of the 
secondary drying stage and improve its efficiency (Pikal et al., 1990). Secondary drying 
is usually stopped when the water content is ≤ 1% w/w. This  ensures optimal freeze-
dried cake stability (Tang and Pikal, 2004).          
1.6.1.2. Challenges and limitations of using freeze-drying to produce solid 
solutions to enhance dissolution 
1.6.1.2.1 Stability of feed solutions 
One of the main challenges with utilizing freeze-drying as a method of manufacturing 
stable amorphous drugs is to overcome the destabilizing stress induced by the creation 
of freeze concentrate at the freezing stage (Tang and Pikal, 2004, Heller et al., 1999b, 
Costantino and Pikal, 2004). These include sharp increase of solute concentration 
which enhances solute-solute interactions leading to aggregation and precipitation; 
sharp change in pH of solution due to crystallization of buffer, a very large increase in 
ionic strength and, in the case of biopharmaceuticals, denaturation of proteins (Tang 
and Pikal, 2004, Costantino and Pikal, 2004). Freeze related stress can be overcome by 
incorporating specific stabilizing excipients known as cryoprotectants. Examples of 
cryoprotectants include sucrose, trehalose, sorbitol, mannitol and PEG (Costantino and 
Pikal, 2004). Many hypothesis were developed to describe the mechanism by which 
cryoprotectants function, the mechanism that seems most applicable to all known 
cryoprotectants is the preferential exclusion mechanism (Arakawa et al., 2001). This 
describes the co-solute cryoprotectants to create a thermodynamically unfavourable 
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situation, which as a consequence prevents the denaturation of proteins (Arakawa et 
al., 2001). 
Additionally, physical and chemical degradation may also occur during the drying 
stages (Bhugra and Pikal, 2008), such degradation can lead to sample collapse and 
hence the crystallization of amorphous drug. Several excipients, known as 
lyoprotectants, may be incorporated into the formulation to enhance the physical and 
chemical stability of the drug at the drying stages of the process; via the formation of 
stabilising hydrogen bonds (Arakawa et al., 2001). These Lyoprotectants include small 
carbohydrate molecules such as sucrose  (Roy and Gupta, 2004).  
1.6.1.2.2 Low aqueous solubility  
An obvious obstacle to freeze-drying organic drugs with low aqueous solubility is the 
need to work with large volumes of feed solutions and therefore large amounts of ice 
to sublime. This will not only be expensive and time consuming but also impractical. 
Many have therefore, resulted to freeze-drying using organic solvents either alone or 
as a co-solvent (Teagarden and Baker, 2002a, Wittaya-Areekul et al., 2002, Oesterle et 
al., 1998, Ni et al., 2001, Teagarden and Baker, 2004). Solvents used in the freeze-
drying process must have a number of critical physical and chemical properties, 
including a freezing point between 30 to -10 oC and relatively high vapour pressure at 
low temperatures (typically higher than vacuum pressures 0.06 mbar - 0.26 mbar (Pikal 
et al., 1984)). One of the most popular organic solvents used in this capacity is tert-
butanol (Ni et al., 2001, Vessot and Andrieu, 2012). CAVERJECT® is one of the marketed 
pharmaceutical products which utilized tert-butanol in freeze-drying (Teagarden and 
Baker, 2002a).  
1.6.1.2.3 Low density  
Finally producing a hard solid oral dosage form via freeze-drying may be a challenge 
especially when the solid solution consists of low density organic polymer (Leuner and 
Dressman, 2000). Making a tablet out of such material may not be practical. In 
addition the process of tableting can exert thermal and physical stress that may induce 
crystallisation. As a solution and to keep the freeze-dried porous structure intact, one 
may result to freeze-drying a formulation while inside a degradable vessel that can be 
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orally administered and can withstand the temperatures of freeze-drying. A standard 
gelatin capsule may be fit for such a role.  
1.7. Rapid buccal delivery 
Another approach to improving the oral bioavailability of water insoluble drugs is 
through the use of rapid buccal delivery systems (Kassem et al., 2014, Badgujar and 
Mundada, 2011, Lam et al., 2014). This is mainly because the buccal route bypasses 
the first pass metabolism and drug degradation or metabolism in the gastrointestinal 
system (Lam et al., 2014). Furthermore, the high blood flow and relatively high 
permeability of the oral mucosa allows a quick onset of action to be achieved (Lam et 
al., 2014). This makes the buccal route ideal for when a rapid clinical effect is required 
(Lam et al., 2014). 
Traditional oral solid dosage forms such as capsules and tablets share a common 
disadvantage of difficulty in swallowing which is thought to affect patients in all age 
groups. A study by (Sastry et al., 2000)  has shown that dysphagia, or difficulty in 
swallowing is a problem encountered by approximately 35% of the general population 
as well as 30-40% of elderly institutionalized patients, and 18-22% of all persons in 
long-term care facilities (Fu et al., 2004). It has been repeatedly published that 
paediatric and geriatric patients alongside bedridden or developmentally disabled 
patients; patients with persistent nausea and patients with limited fluid intake, due to 
their condition, as well as travelling patients with limited access to water are all in 
need of a new dosage form that can readily disintegrate or melt once placed inside a 
patient’s mouth (Dobetti, 2001, Seager, 1998). This in return will eliminate the faced 
difficulties with swallowing a solid dosage form as a whole and thus enhance patient 
compliance.  
1.7.1. Orally fast disintegrating tablets 
In the past two decades a great deal of attention has been drawn to a new form of 
solid dosage form commonly known as fast disintegrating tablets, which has the ability 
to quickly dissolve, disintegrate or melt inside a patient’s mouth without the need of 
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water intake (Fu et al., 2004). Such tablets are also known as fast dispersing, rapid 
dissolve, rapid melt, quick disintegrating and/or instant melt tablets (IMTs), in relation 
to the properties of the tablet and thus the time it requires to fully disperse or 
disintegrate (Fu et al., 2004). The European pharmacopeia has adopted the term 
orodispersible tablet for all tablets that disintegrate or disperse inside the mouth with 
in a period equal to or less than 3 min or alternatively, disintegrate within 3 min under 
the USP disintegration test.  Nevertheless a good FDT should disintegrate within one 
minute of administration to enable rapid drug absorption (Fu et al., 2004), an 
additional advantage of FDTs is the possibility of a pre-gastric drug absorption and thus 
avoiding the first-pass metabolism which in return can induce a rapid drug therapy 
intervention and enhance the drug’s bioavailability (Fu et al., 2004). Furthermore FDTs 
must also share all of the advantages of using the conventional oral solid dosage form, 
such as accurate dosing, easy manufacturing, ease in handling and transport in 
addition to easy handling by patients (Dobetti, 2001, Habib et al., 2000, Seager, 1998, 
Fu et al., 2004).               
Unlike the conventional tablets, FDTs are required to disintegrate and sometimes 
dissolve in a very short period of time and in the presence of a limited amount of 
water despite the large difference in performance. Listed below, are each of the 
factors that contribute to the overall performance of the FDTs (Fu et al., 2005). 
1.7.2. Disintegration and dissolution. 
As the disintegration fluid is provided by the patient’s saliva, FDTs are presented with a 
challenge of disintegrating in a very limited volume of solvent. On average the 
minimum salivary volume, being the residual volume in the mouth after swallowing, 
is 0.8 mL. While the maximum salivary volume (Vmax), being the volume in the mouth 
just before swallowing, is 1.1 mL (DiSabato-Mordarski and Kleinberg, 1996). 
Furthermore, when aiming to deliver an emergency drug via the buccal absorption, 
FDTs must have rapid dissolution as a vital property. The key properties for FDTs are 
therefore fast absorption of water and rapid dissolution, such process is usually 
expected to take place in less than one minute. 
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1.7.3. Physical properties of FDTs 
To ensure fast disintegration and dissolution, FDTs should maintain a very porous 
structure. Methods and parameters of manufacturing have great influence over pore 
diameter, freeze-dried ODT formulations for example, produce tablets with more 
porous structures than any other of the methods used in manufacturing FDTS, such as 
compressions. However the pH of the feed solution used in freeze-drying, has a further 
effect on the pore diameter. A study by (Jones et al., 2011) has shown that adjusting 
the pH of the feed solutions to approximately 8, may be done by incorporating sodium 
bicarbonate in the formulation, can improve the average pore diameter from 90 µm to 
140 µm, while the wall thickness was seen to reduce from 40 µm to 20 µm, therefore 
making the structure of the tablet more porous. Nevertheless porosity could have a 
negative effect on the mechanical strength of tablets, otherwise known as tablet’s 
hardness (Shang et al., 2013), which also is greatly influenced by the method and 
parameters of manufacturing (Shang et al., 2013). For industrial convenience, tablets 
should have hardness strength of 5 to 8 Kg/cm3 to survive packaging processes, the 
pressure of being pushed through the foil of the conventional blister packages and the 
physical handling of the tablet by patients. One way of overcoming the friability of 
porous tablets is to design a special packaging.  
1.7.4. Stability 
FDTs usually consist of highly water soluble excipients to enhance its ability to absorb 
water and thus disintegrate and dissolve faster, this in return makes FDTs very 
sensitive to moisture and thus can shorten their shelf life considerably (Malik et al., 
2012b). A typical shelf life of solid dosage form is 2 to 5 years (FDA, 2004). To ensure 
an acceptable shelf life, FDTs should be packaged by hermetically sealing under inert 
gas in protective blisters, impervious to air or any other gas under normal handling and 
shipment, following the World Health Organization (WHO) and International 
conference of harmonization (ICH) guidelines for packaging pharmaceutical products 
(WHO, 2002, ICH, 2009). 
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1.7.5. Drug taste and properties.  
One of the critical factors to patients’ acceptance and thus compliance is taste 
(Badgujar and Mundada, 2011). As FDTs are to be disintegrated and/or dissolved inside 
the patient’s mouth, it is important to ensure that while dealing with a bitter tasting 
drug, an ideal taste-masking technology is implemented (Badgujar and Mundada, 
2011). Nevertheless, it is also critical to ensure that the physiochemical properties of 
the drug and that of taste-masking compounds are compatible with the tablet’s 
properties (Badgujar and Mundada, 2011). This includes drug’s solubility, crystal 
morphology, particle size, hygroscopicity, compressibility and bulk density, as each 
may have an impact on the tablets final characteristics (Fu et al., 2004). 
1.7.6. Formulation process for manufacturing FDTs 
There are several different commercial technologies for manufacturing FDT. Table 1.4 
below presents an example of some of the commercial products that use FDT 
manufacturing technologies. Although they all, to some extent, meet the special 
requirements of the FDTs, none provide all desired components of an optimum FDT, 
specially the requirement of hardness and porosity. The current technologies have 
been reviewed in the following literature (Dobetti, 2001, Fu et al., 2004, Habib et al., 
2000, Sastry et al., 2000). Although the FDT manufacturing technologies differ from 
one another, they can be grouped under the general producing methods table 1.3; (Fu 
et al., 2004). The most dominant ones are: freeze-drying, molding and compressions. 
While freeze-drying produces porous tablets with instant disintegration (2-10sec) and 
enhanced dissolution (Fu et al., 2004), they lack mechanical strength and are very 
sensitive to humidity and hence require special packaging to ensure physical stability. 
Moreover, freeze-drying is a more expensive manufacturing method, making it less 
profitable for the pharmaceutical industry (Fu et al., 2004). Compression on the other 
hand is an ideal choice for the pharmaceutical industry, as it simply utilises standard 
tabletting equipment and materials. However the standard compression procedures 
used in tabletting are not designed to FDT specifications, as a result, FDTs produced by 
compression take much longer to disintegrate. This may not be a great problem in 
general, but may act as a barrier when it comes to the delivery of emergency medicine. 
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Several strategies have been implemented in the standard tabletting method in order 
to produce higher porosity while maintain the tablets strength. One of the strategies 
included several granulation methods that are thought to be more suitable for making 
FDT. These include wet granulation, dry granulation, spray drying and flash heating 
methods. Another was looking at varying the compressing pressure and applying after 
treatments (Fu et al., 2004).  
Table ‎1.3 Summary of technologies used to manufacture FDTs (Fu et al., 2004). 
Method Technology Company 
Freeze-drying process 







FlashDose Biovail (Fuisz) 
OraSolv /DuraSolv Cima Labs 
WOWTAB Yamanouchi 
Fast Melt Elan Corp. 
Flashtab Ethypharm 
AdvaTab /Ziplets Eurand 
OraQuick KV Pharmaceutical 
Pharmburst SPI Pharma 
Frosta Akina 
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Table ‎1.4 Examples of Marketted predominantly amorphous FDTs with details on drug solubility, BCS class and the technology used to manufacure the FDT (Fu et al., 2004). 
Brand name Application Drug 
Solubility of drug 
in water (µg/mL) 








Company FTD Technology Ref 
Claritn® 
RediTabs® 










Analgesic Paracetamol 12.65 x 10
3





 (Chahiyan et al., 















 (Nainar et al., 
2012, Chahiyan 
et al., 2014) 
Nurofen® 
Flashtab® 












3.56 20 in pH 9.5 II 
ETHEX 
Corporation 
OraQuick  (Maynard, 1997) 
Cibalginadue 
FAST 







 (Yalkowsky and 
Dannenfelser, 
1992) 
* In water if not specified. 
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1.8. Research aim and objectives: 
The aim of the research reported here was to develop two novel freeze-dried 
formulation platforms. The aim of the first formulation platform was to enhance the 
release of PWSD’s, and the aim of the second was to enhance the rapid disintegration of 
the formulation matrix, to release soluble drugs in biorelevant conditions to the buccal 
cavity. The purpose of investigating these two platform designs was to gain better 
insights into the underpinning science and applications of freeze-dried formulations 
destined for the oral & buccal delivery routes. 
1.8.1. Research Objectives 
1) To develop a simple freeze-dried formulation of a poorly water-soluble model 
drug by exploring the relationship between the concentration of the 
ingredients and the quality of the freeze-dried material. 
2) To transfer this design from ampoules into capsules. 
3)  To test the physical & chemical stability of these formulations. 
4)  To investigate the dissolution rates and compare to the marketed formulation. 
5)  To develop a fast disintegrating tablet that contains a model drug used as an 
emergency medicine. 
6)  To develop a simple buccal dissolution model to test the new design. 
7) To manufacture the novel FDT under GMP and prepare this for a clinical trial. 
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Chapter 2. Production and characterization of freeze-
dried nifedipine solid solutions 
The following chapter reports the investigation of the freeze-drying method used for 
the production of solid solutions, containing the class II BCS drug nifedipine dispersed 
in a solubilizing and stabilizing polymer PVP. The effects of varying the w/w % of drug 
in polymer on the physical characteristics of the freeze-dried materials are also 
described in detail. 
2.1. Introduction  
Patients are more accepting of medications delivered by the oral rout, thus making this 
delivery route more favourable for patients with regards to compliance(Andrews, 
2007, Marwaha et al., 2010, Jin et al., 2008). Moreover, pharmaceutical companies are 
interested in oral solid dosage forms, as they are more economically effective 
(Rasenack and Muller, 2002). Nevertheless for a drug to be absorbed into the 
circulatory system, it must first be in solution. Drugs with high permeability but low 
water solubility and dissolution rate, i.e. class II BCS drugs, have a limited oral 
bioavailability (Leucuta, 2014).  
Several techniques have been developed over the years to overcome the challenge of 
formulating PWSD’s into solid dosage forms (Pouton, 2006). One of the most effective 
techniques in enhancing the intrinsic solubility and dissolution rate is to molecularly 
disperse the drug in a solubilizing carrier, either by a heat melt or a solvent 
evaporation technique, and therefore rendering the drug into its amorphous form 
(Kaushal et al., 2004). However, despite the amorphous form’s high efficiency in 
enhancing solubility and dissolution rate, it is not widely used in the pharmaceutical 
industry (Kaushal et al., 2004, Van den Mooter, 2012). This is due to the lack of a 
robust, manufacture convenient, method of rendering PWSD’s into amorphous 
materials, without the exposure to devitrification inducing conditions, such as excess 
heat or humidity (Kaushal et al., 2004).  
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2.1.1. Freeze-drying 
One of the methods that have attracted the interest of many researchers, in the field 
of solid dispersions, is freeze-drying (Vessot and Andrieu, 2012). Which unlike other 
methods of producing solid dispersions, it does not expose samples to high 
temperatures and therefore lowers the possibility of inducing thermal based chemical 
degradation and in some instances crystallization (Craig et al., 1999, Bhugra and Pikal, 
2008). Freeze-drying is widely recognized by the pharmaceutical industry as an 
important preservation technique that can enhance the shelf life of pharmaceutical 
products (Craig et al., 1999, McPhillips et al., 1999, Tang and Pikal, 2004). Modern 
freeze-drying was developed in the second world war as a solution of overcoming the 
instability of serum, which was spoiling upon transport from the United States to 
Europe due to lack of refrigeration during transport (Meryman, 1976). The process of 
freeze-drying allowed serum to be rendered chemically stable and viable, without 
having to be refrigerated. More importantly, freeze-dried serum was very easy and fast 
to hydrate, which makes freeze-drying an effective technique to use in developing 
solid oral dosage forms intended for rapid hydration and therefore dissolution. 
2.1.1.1. Tert-butanol 
The conventional solvent used in freeze-drying feed solutions is water, this puts freeze-
drying at a great disadvantage when dealing with PWSDs. Depending on the solubility 
of the drug, large amounts of ice may need to be sublimed for very little mass of drug 
in the final product, which is not cost effective and hence unattractive to the 
pharmaceutical industry. Recent research has shown that organic solvents may also be 
used in combination with, or in place of water (Srinarong et al., 2010). One of the most 
successful organic solvents that have been used in freeze-drying is tert-butanol (TBA). 
The reason behind its success is the favourable physicochemical properties of TBA. TBA 
has a convenient freezing point of 24 oC (Teagarden and Baker, 2002b), this is 
beneficial for freeze-drying as maintaining TBA based feed solutions under freezing 
point is possible using the standard freeze dryers used for water based feed solutions. 
Additionally high freezing points can help with reducing the chance of sample collapse 
(Vessot and Andrieu, 2012). Furthermore, TBA has a high vapour pressure of 35.72 
mbar at 20 oC (Teagarden and Baker, 2002b). High vapour pressure leads to faster 
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sublimation (Vessot and Andrieu, 2012), this makes TBA a highly appropriate solvent to 
use in the process of freeze-drying. Not only is TBA a good solvent for water insoluble 
drugs, but it is also freely miscible in water. This is an important advantage as it allows 
water to be used as a co-solvent with TBA, to allow the mixing of TBA insoluble carriers 
with a water insoluble drug. Nevertheless commonly used water soluble carriers, such 
as PVP, are found to be freely soluble in TBA (Vessot and Andrieu, 2012). 
A major disadvantage to using TBA is its toxicity (McGregor, 2010). TBA is absorbed 
rapidly upon inhalation or oral ingestion and is then distributed to all tissues around 
the body. The elimination of TBA from blood is a slow process with half-life being 
dependent on the dose. Metabolism of TBA in the body is mostly by oxidation through 
2-methyl-1,2-propanediol to 2-hydroxyisobutyrate, which are the main metabolites 
found in urine (NSF-Toxicology-Services., 2003). Conjugation can take place, which 
leads to the presence of acetone in urine at high doses. Although a single dose of TBA 
has a low systemic-toxicity, it is however an irritant to skin and eyes. Large oral doses 
cause ataxia while repeated small exposures may induce dependence. The maximum 
accepted oral reference dose published by the NSF international is 1.0 mg/kg-day (NSF-
Toxicology-Services., 2003). Studies on rats show the target organs for TBA’s toxicity 
are the kidney and urinary bladder (NSF-Toxicology-Services., 2003). 
Using TBA as a solvent in the production of a solid oral dosage form may therefore 
introduce a health risk. However, considering that the industrial standard of residual 
solvent after freeze-drying is ≤ 1.0 %, the expected content of TBA to reach a patient is 
much lower than the maximum accepted oral reference dose published by the NSF 
international. Additionally, several authors found TBA or TBA/water freeze-dried 
systems to be useful in preparing clinically acceptable medicinal products on a large 
scale (Li and Deng, 2004, Cui et al., 2006). 
2.1.1.2. Freeze dryers 
Freeze dryers are instruments that subject feed solutions to controlled conditions of 
temperature and pressure, in order to optimise the rate of sublimation. While 
maintaining the same principles, freeze driers have greatly developed over the past 
few years, making the process of freeze-drying more practical and cost effective for 
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large scale manufacture (Tsinontides et al., 2004). Many university laboratories 
however use bench top freeze dryers for development purposes. A bench top freeze 
dryer, such as Lyotrap from LTE scientific, provides the bench top conditions of freeze-
drying which are low temperature (-50 to -40 oC) and pressure (≥0.1 mbar). Such bench 
top or laboratory freeze dryers are commonly used for developing new formulations 
(Crum et al., 2013, de Waard et al., 2008). Such freeze-drying cycles may then be 
transferred into large scale production freeze dryers (Kuu et al., 2005). 
The structure of a typical bench top freeze dryer (figure 2.1), for example the Lyotrap,  
consists of a condensing chamber (figure 2.1 a) which is a cylindrically shaped metal 
chamber (18.0 cm in diameter and 35 cm in length) located to the bottom of the 
freeze-drying shelf (FDS) (figure 2.1 c), on which samples are placed to be freeze-dried. 
The walls of the condensing chamber may be set to -55 oC using an inbuilt cooling unit. 
The condensing chamber is designed to act as a trap for all solidified solvent that 
sublimes from the samples while freeze-drying. 
The freeze-drying shelf (FDS) (figure 2.1 c) is cooled by conduction as it is in contact 
with the walls of the condensing chamber. Figure 2.1 illustrates how the FDS (diameter 
of 17.7 cm, thickness of 6 mm) stands on three metal rods (40 cm in height), which 
extend to the bottom of the condensing chamber. The position of the FDS is adjustable 
with regards to height, this gives some manipulation over the initial shelf temperature 
prior to pulling a vacuum. For example, if the samples are required to be introduced to 
FDS of a lower temperature, i.e. closer to the condensing chamber’s temperature, the 
FDS is simply lowered down to be closer to the condensing chamber. 
The chamber located directly above the condensing chamber (figure 2.1 b) is the 
drying chamber at which samples are freeze-dried. This chamber consists of a see-
through pressure resistant acrylic cylinder (26.6 cm in diameter and 30.5 cm in length) 
that is situated directly on top of the condensing chamber. The drying chamber is 
partially separated from the condensing chamber by the FDS, which contains sufficient 
number of holes (0.5 cm in diameter) to allow free movement of sublimed solvents 
from the drying chamber to the condensing chamber. Sublimation of solidified solvent 
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in samples is enhanced by creating a high vacuum in both chambers, this is achieved by 
connecting the condenser chamber to a vacuum pump (Fig 2.1 f-h). 
Simply by assembling the different parts of the set-up illustrated in figure 2.1, both the 
drying and condensing chambers become sealed, preventing external air from entering 
the chambers. However, the draining valve (figure 2.1 i), which is connected directly to 
the condensing chamber, may allow air flow into the freeze-drying chambers if 
opened. To allow the build-up of vacuum inside the freeze-drying chambers, the 
draining valve must be sealed and the vacuum pump must be turned on. This set-up 
(figure 2.1) is designed to reduce the temperature of the condensing chamber to a 
minimum of -55 ± 5 oC (measured via a built in digital thermometer). In addition the 
vacuum pump used with the setup in figure 2.1 is designed to reduce the pressure 
inside both the drying chamber to a minimum of 0.03 mbar (± 0.002 mbar) (measured 
via a built in digital pressure meter). However, the achievement of such conditions may 
be subject to the size of sample batch as well as the physicochemical properties of the 
solvent to be removed such as vapour pressure and melting temperature. 
 
Figure ‎2.1 Structural diagram of the Lyotrap freeze dryer. The structure of the lyotrap is based on LTE 
Lyotrap operating instructions (Ltd, 2014). This diagram was created using Microsoft PowerPoint.  
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2.1.1.3. Freeze-drying accessories  
Commonly freeze-drying feed solutions are held in freeze-drying vials (figure 2.2). Such 
vials can be designed to allow practical packaging of freeze-dried formulations while 
maintaining an efficient freeze-drying process by ensuring a sufficient surface area, 
allowing sublimation to undergo at a cost effective rate (Hibler et al., 2012). The design 
and thickness of vial walls ensures good conductivity, allowing sufficient heat flux, 
which is vital for the process of sublimation (Hibler et al., 2012). Freeze-drying vials 
come with useful accessories such as rubber stoppers that prevent the escape of large 
particles during freeze-drying whilst allowing sublimed solvent to be freely removed 
(figure 2.2 a). The same rubber stopper may be used to temporary seal the vial, at the 
end of a freeze-drying cycle, to prevent water vapour in ambient atmosphere from 
entering the vial (figure 2.2 b) (Barbaree et al., 1985). This is very important as water 
vapour can greatly influence the physical and chemical stability of freeze-dried 
products (Craig et al., 1999). Finally for long term storage, a metal cap may be crimped 
or screwed on top of the stopper rubber to ensure the vial is absolutely sealed 
(Barbaree et al., 1985). 
 
Figure ‎2.2 Freeze-drying vial in different closure positions. A typical volume of feed solution per vial is 2 
mL. This diagram was created using Microsoft PowerPoint. 
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2.1.1.4. Nifedipine  
To investigate the enhancement in drug solubility, dissolution rate, physical and 
chemical stability by a freeze-dried solid solution platform, a representative model for 
water insoluble drugs, nifedipine, was chosen to be incorporated into the formulation 
platform. 
Nifedipine (4-(2-nitrophyenyl)-2,6-dimethyl-3,5-dicarbomethoxy-1,4-dihydropyridine) 
Figure ‎2.3 (Ali, 1989), which was used as a model for water insoluble drugs in this 
research, is a class II BCS drug that is widely used in the treatment of cardiovascular 
disorders. It was first synthesised in 1966 by F. Bosset in search for orally active drugs 
for the treatment of coronary insufficiency, following its introduction as nifedipine 
(Adalat) in 1975, it since became one of the major cardiovascular drugs (Ali, 1989). The 
synthesis of nifedipine is based on the classical Hantzsch 1,4-dihydropyridine synthesis, 
i.e. the reaction of 1 mole 2-nitro-benaldehyde with 2 moles methyl acetoacetate and 
1 mole concentrated aqueous ammonia in refluxing methanol which leads to the 
formation of nifedipine (Ali, 1989). Although nifedipine has a high permeability, it is 
known to often show low bioavailability after oral administration, due to being 
practically insoluble in water (0.0058 g/L at pH:4, 0.0056 g/L at pH:7,0.0078 g/L at pH:9 
and 0.006 g/L at pH:13)(Ali, 1989), therefore making nifedipine a good model for 
hydrophobic drugs. The reason nifedipine is practically insoluble in water, is because of 
its flat molecular shape which allows close and organised stacking of molecules into 
high energy lattice crystals. The presence of delocalised benzene rings introduces pi to 
pi stacking which holds the crystal lattice together and leads to a high melting point, 
for nifedipine (172-174 oC), in comparison to a hydrocarbon molecule of a similar 
molecular weight. Furthermore nifedipine molecules consist of hydrophobic functional 
groups as presented in figure 2.1. Nifedipine has a Tg value of 46.2 ± 0.2 
oC (Miyazaki et 
al., 2007), which makes it a good model drug to illustrate the challenges of physical 
instability observed when dealing with small organic amorphous molecules with low Tg 
values. 
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Figure ‎2.3 Structure of nifedipine. Molecular mass: 346.3g, melting point: 172-174°C, crystalline form, 
very insoluble in water. Log P = 2, pKa = 2.6 (Shalaeva et al., 2008). Nifedipine exists as a yellow crystal 
with a melting point between 172-174 
o
C (Ali, 1989, Vippagunta et al., 2002, Mehta et al., 2002, Cilurzo 
et al., 2002). This figure was constructed using ACD/ChemSketch. 
Nifedipine is also a good model drug to illustrate the problems encountered with 
chemical instability of amorphous material, as nifedipine is a relatively sensitive 
compound. Exposure to light, high temperature and presence of oxidizing agents can 
cause nifedipine to degrade to predominantly two degradation products as illustrated 
in figure 2.2 (Ali, 1989). It was found that nifedipine partially decomposed within five 
minutes when exposed to day light and up to thirty minutes when exposed to bulb 
light (Ali, 1989). Nifedipine in solution is extremely sensitive to visible and ultra-violet 
light. On exposure to day light its UV-Vis spectrum changes very quickly (Ali, 1989). 
Under constant conditions the degradation of nifedipine is found to follow a first order 
kinetics, table 2.1. Working with nifedipine solutions in day light is challenging (Ali, 
1989) due to the effect of day light on its decomposition rate. Therefore it has been 
recommended to perform all experimental work with nifedipine solutions under red or 
yellow light. Nifedipine is only affected by light with wavelengths of < 450 nm. When 
placing nifedipine solutions in amber vials it was found to degrade by 10 % of its 
original value within the first 20min, where as in clear vials, nifedipine is found to 
degrade by 50 % for the same period of time (Ali, 1989). The photolytic decomposition 
of solid crystalline nifedipine is not substantial, this is thought to be due to the inability 
of light rays to deeply penetrate the crystalline surface (Ali, 1989). 
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 Table ‎2.1 Light degradation of dissolved nifedipine in alcoholic solutions, where irradiated by a different 
light sources (Ali, 1989). t10 and t50 time needed for 10% and 50% degradation respectively. 
Light source k min-1 t10 /min t50 /min 
Day light 0.015 7 45 
Light bulb 0.005 20 135 
Spectro-test (xenon lamp) 700-372 nm 0.798 0.5 3.5 
Spectrotest (xenon lamp) 700-471 nm 0.04 2.5 17 
 
Figure ‎2.4 In vitro degradation of nifedipine to nitrophenylpyridine (NIF II) and nitrosophenylpyridine 
(Ali, 1989). This figure was constructed using ACD/ChemSketch.  
An additional advantage of using nifedipine as a model drug in this research, is that it 
has been extensively investigated in the literature, and thus a verity of analytical 
methods have been established and published, of these references (Potter and Hulm, 
1988, Chan et al., 2004, Iqbal and Chan, 2015, Ali, 1989). Nifedipine does not require a 
controlled drug licence and is relatively cheap to buy, which makes it easy to obtain by 
university laboratories around the world. Another advantage to choosing nifedipine as 
a model drug for this research is that marketed forms are available for comparison.   
NIFII 
NIFIII 
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From the clinical point of view, nifedipine works by slowing the influx of calcium ions 
into vascular smooth muscles, muscle cells that are found in the walls of blood vessels, 
it does so by acting as a highly specific antagonist to the voltage-dependent Ca2+ 
channels present on the cell membrane of such muscles (Opie, 1987). Calcium ions are 
essential for the contraction of muscle cells and thus deprivation of calcium ions 
inhibits the ability to contract, therefore inducing vascular smooth muscles to relax 
(Opie, 1987). This results in vasodilation of blood vessels, specifically arteries as they 
are more targeted by nifedipine. The induced effect of nifedipine has two main uses; 
the relaxing and widening of arteries in the body, thus minimising resistance to pump 
blood around the body, lowering the work load on the heart to circulate blood. This 
reduces pressure within blood vessels, therefore making nifedipine a good drug to 
treat high blood pressure. Vasodilation of small arteries in the heart improves oxygen 
supply to cardiac muscles, these properties show that nifedipine may also be used to 
treat, manage and prevent angina, chest pain caused by insufficient oxygen supply to 
the heart (Opie, 1987, Crum et al., 2013, Garbacz et al., 2009, Snider et al., 2008, 
Huang et al., 2006, Vippagunta et al., 2002, Mehta et al., 2002, Cilurzo et al., 2002, 
Mehta et al., 1995, Fujii et al., Ali, 1989). A fast release nifedipine dosage form is 
advantageous as an emergency medicine to treat life threatening heart conditions. 
Nifedipine is also used to treat the symptoms of a circulatory disorder called Raynaud's 
phenomenon. In this condition the blood vessels in the hands go into spasm and 
contract excessively when the hands are cold (Opie, 1987, Snider et al., 2008). This 
causes the hands to go white, numb and painful. Nifedipine relaxes the peripheral 
arteries in the hands, causing them to widen and the blood circulation to the fingers to 
improve (Opie, 1987, Snider et al., 2008). 
The pharmacokinetic studies of nifedipine show that, independent of the method of 
administration, 70 to 80 % of the absorbed nifedipine is eliminated via urine. Majority 
of which, approximately 90%, was eliminated with in the first day of administration, 
giving nifedipine a half-life of 4 to 5 hours. Figure 2.5 below presents the metabolites 
of nifedipine (Ali, 1989).  
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Figure ‎2.5 Metabolism of nifedipine (Ali, 1989).  This figure was constructed using ACD/ChemSketch.  
As discussed in chapter 1, there are great stability benefits to using a large molecular 
weight carrier compared to a small carrier, due to the substantial increase it provides 
in glass transition as it can increase the physical stability of amorphous drug (Kaushal 
et al., 2004). Polyvinylpyrrolidone (PVP) is one of the most successful carriers due to its 
efficient and stabilising properties (Kaushal et al., 2004). Not only does PVP increase 
the glass transition of the amorphous drug when incorporated into the solid 
dispersion, PVP has been found to enhance the physical stability of amorphous drugs 
even further by forming hydrogen bond complexes that inhibit molecular mobility and 
therefore considerably reduce the rate of crystallization. The addition of 10% w/w of 
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PVP K40 to amorphous nifedipine can reduce the rate of drug crystallization by 2 to 3 
orders of magnitude, which has been attributed to hydrogen bond interactions 
between the carbonyl group of PVP and nifedipine (Aso and Yoshioka, 2006). Although 
many studies have concluded that PVP inhibits the recrystallisation rate of nifedipine 
through hydrogen bond interactions, rather than just by increasing the Tg value of the 
solid dispersion, very few of the related studies attempted using a PVP from the far 
lower end of the molecular weight range such as PVP K10 (K = 1000).  
PVP has shown to increase the solubility of nifedipine as well as many other water 
insoluble drugs. This is by firstly increasing the life of amorphous nifedipine and 
therefore, maintaining the enhanced intrinsic solubility. Secondly, as mentioned 
above, PVP was found to interact through hydrogen bonding with nifedipine, as well as 
other water insoluble drugs, this as a result prevents nifedipine molecules from 
recrystallizing and precipitating out of solution, instead the drug is maintained in 
solution as a soluble drug-polymer complex. PVP is therefore an ideal carrier to use in 
the formation of a nifedipine solid dispersion. Another advantage to using PVP is that it 
is freely soluble in TBA, which therefore means that no co-solvents are needed to mix 
PVP and nifedipine when forming feed solutions.   
PVP comes in a range of molecular weights, the most commonly used PVP molecular 
weights are K30 and K40. Despite the stability enhanced benefits of using the larger 
molecular weights of PVP, the dissolutions of lower molecular weights of PVP are 
much higher (Kaushal et al., 2004), therefore low molecular weight PVP are more fit 
for purpose when it comes to developing fast releases formulations.  
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Figure ‎2.6 Structure of a PVP monomer. The molecular weight of 1 monomer = 111.14 with one 
hydrogen bond acceptor per monomer. Tg = 65 to 123 
o
C (Buera et al., 1992). This figure was 
constructed using ACD/ChemSketch. 
Therefore aims of the study reported in this chapter were to establish a robust freeze-
drying method of producing a solid solution of nifedipine in PVP, to determine the 
effect of changing the w/w % of PVP on the physical state of nifedipine and to 
investigate any possible interaction.   
To fulfil the aims, the following objectives were set: 
1. Developing a robust and easily transferable method for producing un-collapsed 
freeze-dried cakes of amorphous nifedipine in PVP.  
2. Production of freeze-dried 0-100 w/w % range of nifedipine in PVP using the 
developed method. 
3. To characterise the physical properties of freeze-dried and physical mixtures of 
nifedipine and PVP by: 
a. Differential scanning calorimetry (DSC) 
b. Optical microscopy 
c. FT-Infra red spectroscopy   
4. To use DSC, optical microscopy and FT-IR data to evaluate phase behaviour in 
the different nifedipine – PVP systems.  
5. Investigating the presence of chemical interactions such as hydrogen bonding 
between nifedipine and PVP using FT-IR   
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2.2. Equipment & Materials 
2.2.1. Equipment 
Alcohol thermometer: G H ZEAL Ltd London UK, product number (PN): L3000, 
specification: +10 oC to -40 oC; Aluminium foil: Fisher scientific Ltd Leicestershire UK, 
Catalogue code (CC): 12369548, specification: 12 µm thickness 450 mm width x 75 m 
length; Analytical balance: Sartorius Ltd Surrey UK, Manufacture number (MN): 
ME215S Genius Series, Serial number (SN): 13507552, specification: 0.01 mg 
readability 60/210 g capacity; AtmosBagTM: Sigma-Aldrich Gillingham UK, product type 
(PT): Two hand non-sterile closure type made from polyethylene, SN: Z112828-1EA, 
Batch number (BN): 3110, specification: medium size; Capillary piston tips: Gilson Inc 
Bedfordshire UK, PT: sterilized, PN: CP1000ST, BN: B00696113S; Complete tear off 
aluminium vial seal: Adelphi health care packing West Sussex UK, PN: COTW20, BN: 
20110778; Crimper for solid aluminium seals: OPS Diagnostics LLC NJ USA, PT: 20 mm 
crimper, PN: SKU:KIHC20-18; Diamond tips: Gilson Inc Bedfordshire UK, PN: D1000, 
specification: 100-1000 µL; Diamond tips: Gilson Inc Bedfordshire UK, PN: D5000, 
specification: 1-5 mL; Differential scanning calorimetry: TA Instruments - A Division of 
Waters Ltd Herts UK, model: Q20, Instrument number (IN): 07051.902, SN: 0020-5023; 
Digital microscope camera: QImaging Surrey BC  Canada, PT: QICAM Fast 1394-12 bit, 
MN: 01-QIC-F-CLR-12, SN: Q23526; Drying Oven: Weiss Technik Loughborough UK 
(formed from two separate companies Weiss Gallenkamp and Design Environmental), 
CC: OVE.100.1106, SN: 89/07/212; Freeze-drying Fiolax® amber 6.0 mL vials: SCHOTT 
Müllheim Germany; PN: 20110876, BN: 6102393931; FT-Infra red spectroscopy: 
PerkinElmer Inc Seer Green UK, model: Spectrum UATR Two, SN: 92100; Immersion 
thermometer (76 mm): Medalcard scientific Ltd Christchurch UK, specification: +10 oC 
to +50 oC; Laboratory Freezer: Prior laboratory supplies Ltd Leicestershire UK, model: -
85 oC ultra-low freezer; Laboratory fridge/freezer: Liebherr UK Ltd Bedford, PT: 
Premium no frost; Laboratory microscopeLeitzDialux 22EB: Leica Microsystems UK Ltd 
Milton Keynes (predecessor previously known as Ernst Leitz GmbH), PT: 020-452.023 
equipped with polarizing filters, SN: 541006; Lambda plate in holder: Leica 
microsystems UK Ltd, Milton Keynes, PN: 11513908; Lyotrap freeze dryer: LTE 
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Scientific Ltd Greenfield UK, model: Lyotrap -55 oC condenser temperature, SN: 
J5467/5; Micro balance: Sartorius UK Ltd Surrey, MN: MC5, SN: 90802138, 
specification: 5.1 g capacity and 1 µg readability: 1; Microscope objective 10/0.25: 
Leica microsystems UK Ltd Milton Keynes, SN: 519864; Microscope objective 25/0.60: 
Leica microsystems UK Ltd Milton Keynes, SN: 519864; Microscope objective 40/0.7: 
Leica microsystems UK Ltd Milton Keynes, SN: 519747; Microscope objective 5/0.12: 
PZO, SN: 35516; Nickel: TA Instruments - A Division of Waters Ltd Herts UK, PN: 
T120323; Oil-Lubricated Rotary Vane Vacuum Pumps: BUSCH (UK) Ltd Telford, Type: R 
5 RA 0160 - 0302 D, SN: C0926000007; Platinum sample pans: TA Instruments - A 
Division of Waters Ltd Herts UK, PN: 952018.908, specification: 50 µL size; Polystyrene 
film: PerkinElmer Inc Seer Green UK, PN: L160-0239; Rubber vial stopper: Adelphi 
health care packing Sussex UK, PN: FDW20RT, BN: 20120010, specification: 20 mm 
diameter; Sonorex Ultrasonic bath: Bandelin electronic Berlin Germany, PT: RK510, 
PN: GB327.00034435.001, SN: D-12207; Stage micrometre: Leitz Wetzlar Deutschland 
Germany, specification: size of 2 mm and an interval of 0.01 mm; Stage micrometre: 
Graticules Ltd Kent UK, specification: size of 1 mm and an interval of 0.01 mm; 
Standard Aluminium Hermetic Lids: TA Instruments - A Division of Waters Ltd Herts 
UK, PN: 900793.901, BN: A3881401; Standard Aluminium Hermetic Pans: TA 
Instruments - A Division of Waters Ltd Herts UK, PN: 900794.901, BN: A3925701; 
Standard sample presser: TA Instruments - A Division of Waters Ltd Herts UK, PN: 
900680.902, SN: 6173; Thermogravimetric analyser: TA Instruments - A Division of 
Waters Ltd Herts UK, model: Q500, IN: 95300.901, SN: 0500-1858; Ultraviolet/Visible 
spectroscopy cells: PerkinElmer Inc Seer Green UK, Part No: B0631009; 
Ultraviolet/Visible spectroscopy: PerkinElmer Inc Seer Green UK, model: Lambda2S, 
Identification number (ID): 166351, SN: 6847; Vacuum desiccator: Smiths scientific 
Kent UK, PT: Vacuum with stopcock And perforated ceramic disc, CC: 262D/k/200; 
Vacuum pump: Edwards Ltd West Sussex UK, model: RV3, SN: 129449289; Variable 
volume M1000 pipette: Gilson Inc Bedfordshire UK, model: MICROMAN® 100 µL - 
1000 µL SN: GK05911; Variable volume P1000 pipette: Gilson Inc Bedfordshire UK, 
model: PIPETMAN classicTM 100 µL - 1000 µL, SN: K25103M; Variable volume P5000 
pipette: Gilson Inc Bedfordshire UK, model: PIPETMAN classicTM 100 µL - 5000 µL, SN: 
CJ58322; Vortex-Genie 2: Scientific Industries New York USA, MN: G560E, SN: 2-
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153495; Water bath-controlled temperature: Grant instruments Ltd Cambridge UK, 
PT: SS40-D2, SN: 899209003. 
All instruments including balances used in this project were validated on an interval of 
6 months or less as part of the college instrumental routinely checks. 
2.2.2. Materials 
Ethanol absolute: VWR International Ltd Leicestershire UK, CAS: 64-17-5, CC: 
20821.321, BN: 1213150524; Hydrochloric acid: Fisher scientific Ltd Leicestershire UK, 
CAS: 7647-01-0, PN: J/4320/24, CC: 10284480, BN: 1214805, specification: 1.0M meets 
analytical specification for BP, EP and USP; Indium: Alfa Aesar Heysham UK, CAS: 7440-
74-6, BN: 0160615, specification: purity ≥ 99.9999%; Methanol: Fisher scientific Ltd 
Leicestershire UK, CAS: 67-56-1, PN: M/4056/17, CC: 10675112, BN’s: 1289045, 
1402809, 1498902, 1414862; Nifedipine: Sigma-Aldrich Gillingham UK, CAS: 21829-25-
4, PN: N7634-5G, BN’s: 041M0056V, SLBD7789V, specification: ≥98% pure (HPLC); 
Oxygen-free Nitrogen compressed gas: British oxygen company Windlesham UK, SN: 
Kings/BHS/NS37/N2-4B; Polyvinylpyrrolidone: Sigma-Aldrich Gillingham UK, CAS: 
9003-39-8, PN: PVP10-100G, BN: BCBG5331V, specification: Average molecular weight 
of 10,000 g per mole, water content by Karl Fischer ≤ 5.0 %; Tert-butanol: Sigma-
Aldrich Gillingham UK, CAS: 75-65-0, PN: 360538-1L, BN’s: BCBG196IV, BCBH4856V, 
specification: ACS reagent ≥99.0%, water content by Karl Fischer ≤0.1%; Tert-butanol: 
Alfa Aesar Ward hill US, PN: 33278, BN: C25Z023, specification: ACS reagent ≥99.0%, 
water content by Karl Fischer ≤0.1%.  
2.2.3. Software 
QCapture Pro6.0: QImaging Surrey BC Canada; TA explorer: TA Instruments - A 
Division of Waters Ltd Herts UK; Universal Analysis 2000: TA Instruments - A Division 
of Waters Ltd Herts UK; PerkinElmer spectrum: PerkinElmer Inc Seer Green UK; 
OriginPro: OriginLab Silverdale Scientific Ltd Buckinghamshire UK. 
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2.3. Method 
2.3.1. Production of freeze-dried cakes containing nifedipine and PVP 
A w/w % range of freeze-dried cakes of nifedipine in PVP k10 were produced using 
tert-butanol (TBA) as a solvent. All production steps were performed in a dark room or 
in isolation from ambient light, using aluminium foil and amber glassware to protect 
nifedipine from photo degradation. 
2.3.1.1. Preparation of feed solutions for freeze-drying nifedipine and PVP  
A 100 ± 0.08 mL of 1% w/v stock solution of nifedipine in TBA was prepared by adding 
a pre weighed 1.0 g ± 1.0%   of nifedipine, in a plastic weighing boat, into a clean and 
dry 100 mL amber glass volumetric flask. The weighing boat was rinsed with liquid TBA 
(40 ± 0.5 oC), and the rinsing was poured into the volumetric flask containing the 
nifedipine. The developing solution was diluted to volume (100 ± 0.08 mL) with liquid 
TBA (40 ± 0.5 oC). The volumetric flask was then caped and sealed. The volumetric flask 
was then placed in a (40 ± 0.5 oC) water bath for 60 to 80 min, with a 20 to 25 min 
interval of 60 to 90 sec of vortex shaking (set to maximum shaking speed of 10 units), 
to ensure full dissolution of drug. A 100 ± 0.08 mL of 1% w/v stock solution of PVP K10 
in liquid TBA (40 ± 0.5 oC) was prepared using the same method. Both stock solutions 
were checked visually for any precipitation or un-dissolved matter, and were kept in 
the (40 ± 0.5 oC) water bath until no particles are visible. Both stock solutions were 
then transferred into individual, labelled 100 mL sample jars and maintained in a (40 ± 
0.5 oC) water bath to prevent TBA from solidifying, however the sample jars were kept 
closed at all times unless they were sampled from. As TBA is a very volatile liquid when 
at 40 ± 0.5 oC, the M1000 pipette was used to transfer the appropriate volumes of 
each stock solution (Table ‎2.2) into labelled, clean and dry, amber freeze-drying vials 
(figure 2.2) to make up the range of solutions. The amber vials were stoppered with 
rubber stoppers immediately after filling (figure 2.2 b) and were maintained at room 
temperature (18-25 oC). This process was repeated 3 times, in order to make 3 batches 
of the whole range, each starting with different stock solutions of nifedipine and PVP 
k10, therefore yielding a total of 30 vials.  
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An additional 20 vials, of 2 mL ± 1.60 µL pure TBA, were prepared using the same 
method.  
Table ‎2.2 Composition of feed solutions for the production of freeze-dried nifedipine in PVP solid 
dispersions (n=3). Volumes were pipetted using the M1000 MICROMAN® pipette, with the following 
systematic errors calculated by the manufacturer (100 ± 3.00 µL, 500 ± 5.00 µL & 1000 ± 8.00 µL) 
(Gilson.S.A.S, 2006).  
Target percentage of 
nifedipine in PVP after 
freeze-drying w/w % 
Target volume of 
nifedipine stock 
solution /mL 
Target volume of 
PVP k10 stock 
solution /mL 
Total target volume 
of solution in each 
FD vials /mL 
0 0.00 2.00 2.00 
10 0.20 1.80 2.00 
20 0.40 1.60 2.00 
30 0.60 1.40 2.00 
40 0.80 1.20 2.00 
50 1.00 1.00 2.00 
60 1.20 0.80 2.00 
70 1.40 0.60 2.00 
80 1.60 0.40 2.00 
90 1.80 0.20 2.00 
100 2.00 0.00 2.00 
2.3.1.2. Freezing solution  
Once the feed solutions for freeze-drying were prepared in a total of 50 vials (20 
containing pure TBA), the process of freeze-drying was started by holding the feed 
solutions at room temperature (18-25 oC) for 20 to 30 min, allowing the TBA based 
solutions to freeze . Following so the stoppers of all vials were readjusted to the upper 
position (Figure 2.1 a) thus allowing an escape route for the subliming TBA.  The 
samples were then stored in an external -70 to -80 oC freezer and held at such 
temperature for 10 to 14 hours. 
2.3.1.3. Preparing the Lyotrap freeze dryer 
Prior to the start of all freeze-drying cycles performed in this chapter, the following 
steps were taken to ensure an efficient, clean and safe freeze-drying was performed. 
The first step was to clean the condensing chamber from any ice build-up. This was 
achieved using the defrosting option on the control panel, after switching on the main 
power supply for the Lyotrap freeze dryer (figure 2.1 j). The drain valve (figure 2.1 i) 
was also opened to allow the escape of any water that resulted from melting the ice 
build-up in the condenser chamber. Once all the ice was melted and the water 
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removed, the walls of both chambers as well as the FDS were cleaned using a lint free 
cloth and 70% v/v ethanol in distilled water. The cleaning process, involved the 
removal of any residue or particulate matter from inside the two chambers. Cleaning 
the drying chamber involved separating the parts of the drying chamber and cleaning 
them individually, this included the drying chamber’s lid and rubber seals (diagram 2.1 
d &e). Once both chambers were cleaned, they were assembled to match the set-up in 
figure 2.1, while the FDS was positioned at 0 to 5 cm above the condensing chamber 
opening. Following so, it was checked that the oil level inside the vacuum pump is 
between the upper and lower limits (figure 2.1 k). The condition of the oil was also 
assessed based on its clarity; cloudy oil indicates the presence of impurities such as 
water or other residual solvents. This can reduce the pump’s efficiency, and therefore 
cloudy oil was changed with fresh oil by following the instructions described in the RV3 
vacuum pump manual (Edwards, 2010). Once cleaned, set up and checked for pump 
oil, the Lyotrap cooling unit was switched on allowing the condensing chamber to 
reach ≤ -30 oC, measured by the inbuilt thermometer. The FDS’s temperature on the 
other hand was measured using an alcohol laboratory thermometer. Once the FDS’s 
temperature reached ≤ -15 oC, the Lyotrap preparation stage was completed. 
2.3.1.4. Primary drying 
The 50 vials containing the frozen feed solutions, for freeze-drying, were transferred 
from the freezer and placed onto the ≤ -15 oC FDS. Vials containing nifedipine and/or 
PVP were situated in the centre of the shelf, away from the edges, and the vials 
containing pure TBA were situated closer to the FDS edges. The drying chamber was 
fixed in place immediately and the draining valve was ensured to be closed.  The RV3 
vacuum pump was switched on, and was set to high throughput mode, this sets the 
vacuum pump to constantly reduce the unified internal pressure of the drying chamber 
to eventually reaching the minimum possible pressure (which in the absence of any 
samples is 0.03 mbar (Edwards, 2010)). The vacuum pump and the cooling unit were 
left on for the entire duration of the primary drying stage: 144 ± 1h. The displayed 
temperature and pressure of the condensing chambers where monitored and 
recorded throughout the primary drying stage.   
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Once the primary drying stage was completed, the pump was switched off, and the 
vacuum was released using the drain valve which was connected to a nitrogen gas 
(oxygen free) cylinder, thus allowing the freeze-drying chambers and the vials to be 
refilled with nitrogen gas. Once the vacuum inside the drying chamber was released, 
the drying chamber was opened and the stopper, for each of the 30 sample containing 
vials, was pushed in immediately as shown in fig 2.2b. Once all vials were partially 
sealed with stoppers, they were transferred out of the freeze drier and into a plastic 
container at room temperature (18-25 oC). The remaining 20 empty vials were recycled 
by rinsing them with 70 % v/v ethanol in distilled water and drying them in a 40 oC 
drying oven. 
2.3.1.5. Secondary drying 
Samples were transferred into a vacuum desiccator containing P2O5 at ambient 
temperature (18-25 oC) and a reduced pressure of 0.69 to 0.86 bar, applied by an 
inbuilt facility vacuum system of BUSCH vacuum pumps. The vials were reopened and 
the stoppers where left in the upper position as shown in figure 2.2 a.  The vials were 
maintained in the reduced vacuum desiccator for the entire duration of the secondary 
drying stage 24 ± 1h (Srinarong et al., 2010).  
2.3.1.6. End of cycle packaging  
The 30 vials containing the freeze-dried samples were removed from inside the 
desiccator and placed inside a two-hand polyethylene AtmosBagTM which was flushed 
with nitrogen gas for 1 to 2min, and then filled with nitrogen gas by sealing all gas 
outlets within the bag. Using the inbuilt hand gloves within the nitrogen bag, the 
rubber stopper for each vial was pushed in to partially seal the vials (figure 2.1 b). 
Following so all samples were crimped with aluminium caps to fully seal the vials, using 
a 20 mm crimper, whilst inside the nitrogen bag (figure 2.1 c). All samples were stored 
away from light, in a vacuum desiccator containing P2O5 at ambient temperature (18-
25 oC) until analysis was performed (Zijlstra et al., 2007). 
All freeze-dried samples were analysed via a number of techniques, therefore 
extracting a sample out of each of the vials for analysis, was performed in a nitrogen 
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bag, to ensure that the remainder of the vial content was not subject to atmospheric 
water and thus may be used for other analytical techniques.  
2.3.1.7. Lyotrap validation 
The Lyotrap system was validated by running a short test run of empty drying and 
condensing chambers. This was achieved by simply by switching on the cooling unit (fig 
2.1 j), sealing the drain valve (fig 2.1 i) and allowing the condenser chamber enough 
time to fall below -30 oC, at which point the vacuum pump was switched on. The 
internal pressure of the drying chamber was allowed to decrease over a period of 
30min.  
After 30min of switching on the vacuum pump, a check list was filled to ensure all 
aspects of the freeze-drying system were performing as expected. This included: 
1- Displayed temperature reaching ≤-40 oC with a fluctuation limit of 2 oC. 
2- Displayed pressure reached ≤0.1 mbar with a fluctuation limit of 0.02 mbar   
On occasions, where the freeze dryer failed to perform as required, the freeze-drying 
cycle was ended and both the vacuum pump and the freeze dryer were examined for 
faults that may be the cause of the failure. A common cause of large pressure 
fluctuations was the presence of an air leak; such problems were fixed by replacing the 
appropriate parts and using the following references as the main guide (Edwards, 
2010, Ltd, 2014).     
2.3.2. Preparation of controlled samples 
Physical mixes of nifedipine and PVP with an equivalent w/w % range to the freeze-
dried samples were produced. For each w/w %, the required amount of nifedipine and 
PVP were weighed (table 2.2) and added to a clean and dry ceramic pestle and mortar. 
The mixture of powder were ground for 2 to 3min and were then transferred to 
labelled bijou glass vials and stored in a desiccator over P2O5. This was repeated 3 
times for each w/w %.   
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Table ‎2.3 Composition of physical mix controlled samples of NIF in PVP (n=3). The samples were 
weighed using an MC5 micro balance with a ± 1.0%.   
Target nifedipine in PVP 
w/w % of the final 
physical mix 
Target weight of 
nifedipine added / 
mg 
Target weight of 
PVP added / mg 
Total target weight 
of sample / mg 
0 0.00 50.00 50.00 
10 5.00 45.00 50.00 
20 10.00 40.00 50.00 
30 15.00 35.00 50.00 
40 20.00 30.00 50.00 
50 25.00 25.00 50.00 
60 30.00 20.00 50.00 
70 35.00 15.00 50.00 
80 1.60 0.40 2.00 
90 1.80 0.20 2.00 
100 2.00 0.00 2.00 
2.3.3. Thermal analysis 
Thermal analysis was used in this research to investigate the physical and thermal 
characteristics of different w/w percentages of nifedipine in PVP for freeze-dried 
(produced in section 2.3.1) and physical mixes (produced in section 2.3.2) (van Dooren 
and Müller, 1984). This included determining the content of crystalline nifedipine, 
determining the glass transition temperature of amorphous material and the melting 
temperature of crystalline material. Additionally thermal analysis was used here for 
determining the content of residual solvent.  
Furthermore, as part of developing the freeze-drying method, thermal analysis was 
used in the process of identifying the temperature at which feed solutions must stay 
below in order to avoid melting or collapse during freeze-drying, otherwise known as 
the collapse temperature (Tc). As there were a range of solutions with different 
nifedipine and PVP concentrations, the Tc value was only determined for the highest 
and lowest concentrations of nifedipine and PVP (Table 2.1).  
2.3.3.1. Differential scanning calorimetry (DSC) 
The DSC instrument used in this research was the heat flux differential scanning 
calorimeter Q20 TA instrument, which consists of a cooling unit, a heating unit and the 
main DSC chamber(van Dooren and Müller, 1984). The size of the endothermic melt 
peak was used to calculate the content of crystalline material present in the sample 
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(Fix and Steffens, 2004). The glass transition temperature (Tg) of samples as well as the 
primary glass transition temperature (T’g) of feed solutions were also determined by 
the literature recognized method (Haines, 2002).  
 
Figure ‎2.7 Components of the Q20 DSC instrument. Photos on the right contain an overview of the DSC 
Q20 instrument coupled with a cooling unit. Photo on the left contain an empty DSC chamber 
illustrating the 2 sensor cells. Photos in this figure were taken on the 20 Sep 2014 in lab number 5.12 
Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH of King’s college of London. 
2.3.3.1.4 Preparation of the DSC instrument 
Before switching on the DSC, a nitrogen gas (oxygen free) cylinder, connected to the 
DSC instrument, was turned on to a flow rate of 50 ± 5 mL/min. The system was 
purged with nitrogen gas for 30min prior to the start of any of the experiments, this 
ensures elimination of all moisture and oxygen from inside the DSC chamber to 
prevent engross of water by hygroscopic samples as well as oxidation upon heating 
(Haines, 2002). The nitrogen air flow was maintained at 50 ± 5 mL/min and the DSC 
instrument was switched on using the main power switch, followed by switching on 
the cooling unit.  
2.3.3.1.5 Preparing DSC pans 
The first step that was taken towards preparing DSC pans was to clean them. The 
presence of any contaminating particles on the inner or outer surface of either parts of 
the DSC pan (i.e. lid and pan fig 2.6) can act as an impurity and hence may influence 
the thermal properties of the sample. Therefore, pans with any signs of contamination 
were washed with 70% v/v ethanol in water and dried by placing inside a 50 to 60 oC 
oven for 5 to 10 min, the pans were then left to cool to room temperature (18-25 oC) 
for ≥ 10min before usage. 
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2.3.3.1.6 Creating pin holed DSC pans 
To ensure the safety of the DSC instrument, all DSC pans used in a thermal cycle that 
involved heating samples above 40 oC were pin holed manually to prevent the build-up 
of pressure inside the pan when heated. The pin hole was achieved by using a 
hypodermic needle with a radius of 0.005 mm to puncher a hole in the centre of the lid 
while reversed and rested on a cushion of clean tissues as illustrated in Figure ‎2.8. Thus 
allowing any burs to protrude out words from the pan.  
In the addition to serving as a safety precaution, the hole also helps in determining the 
w/w % of residual solvent present in samples, as the escape of residual solvent would 
be the dominant contributor to sample weight loss (McPhillips et al., 1999, Haines, 
2002, Grodowska and Parczewski, 2010). 
 
Figure ‎2.8 Puncturing an outward hole in the lid of a DSC pan to create a pin-holed DSC pan. This 
diagram was produced using Microsoft PowerPoint. 
2.3.3.1.7 Preparing and loading DSC Pans 
This method is particularly aimed for the analysis of freeze-dried material and 
therefore it is designed to prevent sample contact with atmospheric moisture, thus to 
prevent the ingress of large amounts of water, the DSC pans were typically loaded in a 
nitrogen atmosphere. This was achieved by firstly cleaning an AtmosBagTM using lint 
free tissue and 70% v/v ethanol in distilled water, then the required equipment (a pair 
of tweezers, a small spatula, pre weighed empty DSC pin holed pans, DSC pan crimper, 
a bijou glass vial and the sample sealed in a freeze-drying vial) were all placed inside 
the AtmosBag via the sealable mouth. The bag was then connected to nitrogen gas 
(oxygen free) cylinder, and the bag was flushed with nitrogen gas for 1 to 2 min. The 
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sealable mouth of the AtmosBag was then sealed and the bag was filled with nitrogen 
gas. Using the nitrogen bag in-built hands, the freeze-dried sample was opened gently 
and a 5 to 15 mg sample was extracted from the vial using the available clean spatula. 
The sample was then loaded into the DSC pan (bottom part) as illustrated in Figure ‎2.9. 
Care was taken to avoid contaminating the walls of the DSC pan as this may affect the 
integrity of the hermetic seal.  
 
Figure ‎2.9 Sample loaded inside a DSC pan must be contained within the inner circle of the pan. The lid 
is not included in this figure. This diagram was created using Microsoft PowerPoint.  
After placing the sample into the pan, the hermetic lid and the pan where cold welded 
(Figure ‎2.10) and sealed into a labelled sample jar whilst under nitrogen atmosphere. 
One empty pan was prepared using the same method; this pan was used as a 
reference pan. Once sample pans are prepared and sealed in nitrogen filled sample 
jars, they were taken out from the nitrogen bag and stored away from light and at 
room temperature (18-25 oC), until analysed, a duration that varied from 0 to 10 days. 
 
Figure ‎2.10 Two separate parts of a DSC pan, pan lid and pan bottom, on the left, forming a cold welded 
DSC pan on the right. This diagram was produced using Microsoft PowerPoint. 
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2.3.3.1.8 Inserting the DSC pans into the DSC chamber 
 It is important to note that before it was attempted to load DSC pans to the chamber, 
the DSC was set to maintain the experimental chamber at 25 ± 1 oC prior to starting 
the cycle. This ensures that the sample is not heated or cooled prior to the start of the 
experiment. To determine the weight of the sample, the full pan was weighed 
immediately before placing it into the DSC chamber. The sample weight was 
determined accurately by determining the difference in weight of the pan before and 
after the addition of sample. The resultant value was put into the details of the 
thermal cycle (under sample weight in mg) using software TA instrument explorer.  
2.3.3.1.9 DSC cycle and data collection 
Once the appropriate sample pan and the reference pan were placed on the 
corresponding sensor cells inside the DSC chamber, a thermal cycle appropriate to the 
aims of the experiment was programmed through the software TA instrument 
explorer.  
2.3.3.1.10 Thermal cycles to characterise physical state of solid samples of 
nifedipine in PVP 
All DSC cycles performed on solid samples such as the freeze-dried materials and 
physical mixtures (unless otherwise stated) were started at ambient temperature 25 
oC. The equilibration step allowed the DSC chamber to reach the specified 
temperature. This was followed by an isothermal step of 5min, which ensured that 
both the reference pan and the sample pan were at the same temperature, (taking 
into account the slight difference in weight between the two pans). Following the 
isothermal step a ramping step was initiated, where the temperature of the DSC 
chamber was increased to 200 oC at rate of 10 oC/min. Followed by a cooling step 
where the temperature was ramped to 25 oC at a rate of 10 oC/min, and lastly a last 
heating step where the temperature was ramped again to 200 oC at a rate of 10 
oC/min. 
This thermal cycle was applied on the complete w/w % range of freeze-dried and 
physical mixtures of nifedipine in PVP, in replicates of 3.  
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2.3.3.1.11 Thermal cycles to determine the primary glass transition of liquid feed 
solutions 
DSC cycles designed for liquid samples such as the TBA based solutions involved 
temperatures ≤ 40 oC and therefore the DSC pans used in these cycles were not pin 
holed. After placing the sample pan and the reference pan in the appropriate places 
inside the DSC chamber, the chamber was sealed and programmed to undergo the 
following thermal cycle: An equilibration step at 25 oC, followed by an isothermal step 
for 5min, followed by a cooling step where the temperature of the chamber was 
ramped to -30 oC at a rate of 10 oC/min, followed by a heating step where the 
chamber’s temperature was ramped to 40 oC at a rate of 10 oC/min.   
This thermal cycle was applied on TBA based feed solutions containing 0, 10 and 90 
w/w % of nifedipine in PVP, in replicates of 3. 
2.3.3.1.12 DSC validation 
Prior to using the DSC instrument, the efficiency of the DSC was verified by running 
two experiments. The first was a test of the heat flow baseline, this was performed by 
running a cycle of heating and cooling an empty DSC chamber from 25 oC to 200 oC and 
200 oC to 25 oC respectively, at a rate of 10 oC/min. This allowed the detection of any 
contaminants or residual precipitation, in the chamber, from previous usage. In the 
presence of any contamination, the resulting thermo-gram would show fluctuations in 
the heat flow baseline. In such case the DSC chamber was heated to 300 oC and cooled 
down to 25 oC, both, at a rate of 10 oC/min. Following so the chamber was cleaned 
thoroughly using a cotton bud soaked in 50% v/v ethanol in distilled water. Care was 
taken to avoid scratching the surface of the sensor cells. The chamber was then heated 
whilst open to ensure all residue solvent from the cleaning process was removed. The 
heat flow baseline test was then repeated to check that all contaminants were 
removed. 
Once the baseline was proven to be stable, showing no decrease or increase in heat 
flow, throughout the experimental temperature range (25-200 oC), the DSC was 
validated for temperature calibration. This was done by running a sample of Indium 
using the same method described in section ‎2.3.3.1.10 to determine the average onset 
Chapter 2. Production and characterization of freeze-dried nifedipine solid solutions 
Page | 83  
 
melting temperature of pure indium, where n=3. This was then compared to the 
reference melting temperature of indium 156.7 oC (Kawase et al., 1990). In the event 
that the determined onset of melting peak for indium deviates from the literature by 
more than 1.0 oC, the DSC instrument would have been re-calibrated by a TA engineer.      
2.3.3.2. Thermogravimetric analyser (TGA) 
The TGA used in this research is the TA instrument TGA Q 500, which may be 
programmed to heating the sample to a temperature of choice and at a rate of choice, 
whilst monitoring the weight of the sample(Xiao et al., 2014). TGA is usually used to 
determine the temperature at which compounds decompose, and the percentage of 
mass loss at each stage of sample collapse or decomposition. In this chapter the TGA 
was used to confirm the content of residual solvent in some of the freeze-dried 
samples(Grodowska and Parczewski, 2010).  
2.3.3.2.13 Preparing TGA  
The TGA was prepared 30 min prior to the start of experiments by purging the system 
with nitrogen gas at a flow rate of 10 mL/min. The flow of nitrogen was further 
adjusted within the instrument and was set to 90 mL/min for the sample chamber and 
10 mL/min for the reference chamber as recommended by the TA Q500 manual. Once 
the purging stage was complete, the weights of empty TGA pans were tarred via the 
TGA instrument. As the Q500 is equipped with a robotic arm, the pans were simply 
placed in numbered pan holders (Figure ‎2.11) and the TGA was programmed to tare 
the pans with corresponding numbered positions on the pan holder. Nevertheless due 
to the hygroscopic nature of freeze-dried samples, they were stored in nitrogen filled 
vials and only placed on the appropriate TGA pans immediately before their individual 
analysis. This is to avoid samples waiting in ambient atmosphere.   
2.3.3.2.14 Programing TGA cycles 
Once all pans to be used have been tarred, a TGA cycle was programmed into the 
software TA instrument explorer. As the instrument used does not come with a cooling 
unit, the cycle was limited to heating steps only. TGA cycles like DSC cycles are 
designed depending on the aims of the experiment as well as the thermal properties of 
the sample. For example determining the content of residual water in freeze-dried 
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samples required a particular cycle that consists of equilibration at 25 oC followed by a 
ramp step to 110 oC, rate of heating is kept at 10 oC per min unless other wises stated. 
It is important to note that when using the Q500, all experiments were force started 
immediately once the sample has entered the heating chamber, this is because the 
constant nitrogen air flow that is maintained inside the heating chamber can result in 
removing adsorbed residual solvent prior to the start of monitoring the weight of the 
sample. 
2.3.3.2.15 TGA calibration and verification 
The TGA was calibrated for temperature, by analysing a high purity magnetic standard, 
Nickel, for its sharp Curie point temperature, 358.28 oC (Legendre and Sghaier, 2011). 
This was achieved by firstly selecting the temperature calibration settings through the 
TA explorer software and erasing the previous temperature calibration values. 
Following so a thermal cycle was programmed to start with an equilibration step at 
250 oC followed by a ramp step to 450 oC at a rate of 10 oC/min. The purging conditions 
were set to the same conditions as all of the other standard experiments (section 
2.3.3.2.1.).  The curie material was placed in a clean tared TGA pan, and was inserted 
into the oven using the auto sampler. The cycle was started, and a magnetic bar was 
gently placed directly under the furnace. The magnetic bar’s position was adjusted in 
such a manner that a maximum weight gained was detected on the real time display of 
the sample’s weight. The magnetic bar was then fixed in that position, and the 
instrument was left to complete the experiment. Once the experiment was completed, 
the resulted thermos gram was analysed for the temperature onset of a sharp drop in 
sample weight, indicating the observed Curie temperature. The observed Curie 
temperature and the theoretical Curie temperature (358.28 oC) were put into the 
calibration temperature table within the TA explorer software.  
The TGA was also verified for weights using TA explorer software inbuilt calibration 
and verification program, a tared TGA pan and upper and lower range calibration 
weights supplied by the TGA manufacturer, TA. By following the instructions of the 
weight calibration program, the observed weights are compared to the theoretical 
weight of the individual calibration weights. In the case that the TGA fails the 
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verification test, it is automatically calibrated for on the bases of the TA supplied 
weights. 
 
Figure ‎2.11 Components of the Q500 TGA instrument. The Photo in this figure was taken on the 20 Sep 
2014 in lab number 5.12 Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH of King’s 
college of London. 
2.3.4. Fourier Transform infra-red (FT-IR) Analysis 
The instrument used to measure IR spectra in this research was a PerkinElmer 
attenuated total reflectance (ATR) FT-IR spectrometer with a Dura-sampler II-Diamond 
ATR. One of the main advantages of using this instrument in place of an IR 
spectrometer is that the FT-IR can easily analyse solid samples without destroying 
them or mixing them with nujol, which could possibility cause the physical state of the 
sample to undergo a phase transition. In fact FT-IR may be re-used in other analytical 
experiments (Iqbal and Chan, 2015) if the samples are not sensitive to the 
environment in which the experiment was performed in (i.e. sensitivity to ambient 
light, or atmospheric humidity). The FT-IR analysis performed in this research was 
particularly aimed at confirming the structural stability of the API as well as excipients 
after manufacturing and stability studies. Furthermore, comparing FT-IR spectra of 
freeze-dried formulations to spectra of individual excipients as well as controlled 
samples (simple physical mixes of drug and carrier) was extremely useful in 
understanding the drug-carrier interactions, such as the presence of hydrogen 
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bonding. A recent review on ATR FT-IR can be found elsewhere (Kazarian and Chan, 
2013).     
2.3.4.1. Experimental settings  
All FT-IR spectra were collected at room temperature (18-25 oC). The resolution was 
set to 4 cm-1 single scan as it is sufficient for determining the present chemical bonds 
(Zijlstra et al., 2007). Transmittance was recorded over the range 4000– 400 cm-1. The 
software Spectrum was used to interpret and correct produced spectra. Furthermore, 
the software was used to convert the transmittance spectra to absorbance spectra.   
2.3.4.2. FT-IR validation 
The calibration of FT-IR instrument was validated using a polystyrene film supplied by 
the manufacturer. Were the observed transition peaks in the developed spectrum of 
the polystyrene film was compared to the theoretical peaks based on the structure of 
polystyrene and a reference spectrum of polystyrene withdrawn from the literature 
(Devinder Gupta, 1995). 
2.3.5. Cross polarization optical microscopy 
An optical microscope slide of each of the samples of interest was produced by 
carefully placing an amount of 1 to 2 mg of the sample onto the surface of a glass 
microscope slide which was then covered with a cover-slip. In the interest of spreading 
the powder into a thin layer, a small amount of pressure and motion was applied to 
the cover-slip. The slide was then placed under the optical microscope instrument 
which was fitted with an imaging camera (QiFastCam), a cross polariser and a red 1 (λ) 
compensator plate to assess birefringence. Magnified pictures, of 5 X, 25 X and 40 X, 
were generated at ambient temperature and pressure using the QCapture Pro 6.0 
software (Carlton, 2011). Representative scale bars were added to all images using 
previously calibrated in built scale bars. 
2.3.5.1. Scale bare calibration  
For each microscope objective a scale bar calibration was performed to allow the 
drawing of scale bars that are representative of the magnification power. The 
calibration was performed using a 1 mm stage micro-meter (Graticules Ltd, Kent UK) 
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with an interval of 1.0 µm. The stage micrometre was placed under the microscope 
and images were taken through different objectives. Using the inbuilt calibration 
program and the developed images of the stage micro-meter, a scale bar was designed 
for each objective.   
2.4. Results 
2.4.1. Method development  
The freeze-drying method used in this chapter was monitored and tested to ensure 
that it does not expose the freeze concentrate solutions to melting or collapse 
conditions. This was performed by defining the edge parameters of failure, in other 
words the lowest temperature freeze-drying samples can reach before collapsing in 
the process, otherwise known as collapse temperature (Tc). Additionally it was 
important to determine the minimum length of time required for primary drying to 
produce room temperature (18-25 oC) stable freeze-dried cake. These conditions were 
defined specifically for the TBA based feed solutions with the highest and lowest 
nifedipine concentrations. 
2.4.1.1. Collapse temperature  
To determine Tc value for the freeze concentrate feed solutions, the primary glass 
transition must first be determined. DSC thermogram for each of 0%, 10% and 90 % 
w/w nifedipine in PVP solutions of TBA were produced. Figure 2.12 below presents one 
of the DSC thermograms developed.  
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Figure ‎2.12 Thermogram of a liquid sample of NIF and TBA dissolved in PVP. The sample was cooled to 
temperatures below -20 
o
C and heated at a rate of 10 
o
C/min. T’g determined to be -8.27 
o
C. All DSC 
thermograms in this thesis, unless stated, will have exothermic transitions upwards. 
As presented in table 2.4, the lowest T’g value is - 9.6 ± 0.1 
oC (n=3). From the 
literature, Tc values are estimated to be 2 
oC higher than the T’g (Tang and Pikal, 2004). 
Therefore the equivalent Tc value is estimated to be -7 
oC. As the Tc value is the 
temperature of failure, a safety temperature margin of 5 oC was implemented 
between the Tc and the target product temperature (Tp) during the primary drying 
stage, making the target product temperature to be -12 oC.  
To ensure that the products are maintained at the target Tp value, the FDS’s 
temperature was set to be at least 2 oC below the target Tp to account for the 
temperature difference between the shelf and the product. Shelf temperature was 
therefore ensured to be ≤ -15.0 oC to avoid sample collapse. 
Table ‎2.4 Average T’g determined by DSC of feed solutions containing highest and lowest concentrations 
of nifedipine in TBA. 0.9% w/v showed the lowest T’g value. DS of n=3.  
Target w/w percentage 
of nifedipine in PVP 
dissolved in TBA (1% 
w/v) 
Final target Conc. of 
nifedipine in feed 
solution w/v % 
Final target Conc. 
of PVP in feed 





0 0 1 -8 0.1 
10 0.1 0.9 -8 0.2 








(freezing of the sample) 
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Based on the outcome of this experiment, the FDS’s position was lowered, while 
measuring the temperature of the shelf using an alcohol thermometer, to a point 
where the shelf’s temperature was ≤ - 15.0 oC. The optimal position of the FDS was 
determined to be 0 to 5 cm above the condensing chamber. To further ensure the 
safety of the products while freeze-drying, several temperature measurements of test 
feed solutions were performed while on the FDS to ensure that the Tp value is ≤ -12 
oC 
when the displayed temperature of the condensing chamber is -40 oC or below .      
2.4.1.2. Temperature and pressure of freeze-drying chambers 
To ensure the temperature of the condensing chamber did not exceed -40 oC, as this 
can increase the TP to be above -12 
oC, the displayed temperature of the condensing 
chamber was recorded over the primary drying course (figure 2.13). Furthermore, the 
pressure inside the freeze-drying chambers was also recorded to allow better 
estimation of the required duration of primary drying. The temperature of the 
condensing chamber was maintained below -40 oC at all times (Figure ‎2.13-A). 
Pressure, of the drying chamber has shown to reach stability after 4 days of freeze-
drying. Thus the primary drying stage of all cycles was given a minimum length of 5 
days to avoid any sample collapse up on starting secondary drying. Figure ‎2.14 shows 
collapsed samples from a batch that was removed from the freeze dryer after 3 days of 
primary drying. Figure ‎2.15 on the other hand presents un-collapsed samples from a 
successful batch removed from the freeze dryer after 5 days of primary drying. 
Nevertheless, the efficiency of the 5 days primary drying is dependent on maintaining 
the sample size at a volume of ≤ 100 mL divided over ≥ 50 vials with a base diameter of 
≥ 22 mm, giving the frozen feed solutions a surface area of ≥ 38 cm2 per vial and a 
minimal total surface of 19 m2.  
It is also important to note that feed solutions with different nifedipine-PVP 
compositions may undergo different sublimation rates, therefore including all different 
compositions in this initial freeze-drying cycle insures that a primary drying stage of 5 
days was sufficient for the composition with the slowest sublimation rate.      
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Figure ‎2.13: (A) Temperature & (B) pressure of freeze-drying chambers monitored over the course of 
primary drying NIF in PVP TBA solutions. Batch contained 50 vials. 
2.4.1.3. Quality control of freeze-dried cakes 
As part of the developed method, a quality control step was implemented where 
freeze-dried batches were inspected for any sign of FD cake collapse. A successful 
freeze-dried product is usually expected to appear as a porous consistent cake. Signs of 
cracks or shrinkage could indicate macroscopic collapse (figure 2.14). As described in 
earlier sections, this is likely to be caused by insufficient primary drying duration, 
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which therefor fails to increase the Tc of the product to be above room temperature 
(18–25 oC) (Tang and Pikal, 2004). Alternatively, collapse can occur if the Tp was raised 
above the T’g during freeze-drying.   
 
Figure ‎2.14 Collapsed samples from a 3 day only primary drying batch. Collapsed samples show clear 
shrinkage signs; such as shrinkage away from the walls of the vial and towards the centre of the vial. All 
vials contain the same formulation 50% w/w nifedipine in PVP. 
2.4.1.4. Formulation composition 
Varying the ratio of NIF:PVP in freeze-dried formulations had a great impact on the 
quality of the cake, the w/w % of residual solvent and the w/w % of crystalline NIF 
present in the formulation. Therefore the impact of each of these variables is 
described in more detail in the following sections. 
2.4.2. Quality of freeze-dried cake 
Preliminary results showed that simply freeze-drying TBA solutions of pure nifedipine 
produced cakes of very poor quality (Figure 2.15). Alternatively freeze-dried cakes 
composed of 100% w/w PVP showed a high quality porous cake with no sign of 
shrinkage. Varying the ratio of NIF:PVP has shown to greatly affect the quality of the 
freeze-dried cake. A minimum of 30% w/w PVP is required to produce a porous freeze-
dried cake containing nifedipine (Figure 2.15).  
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Figure ‎2.15 Freeze-dried samples from a 5 day primary drying batch. The presented percentage indicates 
the w/w percentage of nifedipine in the overall weight of vial content. Left to right showing low to high 
w/w % of NIF in PVP.   
2.4.2.1. Residual solvent 
Freeze-dried cakes were tested for residual solvent by loss of weight method using 
differential scanning calorimetry (Grodowska and Parczewski, 2010). Figure 2.16 below 
presents average (n=3) w/w % residual solvent for each of the freeze-dried 
compositions, determined as the weight loss upon heating samples between 5 to 8 mg 
to 200 oC under nitrogen (Grodowska and Parczewski, 2010). The w/w % of residual 
solvent was calculated based on the accurately determined weight of the sample 
before and after heating, measured using a 6 digit figure. The same measurements 
were performed on physical-mix samples with the same number of replicates. To 
confirm accuracy of the DSC method, the residual solvent content for FD 50% NIF in 
PVP was also determined using the TGA. Results generated by the TGA method found 
to fall within the range of residual solvent content determined by the DSC method (13-
14 w/w %).  
Results have shown that freeze-dried and non-freeze-dried samples of nifedipine hold 
similar amounts of residual solvents of just below 2% w/w. Similarly, freeze-dried and 
non-freeze-dried pure PVP, hold similar amounts of residual solvent: 12.5% and 14.9% 
w/w respectively (Figure 2.16). The increment in the observed w/w % residual solvent 
in physical-mix was linear with increasing PVP concentration (w/w % of residual 
solvent = -0.132 [w/w % of NIF in PVP] + 0.138; R2 = 0.9, n = 33). This is expected, as for 
every mole or unit weight of PVP added to the physical-mix, the same amount of water 
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is added. Freeze-dried formulations on the other hand, showed a jump of 
approximately 7% in the residual solvent content between pure nifedipine and 90% 
w/w NIF in PVP, indicating that freeze-dried cakes of NIF-PVP hold more residual 
solvent. This may be as a result of their open and porous structure. 
 
Figure: ‎2.16 Average w/w % of residue solvent in FD samples and physical mix controls. (Error bars 
present standard error of n=3). 
2.4.3. Crystalline of nifedipine in formulation 
The physical state of the freeze-dried material was characterised using thermal, optical 
microscope and FT-IR techniques. The aim was to determine whether or not nifedipine 
was molecularly dispersed in PVP, and therefore determining the physical state of 
nifedipine in different freeze-dried compositions as well as the controlled samples. As 
a result the effect of w/w % of PVP on the physical state of freeze-dried nifedipine was 
investigated.     
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2.4.3.1. Analysis by differential scanning calorimetry 
The thermal properties of the individual components were investigated. Figures 2.17 
and 2.18 present the thermograms of pure as-received nifedipine and PVP 
respectively. Using the DSC developed method, it was found that nifedipine as 
received, when in the crystal form, melts at 172.4 ± 0.1 oC (Fig 2.17-first heat). 
Literature value of nifedipine melting onset ranges from 172-174 oC (Wang et al., 
2005). Nifedipine can exist in three mono-tropically related modifications, modification 
I, otherwise referred to as α-NIF (Gunn et al., 2012), which is thermodynamically stable 
at room temperature, was reported to melt in the range 169-173 oC. Modification II or 
β-NIF, m.p. 161-163 oC, and modification III or δ-NIF, m.p. 135 oC, (Gunn et al., 2012) 
are metastable modifications. DSC thermograms performed in this study have shown 
that as received nifedipine is present as α-NIF, later confirmed using FT-IR. However, 
second heat thermograms of as received nifedipine show an additional small peak at 
162.9 ± 0.2 oC (Fig 2.17), this peak is attributed to β-NIF (Wang et al., 2005). The 
second heat thermogram of NIF, also shows a slight endothermic drop in the bassline 
at 46.7 ± 0.3 oC, indicative of the Tg of amorphous nifedipine. Literature Tg of nifedipine 
equals 46.2 ± 0.2 oC (Miyazaki et al., 2007). The second heat also shows an exothermic 
peak at 100.9 ± 0.2 attributed to the recrystallization of amorphous nifedipine.  
First and second heat thermograms for the as received PVP (Fig 2.18) appear different. 
A large broad endothermic peak is observed with an onset of 53.1 ± 8.3 oC and peak 
max at 98.03 ± 9.2 oC on the first heat thermogram. This peak is diminished in the 
second heat, thus attributed to the evaporation of residual water retained by PVP. 
Weight loss of sample after first heat (14.9 ± 0.6% w/w) further supports this 
conclusion. Due to this broad solvent peak, the glass transition of PVP K10 is only 
apparent in the second heat thermogram 146.06 ± 2.8 oC. Comparison of the observed 
Tg for PVP K10, of “zero” moisture content, with data reported by other authors was 
not possible as the literature values for Tg of dried PVP K10 vary widely from one study 
to another (65.8-123.8 oC) (Buera et al., 1992). This could be a result of differences in 
the method of drying and the rate of heating. The average molecular weight 
distribution and the cross-linking degree will also influence Tg (Buera et al., 1992).  
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Figure ‎2.17 First and second heat thermogram of nifedipine as received. Heating and cooling rates were 




Figure ‎2.18 First and second heat thermogram of PVP K10 as received. Heating and cooling rates were 




Chapter 2. Production and characterization of freeze-dried nifedipine solid solutions 
Page | 96  
 
Freeze-dried formulations and physical-mix were analysed using the same method as 
nifedipine and PVP above (Fig 2.19 and 2.20 respectively). First-heat thermograms of 
freeze-dried formulations in figure 2.19 show the melting peak of nifedipine to 
broaden and diminish as the w/w % of PVP increases in the formulation, therefore 
indicating a decrease in the crystallinity of the formulation. The melting peak further 
disappears completely from thermograms of freeze-dried formulations containing ≤ 
50% w/w NIF in PVP, therefore forming predominantly amorphous freeze-dried 
formulations. 
 
Figure ‎2.19 First heat of freeze-dried formulations. DSC cycle include a ramp from -10 to 190 ºC at a rate 
of 10 ºC/min. Each trace is labelled with the percentage of nifedipine w/w of the formulation it 
represents.  
To accurately determine the content of crystalline nifedipine in formulations, a DSC 
assay based on enthalpy peak area (PA) was developed (Fig 2.21) for quantifying 
crystalline NIF in PVP. First-heat thermograms of physical-mix formulations (Fig 2.20) 
were used as calibration standards where the melting PA of nifedipine in the range 
140-180 oC was measured for each of the equivalent nifedipine concentrations (n=3).   
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Figure ‎2.20 First heat of physical-mix formulations. DSC cycle include a ramp from -10 to 190 
o
C at a rate 
of 10 
o
C/min. Each trace is labelled with the percentage of nifedipine w/w of the formulation it 
represents.  
PA’s were recorded as enthalpy J/g using software TA universal analysis. Once 
recorded, the PA’s were corrected for true sample weights by subtracting weigh of 
residual solvents. An example is provided below: 
Example of PA correction for true sample weight (10% w/w NIF in PVP physical-mix) 
Sample weight including residual solvent (RS) = 2.649 mg 
Observed PA (for sample weight containing residual solvent) = 5.183 J/g or 13.730 x10-
3 J for 2.649 mg of sample   
Sample weight after heating (true sample weight) = 2.340 mg 
Corrected Enthalpy = 16.995 x10-3 J for 3.380 mg of sample or 5.865 J/g  
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Figure ‎2.21 DSC assay for crystalline NIF, showing a linear relation between w/w % of crystalline 
nifedipine in PVP (x-axis) and enthalpy J/g (y-axis) measured in the range 135 – 185 
o
C. (Error bars 
represent the standard error of n=3).  
The limit of detecting and quantifying crystalline nifedipine using the melting peak 
determined via the DSC method was calculated based on the ICH calibration curve 
method (ICH, 1996). The standard deviation of y-intercept of regression line, otherwise 
known as standard error of the regression, was calculated by performing regression 
analysis using Microsoft excel (table 2.5). Limit of detection (LOD) and limit of 
quantification (LOQ) are in w/w % crystalline nifedipine in PVP as presented in table 
2.5 below. 
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Table ‎2.5 LOD and LOQ of crystalline nifedipine in PVP (w/w %). 
Parameter Source or equation Value 
Slope (𝑆) From figure 2.21 1.01 
Standard error of intercept (𝑆𝐸) From figure 2.21 1.57 








The developed DSC assay was used to determine the w/w percentage of crystalline 
nifedipine in freeze-dried formulations and the equivalent melt-cooled formulations 
formed in DSC second heat. Figure 2.22 below presents a phase diagram of the effect 
of changing the composition on the crystallinity of the formulation.    
 
Figure ‎2.22 Crystallinity phase diagram for freeze-dried samples at first and second heat. 
Recrystallization peak, if present, was deducted from melting enthalpy to determine original amount of 
crystalline nifedipine in freeze-dried samples (Error bars represent the standard error of n=3).  
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2.4.3.2. Cross Polarization microscopy. 
Crystals have a specific property of bending polarized light travelling through them, 
this result in decreasing the speed of light leading to an effect known as birefringence. 
A full review on this topic can be found in the following reference (Carlton, 2011). This 
property of crystals allows them to be distinctively visible when observed under cross 
polarized microscopy. Amorphous material on the other hand, causes light, travelling 
through them, to scatter. Therefore, in the presence of polarized light, a microscopic 
image of an amorphous material would show no sign of birefringence. This technique 
was used in this study to qualitatively analyse freeze-dried formulations. Table 6 below 
presents the images taken of different freeze-dried compositions using unpolarised 
and polarized light. A difference was observed between pure amorphous PVP and 
crystalline nifedipine polarized images. The absence of birefringence indicates the 
absence of crystalline material. Freeze-dried formulations ≤50% w/w NIF in PVP 
appeared to be free from crystalline material. Images taken with polarized light for 
≥70% w/w NIF in PVP showed a gradual increase of formulation crystallinity as the w/w 
% of nifedipine increases (replicate images of n=3 show similar results). Nevertheless, 
quantitatively comparing crystallinity of different formulations was difficult to achieve, 
as many factors can influence the number of crystals observed, such as mass and 
thickness of sample.   
Table ‎2.6 Polarized and unpolarised light microscopy images of FD formulations   
Images taken with unpolarised 
light 
Images taken with polarized light Description 
  
PVP as-received 
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Images taken with unpolarised 
light 








































Chapter 2. Production and characterization of freeze-dried nifedipine solid solutions 
Page | 102  
 
Images taken with unpolarised 
light 
Images taken with polarized light Description 
  





































2.4.3.3. FT-IR Amorphous and crystalline content  
FT-IR is another analytical tool that was explored in identifying amorphous and 
crystalline nifedipine (Chan et al., 2004, Hishikawa et al., 1999). Presented below 
(Figure ‎2.23) is an FT-IR spectrum of pure nifedipine as received, pure PVP as received, 
pure amorphous nifedipine (as a result of heat-melt), 50% w/w NIF in PVP freeze-dried 
formulation (labelled NIF in PVP FD) and 50% w/w NIF in PVP physical-mix (labelled NIF 
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in PVP PM). FT-IR spectrum of nifedipine as received has shown the main 
characteristics of the thermally stable α-NIF spectrum reported by (Chan et al., 2004), 
which exhibits relatively low C=O (doublet centred at 1680 cm-1) and N-H (3328 cm-1) 
wavenumbers, compared to other nifedipine polymorphs. This is due to strong 
intermolecular hydrogen bond interactions between the ester carbonyl and the NH 
group of the adjacent molecule. (Chan et al., 2004) Pure amorphous nifedipine was 
created by melting nifedipine in a DSC pan and cooled rapidly. The FT-IR spectrum of 
amorphous nifedipine shows distinct difference to the crystalline nifedipine in the 
sharpness and definition of peaks, specifically in the 1700 cm-1 region, this is 
characteristic of amorphous material (Grisedale et al.). The (N-H) was also shifted to 
the left indicating less or weaker intermolecular hydrogen bond interactions in 
amorphous nifedipine.  
Freeze-dried nifedipine in PVP (Fig 2.23) also shows clear distinctive IR features from 
the crystalline physical-mix nifedipine in PVP, with the most pronounced differences 
also found in the (N-H) and the carbonyl regions. The single peak observed in the (C=O) 
region in the freeze-dried formulation spectrum is distinctive of molecularly dispersed 
amorphous nifedipine (Iqbal and Chan, 2015). This distinctive peak is seen to shift to 
1678 cm-1 in the crystalline physical mix, and therefore may be used as a marker to 
monitor the crystallization of nifedipine in freeze-dried formulations. However the 
1678 cm-1 band is thought to be affected by the water band bending mode absorption 
at ~1640 cm
-1 (Iqbal and Chan, 2015). Additionally, PVP was shown to absorb in the (N-
H) and carbonyl regions (Fig 2.23), which made these regions difficult to use to semi-
quantitatively monitor crystalline nifedipine in freeze-dried formulations. 
Nevertheless, the shape and location of peaks in these regions (N-H and C=O) may be 
used to qualitatively analyse the physical state of nifedipine in freeze-dried 
formulations. Figure 2.24 presents the N-H and carbonyl regions of the full range of 
freeze-dried formulations. A clear change in the shape and location of the C=O peak 
(1660 – 1680 cm-1) was observed at 70 and 80% w/w NIF in PVP. Due to the presence 
of strong and broad PVP absorbance in the N-H region, it is very difficult to monitor the 
change in the N-H peak as the composition of freeze-dried formulations ranges from 
10-90 w/w %.          
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Another region that was observed to be distinctively different between molecularly 
dispersed amorphous nifedipine in PVP and the crystalline nifedipine in PVP physical-
mix is the 800-700 cm-1 out of plane δ(C-H) vibration of the ring regions, where PVP 
has very little absorbance effect (Fig 2.23 and 2.24). Pure crystalline nifedipine shows 
distinctive peaks at 793, 762 and 744 cm-1 which are also shown in crystalline 
nifedipine in PVP physical-mix (Chan et al., 2004, Iqbal and Chan, 2015). Pure 
amorphous nifedipine on the other hand, shows distinctive peaks at 784 and 754 cm-1 
which are also observed in freeze-dried nifedipine in PVP. Peak located at 711 cm-1 is a 
common peak present in all nifedipine containing spectra, independent of the physical 
state of nifedipine, and may therefore be used as an internal standard for quantitative 
analysis (Iqbal and Chan, 2015). Iqbal and Chan (2015) was reported to  using the ratio 
of the crystalline indicative 762 cm-1 PA against the standard PA at 711 cm-1 to semi-
quantify crystalline nifedipine in molecularly dispersed nifedipine formulations. The 
absence of the 762 cm-1 peak indicated the absence of crystalline nifedipine on the 
outer surface of the sample, and thus samples showing PA rations ≤0.05 where 
considered, by Iqbal and Chan (2015), predominantly amorphous.  
Unlike the study performed by Iqbal and Chan (2015), this study has shown all freeze-
dried formulations do not show a peak at 762 cm-1. However, a clear change in the 754 
cm-1 peak shape accompanied with a slight change in peak position was observed 
(figure 2.25). While amorphous NIF shows a single broad peak at 754 cm-1, crystalline 
NIF shows two peaks either side this wave number, 744 cm-1 and 762 cm-1. The gradual 
change from amorphous to crystalline NIF, causes the amorphous 754 cm-1 peak to 
gradually change in shape where for example, freeze-dried 90% w/w NIF in PVP shows 
a clear shoulder towards the 762 cm-1 crystalline peak, which maybe early signs of 
nifedipine crystallization, such as the formation of nifedipine dimers in small clusters.  
 To semi-quantify the change in peak shape, peak asymmetry was calculated for each 
formulation (n=3), after adjusting spectra bassline by subtracting pure PVP spectra. 
The peak asymmetry was calculated using the HPLC frequently used equation (Peak 
Asymmetry = B/A at 10% peak height) where B and A are the left and right half widths 
of the peak respectively. Using OriginPro software, peak asymmetry was calculated 
and plotted for the composition range of the freeze-dried formulations (Figure 2.26). 
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Freeze-dried 10% w/w NIF in PVP was not included, as peaks in the range 800-700 cm-1 
were very small and difficult to integrate. Figure 2.26 shows the 754 cm-1 peak 
asymmetry of ≤ 60% freeze-dried NIF in PVP formulations to be in the range 0.9-1.1, 
which is considered asymmetrically acceptable by HPLC ICH guidelines (Deepti and 
Pawan, 2013). However, changing the composition of the freeze-dried formulation to 
contain ≥ 70% NIF in PVP resulted in a sharp increase in the peak asymmetry, 
indicating a large change in the shape of peak and thus strong early signs of small 
clusters of crystalline nifedipine.             
 
Figure ‎2.23 FT-IR spectra of crystalline nifedipine as received, amorphous nifedipine (produced by heat 
melt), PVP  as received, 50% w/w crystalline NIF in PVP as physical-mix (NIF in PVP PM) and Freeze-dried 
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Figure ‎2.24 N-H (3288-3330 cm
-1
), Carbonyl (1660-1680 cm
-1
) and out of plane δ(C-H) vibration of the 
ring (800-700 cm
-1
) regions of the FT-IR spectrum for the full range of freeze-dried NIF in PVP 
formulations compared to the 90% w/w NIF in PVP physical-mix of crystalline NIF in PVP. All percentages 
listed are of NIF in PVP. FT-IR measurements were repeated to ensure data reproducibility (n=3). 
    
Figure ‎2.25 FT-IR spectra, (800-700 cm
-1
 only) of freeze-dried formulations 20-100% w/w NIF in PVP. 
Peak symmetry change at 754 cm
-1
 (peak distinctive of amorphous nifedipine) was examined. 90% w/w 
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Figure ‎2.26 Monitoring NIF crystallinity in freeze-dried formulations using FT-IR peak symmetry at 754 
cm
-1
. A change in peak symmetry is indicative of a change in physical state, as amorphous NIF presents a 
single broad and asymmetric peak at 754 cm
-1





, the gradual change from the broad amorphous peak to the double crystalline peaks can 
be quantitatively measured through peak symmetry measurements. Error bars represent standard error 
of n=3.  
2.4.4. Drug Polymer interaction 
2.4.4.1. FT-IR intermolecular bonding 
FT-IR results show the N-H peak in pure amorphous nifedipine 3342 cm-1 (Fig 2.27 A) 
shifts to 3288 cm-1 in freeze-dried formulations of nifedipine in PVP. Indicating a strong 
intermolecular hydrogen bonding between the N-H group of nifedipine and the 
carbonyl group in PVP (Rumondor et al., 2009). Equally the shift of the C=O carbonyl 
group from 1681 cm-1 in pure amorphous nifedipine to 1660 cm-1 in freeze-dried 
formulations (Fig 2.27-B) is another strong indication of hydrogen bonding interactions 
between the carbonyl group of PVP and the N-H group of nifedipine (Rumondor et al., 
2009) (Fig 2.28).  
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Figure ‎2.27 (A) N-H and (B) Carbonyl regions of a range of nifedipine containing samples to demonstrate 
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This drug-polymer interaction observed through FT-IR analysis has shown to be 
present in both freeze-dried formulations as well as heat-cycled formulations resulted 
by melting freeze-dried samples by DSC. Melting a cooled (heat-melt) sample for the 
second time has shown not to affect the drug-polymer interactions nor degrade the 
drug at a detectable level using FT-IR analysis (Fig 2.27). However stability indicating 
HPLC assay for NIF will be used to further confirm the effect of heating on the chemical 
stability of NIF in following chapters (Chapter 3).    
 
Figure ‎2.28 A proposed model for the intermolecular hydrogen bonding between nifedipine and PVP 
based on the IR spectra (Fig 2.27). Hydrogen bonds are presented in red. This figure was constructed 
using ACD/ChemSketch.  
2.4.4.2. Glass Transition 
The experimentally determined glass transition temperature (Tg) of pure amorphous 
nifedipine, created by heat-cooling freeze-dried pure nifedipine in the DSC, was 
determined to be 46.7 ± 0.8 oC, which as would be expected, is similar to the 
determined Tg of amorphous nifedipine prepared by heat-cooling as received 
nifedipine, in the DSC, (46.7 ± 0.3 oC). Pure amorphous PVP k10, prepared from freeze-
dried pure PVP, showed a reproducible Tg of 151.8 ± 1.5 
oC, slightly higher than the 
determined Tg of PVP as received 146.1 ±2.8 
oC, both of which determined via second 
heat DSC. (Literature values listed in section 2.4.2.3.1).  
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Dispersing the two components into a continuous phase has shown to result in a 
material with a single compensated Tg value, which as shown by figure 2.29 is 
dependent on the ratio of both components. One of the most used models to study 
the dependence of Tg on the composition of binary dispersions is the Gordon-Taylor 
equation (Brostow et al., 2008): 
 
 
𝑇𝑔 =  
𝑥1𝑇𝑔1 + 𝐾𝐺𝑇(1 − 𝑥1)𝑇𝑔2
𝑥1 +  𝐾𝐺𝑇(1 − 𝑥1)
 Equation ‎2.1 
Where Tg1 and Tg2 are the experimentally determined glass transition temperatures of 
pure component 1 and 2 respectively, x1 is the mass fraction of component 1, KGT 
(referred to as Gordon-Taylor’s constant) is the constant ratio of thermal expansion 
coefficient difference between a glassy and a liquid state of the components 1 and 2 
(Seo et al., 2006), i.e. the unequal contributions of components 1 and 2 to the Tg of the 
binary solid dispersion (Brostow et al., 2008, Seo et al., 2006). KGT can sometimes be 
approximated to the ratio of the density of the 2 components (Royall et al., 1999). 
Finally Tg is the resulting glass transition temperature of the binary solid dispersion 
(Brostow et al., 2008). The Gordon-Taylor model assumes perfect volume additivity 
(Royall et al., 1999), where the size and shape of the 2 components, in the binary mix, 
is unchanged (Seo et al., 2006); thus the packing fraction of the 2 components in the 
binary dispersion remains the same with no intermolecular interaction between the 2 
components (Royall et al., 1999).   
Figure 2.29 below, shows the experimentally determined Tg’s for each of the freeze-
dried NIF-PVP cakes. Despite the FT-IR based evidence of drug-polymer interactions 
observed in freeze-dried and hot-melt formulations of NIF in PVP, the observed 
experimental Tg values were found to fit the Gordon Taylor equation (Fig 2.29) whilst 
KGT equalled 1.02. The KGT value was correlated to the strength of the interaction 
between the 2 components (Lu and Weiss, 1992).   
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Figure ‎2.29 Average Tg of heat cycled samples of nifedipine in PVP. The data was fitted with a Gordon 
Taylor equation using OriginPro. (Error bars represent standard error of n=3).   
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2.5. Discussion 
A freeze-drying method was developed to produce molecularly dispersed amorphous 
nifedipine in PVP freeze-dried formulations. The freeze-drying cycle was designed to 
provide the needed conditions to ensure a porous freeze-dried cake is produced with 
no signs of shrinkage or melting. The freezing stage is one of the critical steps in the 
process of freeze-drying. Franks and Auffret (2008) have described slow cooling rate as 
a critical step in the creation of large ice crystals which later have a positive effect on 
the rate of sublimation. Taking this into account, the TBA based feed solutions in this 
study were left to crystalize just below room temperature (18-24 oC) to ensure the 
formation of large TBA solid crystals. Furthermore, Tang and Pikal (2004) described the 
disadvantage of using a precooled shelf as a mean to freeze feed solutions, as it was 
shown to give large heterogeneity in cooling between vials. This therefore supports the 
initial freezing step performed at stable room temperature. Once feed solutions have 
crystallized, they were cooled further to -80 oC to ensure product temperature is 
below collapse temperature and thus avoid sample melting or collapse during freeze-
drying (Tang and Pikal, 2004). 
Determining the primary drying end point was directly related to the sublimation 
process of TBA. Tang and Pikal (2004) described how the end point of primary drying 
may be determined by chamber pressure. Once all ice crystals have sublimed, or in the 
case of this study, TBA crystals, the vapour composition in the freeze-drying chamber 
changes from essentially all TBA vapour during primary drying to mostly air, thus a 
drop in pressure along with stabilization is a good indication of primary end point. 
Although product temperature, determined by micro thermocouples, is also used by 
many to determine the end point of primary drying, it can be very miss leading. Roy 
and Pikal (1989) have shown that vials containing thermocouples are not 
representative of the batch as a whole due to the formation of larger ice crystals and 
thus show a faster sublimation which as a result require shorter primary drying time. 
Nevertheless the temperature of the drying chamber was monitored throughout the 
primary drying stage to ensure it is maintained above T’g.    
Secondary drying is a stage at which remaining solvent is removed by desorption to 
further increase the product stability at room temperature. A critical requirement of 
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this stage is heating, nevertheless, the laboratory freeze dryer (Lyotrap) used in this 
study does not provide a heating option, thus secondary drying was performed under 
room temperature (18-25 oC) for a period of 24 h. Pikal et al. (1990) have shown that 
short secondary drying stages (3-6 h) at high temperatures are better than a longer 
secondary drying at a low temperature as water desorption rate decreases 
dramatically with time at a given temperature. As part of the developed method, 
quality control tests have been implemented to ensure successful freeze-drying cakes 
are produced.   
Freeze-dried formulations in the range 0-90% w/w NIF in PVP have shown the ability to 
retain residual solvents significantly greater than FD-100% formulation. This may be 
used as an indication to the physical state change between the FD-100% and other FD 
percentages as amorphous material is reported by Tang and Pikal (2004) to have a 
higher affinity to residual solvents than crystalline materials. Additionally the large 
jump in % residual solvent (Fig 2.16) may be a direct result of a sharp increase in 
surface area by developing FD porous structures. Increasing the ratio of PVP to 
nifedipine in the freeze-dried system has showed to steadily increase the materials 
ability to retain residual solvent. However a significant drop in w/w % residual solvent 
was observed in FD 10% w/w NIF in PVP (Fig 2.16). This may indicate that, at this 
particular ratio of NIF to PVP, some of the PVP hydrogen bonded water molecules 
were displaced by amorphous nifedipine.     
 Freeze-drying nifedipine alone has generated poor quality freeze-dried cakes of α 
crystalline nifedipine. Both DSC thermograms and FT-IR spectra have shown α-NIF 
characteristics. Addition of low concentrations (≥20% w/w) of PVP to the formulation 
has shown to improve the quality of the freeze-dried cakes, while crystalline nifedipine 
remind detectable with DSC analysis. Decreasing the ratio of NIF:PVP in freeze-dried 
formulations have shown to broaden and decrease the melting peak of nifedipine to a 
disappear at 50% w/w NIF in PVP. A novel quantitative deferential thermal assay was 
developed based on the enthalpy of nifedipine endothermic melting peak, determined 
by differential scanning calorimetry (Fig 2.21). The assay used binary physical mixtures 
of crystalline nifedipine and amorphous PVP, and was based on the assumption that 
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the melting enthalpy of crystalline drug is linearly correlated to the content of 
crystalline drug in the sample (Fig 2.21). 
The use of thermal analysis as a quantitative analytical tool has been developed by 
many studies and used for routine quantitative analysis of polymorphism. A review of 
studies in this field can be found else were (Giron, 1995). Recent studies in the field of 
pharmaceutics have developed quantitative deferential thermal analysis for 
quantifying crystalline drug in formulation. Kushida (2012) developed a DSC based 
assay for quantifying E1010, a crystalline drug, in binary physical mixtures of 
amorphous and crystalline drug. The binary mixtures were prepared by mixing 
different proportions of crystalline and amorphous drug using pestle and mortar. This 
very action may cause drug recrystallization, thus changing the ratio of amorphous to 
crystalline nifedipine. Furthermore, heating amorphous drug in the absence of 
stabilizing polymers can induce recrystallization as part of the thermal test, which as a 
result would increase the ratio of crystalline to amorphous drug in the sample. The use 
of an amorphous polymer, in this study, as the diluent for the crystalline drug, 
prevents the cross contamination between amorphous and crystalline components. 
However, samples containing high concentrations of PVP seem to give lower melting 
peaks than expected by the assay in figure 2.21. As the glass transition of PVP is lower 
than the melting point of nifedipine, it is believed that a small proportion of crystalline 
nifedipine is dissolving in the viscous PVP liquid above its glass transition, which as a 
result reduces the size of the melting peak (Fig 2.20). Increasing the PVP concentration 
in binary physical mixtures has shown to broaden melting peaks and lower onset of 
melting by as much as 35 oC (Fig 2.20). PVP is thought to act as an impurity and thus 
reduce the melting peak onset of nifedipine. The developed DSC assay (Fig 2.21) has a 
detection limit of about 5%, w/w crystalline nifedipine in formulations, therefore, it 
may be concluded that ≤50% w/w freeze-dried nifedipine in PVP formulations, are 
predominantly amorphous.  
As demonstrated in this study, DSC limit of detection was previously reported by 
authors to be in the range of 5-10% w/w (Buckton and Darcy, 1999). As a result, many 
studies have explored the use of polarized light microscopy (PLM) for the quantitative 
monitoring of crystalizing formulations and therefore attempting to determine kinetics 
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of drug crystallization in solution (Xia et al., 2012). As PLM is a visual based technique, 
it is considered to have a high sensitivity; especially as nucleation, and crystal growth, 
may be monitored down to the individual crystal. Table ‎2.6 presents PLM images of 
different compositions of freeze-dried formulations as well as pure, as received, PVP 
and crystalline nifedipine. Gunn et al. (2012), Raina et al. (2014) and others have 
reported similar PLM based images of crystalline nifedipine. PLM is based on the 
anisotropic property of crystalline material, and the isotropic property of amorphous 
material, and therefore observation of birefringence is key in determining the 
crystallinity of a sample. The results presented in Table ‎2.6, much like DSC results, 
show ≤50% w/w freeze-dried nifedipine in PVP to be the cut-off point where crystalline 
nifedipine is no longer detected. However, visually finding a crystalline particle in 
formulations with low NIF:PVP ratio is dependent on the amount of sample observed. 
This is subject to many factors such as the focus of the image, as neighbouring particles 
may only be visible in different focus settings when particles are of different heights. 
The spread and thickness of sample is critical as crystalline particles embedded in 
amorphous material can appear absent. Additionally photo sensitive drugs, such as 
nifedipine, are more prone to photo degradation when in amorphous state due to 
their intrinsic instability. Degradation product may show different crystallization 
behaviour (Miyazaki et al., 2007). Finally, the PLM technique can be dependent on 
labour intensive consistent counting and measuring of each polarized light micrograph 
(Wu et al., 2012). Due to the complexity of the different factors influencing the 
outcome of PLM analysis (Xia et al., 2012), and the lack of a definitive detection limit, 
many prefer the use of PLM as a qualitative technique (Wu et al., 2012).    
ATR FT-IR spectra of amorphous nifedipine in PVP show clear characteristic signs of 
molecularly dispersed amorphous nifedipine in PVP, these include the single peak 
located in the carbonyl region (Iqbal and Chan, 2015) and the shift of N-H peak 
towards lower wavenumbers (Rumondor et al., 2009, Chan et al., 2004). Semi-
quantitative analysis of dispersed crystalline nifedipine in PEG  was attempted in the 
past by Iqbal and Chan (2015). The approach was based on the frequently used 
method of peak response ratio between a crystalline indicative peak (762 cm-1), and a 
reference peak that is independent of the crystalline state (710 cm-1) in the 800-700 
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cm-1 out of plane δ(C-H) vibration of the ring regions (Shah et al., 2006). Results from 
this study show the 762 cm-1 crystalline indicative peak to be absent in all freeze-dried 
formulations of nifedipine in PVP, and only present in freeze-dried pure nifedipine and 
physical mixtures of crystalline nifedipine and PVP (Fig 2.25). Instead a broad peak 
centred at approximately 754 cm-1 was observed in freeze-dried formulations. Careful 
examination of this peak showed a slight change in peak shape as the ratio of NIF:PVP 
is increased. Figure 2.25 shows a clear shoulder on the left side of the peak which is 
thought to be early indications of the crystalline indicative peak 762 cm-1. The peak 
symmetry was found to be a representative measure of the change in shape observed 
in the 754 cm-1 peak. Figure 2.26 shows the 754 cm-1 peak to be asymmetric (0.9-1.1) 
of freeze-dried 10-60% w/w nifedipine in PVP, with 60% closest to the out of range. 
The symmetry of the peak further exceeds the 0.8-1 range as the ration of NIF:PVP 
increases. As the crystalline indicative peak 762 cm-1 is not shown in freeze-dried 
formulations, it is believed that the shape change observed in peak 754 cm-1 is 
indicative of early stages of nifedipine crystal nucleation such as clusters of dimers. 
This is further supported by PLM images in table 2.6, where smaller crystals of 
nifedipine are observed in 70% w/w freeze-dried formulations compared to as 
received nifedipine (Xia et al., 2012). 
FT-IR results also show the presence of intermolecular hydrogen bonding between the 
N-H group of nifedipine and the carbonyl group of PVP (Fig 2.27 & 2.28). The peak 
shifts observed in N-H region (3342 to 3288 cm-1) between pure amorphous NIF and FD 
NIF-PVP cakes, is an indication of the presence of hydrogen bonding in FD NIF-PVP 
cakes compared to amorphous nifedipine. This drug polymer interaction was also 
observed in het-cycled formulations developed by heat-cycling the freeze-dried 
formulations via DSC, however, the carbonyl peak of the heat-cycled formulation, at 
1660, has, very slightly, changed in size and shape from that in the freeze-dried 
formulation. This maybe an indication of drug degradation due to thermal stress (Ali, 
1989). 
Glass transitions of heat-cycled formulations, for all of the ratios of NIF:PVP (Fig 2.29), 
fitted the Gordon Taylor equation, which is based on volume additivity (Lu and Weiss, 
1992, Royall et al., 1999); therefore, the drug-polymer interactions, presented in the 
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FT-IR work, must not influence the Tg or the mobility of PVP. Furthermore, NIF still acts 
as a plasticizer to PVP (i.e. lowers the Tg of PVP upon simple mixing), which supports 
the hypothesis of PVP not to being dramatically affected by being hydrogen bonded to 
NIF. Knowing that the NIF-PVP system obeys Gordon Taylor is very useful, as it allows 
the prediction of Tg of un-prepared ratios of NIF:PVP. Figure 2.29 above lists the 
Gordon Taylor equation and parameters specific for the NIF-PVP system. However, 
upon further examination the ratios of NIF:PVP, in figure 2.29 did not show to account 
for the 14.9% w/w residual water carried by PVP and 1.3% w/w by NIF (Fig 2.16). 
Taking the weight of water away from PVP, figure 2.30 below presents the observed 
NIF-PVP weight ratios and thus the Gordon Taylor equation and parameters for the 
binary NIF-PVP systems corrected for the absence of residual solvent. In comparison to 
authors in the field, where values of KGT above 1 indicates some interaction, the 
corrected KGT value, supports the IR work, where interactions between PVP and NIF 
exists, and from IR, this is predicted to be hydrogen bonding.   
 
Figure ‎2.30 Glass transition of NIF-PVP system replotted, from figure 2.29, whilst the ratio of NIF to PVP 
was corrected for the % w/w of residual water observed in as received PVP (14.9% w/w) and NIF (1.3% 
w/w). 
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2.6.  Conclusion   
A robust and transferable freeze-drying manufacturing method was developed for 
producing a freeze-dried solid solution of NIF in PVP, using TBA as a common solvent. A 
0-100% w/w range of NIF in PVP freeze-dried and physical mix was prepared and 
characterised using thermal, optical and spectroscopic methods to evaluate phase 
behaviour of NIF in different NIF:PVP ratios. Differential scanning calorimetry analysis 
showed freeze-dried ≤50% w/w NIF in PVP formed freely miscible, single Tg, solid 
solutions that comply to the Gordon Taylor equation with a KGT value of 1.3, indicating 
intermolecular interactions between NIF and PVP. This was further confirmed by FT-IR 
analysis, as strong signs of hydrogen bonding were observed in the N-H region for NIF. 
This therefore provides insights to production, composition and the underpinning 
mechanism to allow a freeze-dried in-situ capsule formulation to be developed; this 
will be discussed in the following chapter. 
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Chapter 3. In-situ capsule freeze-dried solid solutions 
of nifedipine 
3.1. Introduction 
Chapter 3 reports the development of a novel in-situ capsule FD formulation of 
nifedipine and builds on the work reported in the previous sections namely the 
preparation and characterisation of amorphous nifedipine in PVP. This new knowledge 
has been used to manufacture an amorphous unit dosage form of nifedipine that 
enhances both the physical stability of the drug product and the chemical stability of 
the drug itself. The aim of such work was to overcome the low physical stability of 
amorphous formulations by avoiding both physical and thermal stress during the 
manufacturing process (Kaushal et al., 2004, Craig et al., 1999, Vasconcelos et al., 
2007). Throughout this research BP regulations were integral, for example the FD 
capsules were required to consistently deliver a constant mass of the drug, such as 
conventional tablets and capsules, conforming to regulatory recommendations 
(MHRA, 2014b). 
Aims of the study reported in this chapter were to adapt the freeze-drying method 
developed in earlier chapters (chapter 2) to manufacture solid oral dosage forms 
containing 10 ± 0.5 mg of amorphous nifedipine per unit dosage form. Key indicators 
of success included developing a predominantly amorphous system, with enhanced 
dissolution rate and greater apparent solubility, whilst maintaining physical and 
chemical stability. These indicators will be achieved by developing an in-situ freeze-
drying method that requires a minimum number of steps to produce the solid dosage 
form, thus eliminating the risks of crystallisation during the manufacturing process. 
The effect of varying ratios of NIF:PVP in freeze-dried formulations on dissolution rate 
and apparent solubility was further investigated. Freeze-dried formulations were 
compared to physical mixtures to determine the effect of PVP on the dissolution rate 
and solubility of nifedipine. In addition, the stability of the novel amorphous 10 mg NIF 
formulation was also investigated.   
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To achieve the aim of this chapter, the following objectives were set: 
1- Adaptation of the method used in chapter 2 for the manufacture of in-situ 
freeze-dried gelatin capsules, containing 10 mg of amorphous nifedipine in 
PVP. 
2- Ensuring the physical and chemical qualities of the in-situ capsule freeze-dried 
formulations are the same as ampoule freeze-dried formulations, taking into 
account the w/w % of nifedipine in PVP. This will be performed using DSC. 
3- Developing and validating a HPLC assay for determining the content and 
concentration of nifedipine in solution.  
4- Determining the effect of the physical state of nifedipine as well as the w/w % 
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3.2. Equipment & materials 
3.2.1. Equipment 
Basket-rack assembly: ERWEKA GmbH  Heusenstamm Germany, Product Type (PT): 
ZT2, SN: 53462; Cannula Filters: SMI-Labhut ltd Gloucestershire UK, Product Number 
(PN): FIL045-01-100, specification: 45µm UHMW Polyethylene Cannula Dissolution 
Filters Agilent/VanKel Compatible; Capsule sinker: SMI-Labhut ltd Gloucestershire UK, 
PN: WIRESK-VK, specification: type 316 Stainless Steel Wire 0.6 mm diameter 15 m 
Roll; Dissolution instrument: CALEVA ltd Ascot UK, PT: 6ST, MN: 02042, SN: 3014764; 
Falcon tubes: Fisher scientific Ltd Leicestershire UK, PN: 14-959-49B, BN: E130505S; 
High performance liquid chromatography: Agilent Technologies Co ltd California US, 
PT: 1100; Humidity and temperature meter: Fisher scientific Ltd Leicestershire UK, 
MN: FB50264, SN: 101822304, specification: Traceable calibration 281-482-1714; 
Humidity and temperature meter: VWR International Ltd Leicestershire UK, PN: I628-
0031, SN: 122720346, specification: Traceable calibration 281-482-1714; Mailbox Box: 
Mailbox international ltd city and country, PN: M202A, SN: 0161-330-5577; pH meter: 
InoLab® Werkstätte Germany, PT: inoLab pH Level 2, SN: 02370005; Sampling Cannual: 
SMI-Labhut ltd Gloucestershire UK, PN: CAN575-SH 5.75, specification: 5.75” (120mm) 
Bent SS Sampling Cannula with Luer Adapter for 900 mL Sampling 0.125” (3.2mm) 
Diameter VanKel Compatible; Syringe Filters: SMI-Labhut ltd Gloucestershire UK, PN: 
FFPV1345-100, BN: ES129259, specification: Cronus 13 mm PVDF Syringe Filter 
0.45µm; Syringes: SMI-Labhut ltd Gloucestershire UK, PN: SS20LS-100, specification: 
20 mL Luer Slip Polypropylene Syringe, Sterile; Temperature controlled room air 
cooler: GEA Group Düsseldorf Germany, PT: GEA Küba DE professional, MN: A08ID, SN: 
6006126, specification: room temperature range from -30 oC to +30 oC); Thermometer:  
VWR International Ltd Leicestershire UK, PN: ENICHEM, specification:  Spirit 
thermometer 76 mm immersion 305 mm long -10 to +110 oC; Tip holder box: Starlab 
Keynes UK, PN: S1126-7810, BN: A108576L specification: TipOne 1000 µL Filter Tip; 
Ultraviolet/visible spectroscopy: PerkinElmer Massachusetts US, PT: Lambda2S, PN: 
166351, SN: 6847; UV/VIS spectroscopy cells: PerkinElmer Massachusetts US, PN: 
B0631009; Verex caps: Pehnomenex® California US, PN: AR0-8957-13-B; Verex vial: 
Pehnomenex® California US, PN: AR0-3901-13, BN: 004; Volumetric flask: Fisher 
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scientific Ltd Leicestershire UK, PN: 11864020, specification: A100 ±0.8 mL in 20 oC; 
Volumetric flask: Fisher scientific Ltd Leicestershire UK, PN: 11894020, specification: 
A25 ±0.04 mL in 20 oC; Volumetric flask: Sigma-Aldrich Company Ltd Dorset UK, PN: 
Z326437-2EA, specification: ±0.08 mL in 20 oC; Volumetric flask: YORLAB Dunnington 
UK, PN: 5276453, specification: A1000 ± 0.4 mL in 20 oC. 
Other equipment used in this chapter was listed under equipment section of previous 
chapters.  
All instruments used in this study were calibrated following manufacturer 
recommendation unless otherwise stated in the method section of this chapter.  
3.2.2. Materials 
Acetic Acid: Sigma-Aldrich Company Ltd Dorset UK, CAS: 64-19-7, CC: 45740-1L-F; 
Ammonium acetate: VWR International Ltd Leicestershire UK, CAS: 631-61-8, PN: 
21198.298, BN: 11K140019; Bupivacaine hydrochloride: Santa Cruz Biotechnology 
Heidelberg, Germany, CAS: 18010-40-7, CC: Sc-252524A, BN: K0410; Empty capsules: 
The-Alchemists Apothecary-amazon.co.uk, PT: Red gelatin capsules size 0, BN: 0299; 
Nifedipine 10 mg capsules: TEVA ltd Castleford UK, BN: 229AG; Sodium Bromide: VWR 
International Ltd Leicestershire UK, CAS: 7647-15-6, CC: 1.06360.1000, BN: K44774260 
331; Sodium Chloride: VWR International Ltd Leicestershire UK, CAS: 7647-14-5, CC: 
567440-1; Water: Fisher scientific Ltd Leicestershire UK, CAS: 7732-18-5, PN: 
W/0106/17, specification: HPLC grade.  
3.3. Methods 
3.3.1. In-situ freeze-drying of nifedipine within capsules 
3.3.1.1. Preparation of feed solution 
A 2% w/v nifedipine in TBA stock solution was prepared by dissolving pre weighed 200 
mg of nifedipine in 20 mL of TBA. Pre weighed PVP K10 (200 mg) was added to the 
readymade nifedipine solution and dissolved, creating a solution with a 1 to 1 NIF:PVP 
ratio (equivalent to freeze-dried 50% NIF in PVP). Both nifedipine and PVP were 
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dissolved in TBA following the method of preparing feeds solutions described in 
section 2.3.1.1. Feed solutions with varying NIF:PVP ratios were prepared using the 
same method while maintaining the concentration of nifedipine in all feed solutions 
constant at 2% w/v.  
3.3.1.2. Capsule filling 
Up to 30 red opaque gelatin capsules size 0 (distributed by The Alchemists Apothecary) 
were fitted, facing upwards, into a capsule holder board, designed for this study. Using 
a positive displacement pipette, a syringe like structured pipette that allows accurate 
uptake of viscus and volatile samples (Gilson), 0.5 mL of feed solution was transferred 
into each capsule bottom and allowed to freeze. Capsules containing frozen feed 
solution, of the same NIF:PVP ratio, were transferred into amber freeze-drying vials as 
presented in figure 3.2. The vials were then labelled with the corresponding w/w % of 
NIF in PVP and stored in a -80 oC freezer (10-14 h).      
 
Figure ‎3.1 Capsule holder used in the process of filling capsule with feed solutions and allowing them to 
solidify at room temperature (18-25 
o
C). This diagram was drawn using Microsoft PowerPoint.  
 
Figure ‎3.2 Fitting filled capsule bottoms into freeze-drying vials to be freeze-dried. This diagram was 
drawn using Microsoft PowerPoint.   
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3.3.1.3. Freeze-drying cycle 
In-situ freeze-drying was performed following the same freeze-drying cycle developed 
in chapter 2, described under section 2.3.1.  
3.3.1.4. Recapping capsules  
Once secondary drying was completed, vials were re-opened, inside nitrogen bags, for 
a capsule recapping step. This process was performed inside the previously described 
nitrogen bags using an adapted version of the method described in section ‎2.3.1.6. All 
vials were re-sealed under nitrogen and stored at room temperature (18-25 oC) over 
P2O5 inside sealed desiccator until tested. 
3.3.2. Quality control testing 
3.3.2.1. Uniformity of weight and appearance  
All capsules were examined for damage or cracks on the outer shell. This was 
performed as part of the recapping step described above (section 3.3.1.4). Additionally 
3 capsules per batch of each of the w/w % formulations were weighed individually.   
3.3.2.2. Drug content  
The content of nifedipine per capsule was determined for 3 capsules per batch of each 
of the w/w % formulations. The content of drug was determined using a reproducible 
and validated stability-indicating HPLC method adapted from a previous study (Helin-
Tanninen et al., 2001). The adapted method is described in the below sections 
(3.4.2.2.1 – 3.4.2.2.7). 
3.3.2.2.1 Stability indicating HPLC system 
The HPLC system used was the Agilent 1100 HPLC system series. This consisted of an 
Auto sampler (Agilent ALS – G1313A, SN: DE11115724), a Diode Array detector (Agilent 
DAD G1315B, SN: DE11112633), a column oven, a binary pump (Agilent 1100 – 
G1316A, SN: DE11121364) and a degasser unit (Agilent Degasser – G1322A, SN: 
JPO5027194). For this method a Gemini-NX C18 revers phase column (particle size 
5µm, width of 4.60 mm and length of 150mm) was fitted. The mobile phase consisted 
of 68% (v/v) HPLC grade methanol and 32% (v/v) 0.1M Ammonium acetate (adjusted 
to pH 5.8 using acetic acid).  
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3.3.2.2.2 Stability indicating HPLC Method conditions 
An isocratic mobile phase was set to a flow of 1.0 mL/min. The flow was not 
interrupted between samples of a given experiment. The column oven was set to 37 oC 
and the DAD unit was set to monitor absorbance at: 238 nm. Injection volume was set 
to 20 µL and the injection needle was programmed to wash with 100% HPLC grade 
methanol after each sample.  
The system was run with no sample injections for 30 min prior to use for conditioning. 
The performance of the HPLC instrument was tested on at least 6 repeated injections 
where flow rate, pressure and measurement response were monitored to ensure 
system suitability in accordance to ICH guidelines  (ICH, 1996). 
3.3.2.2.3 Preparation of mobile phase 
0.1M Ammonium acetate stock solution was prepared by adding 7.708 g of ammonium 
acetate to a 1.0 L volumetric flask and diluting to mark using HPLC grade water. The 
solution was sonicated for 10 min. The pH of the solution was adjusted to 5.8 using 
acetic acid.  HPLC grade methanol was used as received.   
3.3.2.2.4 Preparation of internal standard stock solution 
Pre-weighed 1.5 g of bupivacaine hydrochloride, as the internal standard, was added 
into a 1.0 L volumetric flask. 0.1M HCL was added to volumetric flask to make up a 
solution of 1.0 L. The solution was sonicated until no solid particles are visible. This 
stock solution was stored at 5 oC (Helin-Tanninen et al., 2007) for a maximum of 28 
days (Karin Janssen, 2009).   
3.3.2.2.5 Preparation of nifedipine dilutions for the construction of calibration 
graph  
A calibration curve was constructed by preparing a series of dilutions of nifedipine 
prepared from stock solution (table 3.1). This was prepared by adding a red gelatin 
capsule containing pre-weighed 10.0 mg nifedipine to a 50 mL amber volumetric flask. 
The volumetric flask was then filled up to the mark with 50% v/v HPLC methanol in 
0.1M HCL. The solution was then sonicated (using a sonicator water bath) until no solid 
particles were visible. A range of volumes were pipetted from the nifedipine stock 
solution into 25 mL volumetric flasks, while a constant 0.83 mL of internal standard 
stock solution (0.15% w/v bupivacaine hydrochloride) was added to all dilutions (table 
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3.1) (Helin-Tanninen et al., 2007). 0.1M HCl was used to dilute all solutions to mark. As 
a result all dilutions contained equal concentrations of internal standard (49.8 µg/mL).   







Pipetted volume of NIF 
stock solution needed 
mL 
Pipetted volume of 
internal standard stock 
solution mL 
2 25 0.25 0.83 
4 25 0.50 0.83 
6 25 0.75 0.83 
8 25 1.00 0.83 
10 25 1.25 0.83 
11 25 1.38 0.83 
12 25 1.50 0.83 
 
The series of nifedipine dilutions were prepared in a replicate of 3, each of which was 
prepared from a different nifedipine stock solution. 
3.3.2.2.6 Preparation of finished product HPLC sample  
The In-situ FD capsule formulation (i.e. the finished product after recapping) was 
placed inside a 50 mL amber volumetric flask. 25 mL of 50% v/v HPLC grade methanol 
in 0.1M HCL was added. The resulting solution was sonicated, while limiting 
temperature of the water bath sonicator to the range 25-37 oC, to full dissolution.  The 
solution was further diluted, to a total volume of 50 mL, using the same solvent 
mixture. The resulted solution was mixed by inverting the 50 mL volumetric flask at 
least 3 times.  
 A volume of 0.63 mL from the resulting solution was pipetted into an amber 25 mL 
volumetric flask, to which a standard volume of 0.83 mL of the internal standard stock 
solution was added. The solution was then diluted to mark using 0.1M HCl. The 
resulting solution was then analysed using the HPLC stability indicating assay. 
3.3.2.2.7  Stability indicating HPLC system validation 
A. Specificity 
An investigation of specificity was conducted to determine and differentiate response 
by the drug and impurities as well as the internal standard (ICH, 1996). This was 
performed by injecting solutions of nifedipine alone, internal standard alone, photo 
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degraded nifedipine, prepared by exposing NIF solutions to day light for no less than 
2h, and finally a solution of all of the analytes to ensure response of impurities and 
internal standard do not interfere with drug response. Identity of peaks appearing in 
the presence of impurities were further confirmed using HPLC mass spec, where 
nifedipine solutions where analysed before and after light degradation (ICH, 1996). 
Selectivity was also investigated by ensuring other components of the freeze-dried 
formulation do not interfere with the response of nifedipine and bupivacaine 
hydrochloride. This was performed by analysing drug free FD capsule formulation (0% 
w/w nifedipine in PVP). HPLC samples of drug free formulations were prepared using 
the same method used for preparing finished product HPLC samples. This experiment 
was repeated 3 times, using 3 different capsules (ICH, 1996).  
B. Linearity & range   
To determine the linear working range of the HPLC method, nifedipine standards of 
known concentration were prepared with concentration range from 2.0 to 12.0 µg/mL. 
This covers the range of 40% to 240% of the expected sample concentration (5.0 
µg/mL) following ICH guidelines (ICH, 1996). 
C. Detection and quantification limits 
This was performed following the method described in previous chapters (‎2.4.3.1) 
following ICH guidelines (ICH, 1996).  
D. Accuracy and precision   
The HPLC assay was tested for accuracy and precision through the analysis of three 
standard solutions of nifedipine (5 µg/mL) at three different times of the day following 
ICH guidelines (ICH, 1996). 
E. Robustness 
a.  Standard solution 
The reproducibility of retention time (RT) and PA of nifedipine and bupivacaine 
hydrochloride was investigated by preparing and testing a standard solution of 
nifedipine and bupivacaine hydrochloride (5 and 50 µg/mL respectively). The same 
solution was injected into the column in a replicate of 10 times. The average RT and PA 
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of nifedipine and bupivacaine hydrochloride was recorded following ICH guidelines 
(ICH, 1996). 
b. Finished product sample  
The reproducibility of the RT and PA of nifedipine and bupivacaine hydrochloride was 
also investigated in finished product HPLC samples. A sample was prepared, using the 
same method used for preparing finished product HPLC samples, using freeze-dried 
capsules of 50% w/w nifedipine in PVP. The same sample was injected into the column 
in a replicates of 10 times. The average RT and PA of nifedipine and bupivacaine 
hydrochloride was recorded. This experiment was repeated 3 times, using 3 different 
samples (ICH, 1996).  
3.3.2.3. Thermal characterisation  
Thermal analysis was performed, following the DSC method described in chapter 2, on 
freeze-dried material extracted from 3 different capsules per batch of each of the w/w 
% formulations (ICH, 1996).  
3.3.3. Dissolution testing 
The optimised dissolution testing method was based on the use of dissolution 
apparatus 2 (paddle apparatus), of which all parameters were calibrated and adjusted 
in accordance to Appendix XII B-dissolution of the BP guidelines (MHRA, 2014b).  
3.3.3.1. Dissolution medium 
The dissolution medium used in this test is 900 mL of 0.1M HCL (MHRA, 2014b), 
nevertheless a novel method of incorporating the internal standard was implemented, 
by which a concentration of 50 µg/mL of internal standard was maintained. This was 
achieved by adding a volume of 33.33 mL of the internal standard stock solution to 100 
mL of 1M HCL and making the solution up to 1.0 L using distilled water. Only 900 mL of 
the resulting solution was poured into the dissolution vessel and the remaining 100 mL 
was maintained in a separate beaker as a dissolution medium reservoir. This ensures 
that all samples withdrawn from the dissolution medium contain the same 
concentration of internal standard.  
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3.3.3.2. Dissolution assembly and parameters 
The dissolution instrument was assembled in accordance to the BP specification of 
appendix XII B. Dissolution (MHRA, 2014b). In addition to avoid sample contamination 
or interference from the equipment used, any plasticizers containing tubing was 
avoided. A special stainless steel cannula was installed to which a 0.45µm non-
adsorptive millipore polyvinylidene fluoride syringe membrane filter was fitted. Finally 
a luer slip polypropylene syringe was fitted to the cannula via the filter to enable 
sample uptake. The temperature of the dissolution bath was set to 37.0 oC ± 0.5, 
paddles were set to rotate at a speed of 50 rotations per minute (MHRA, 2014b). Both 
the paddle and the sampling cannula were positioned in accordance to the BP 
guidelines (MHRA, 2014b), this is to ensure samples are withdrawn from a zone 
midway between the surface of the dissolution medium and the top of the rotating 
paddle, 1.3 cm away from the vessel wall (MHRA, 2014b). The bottom of the sampling 
cannula was fitted with a 20 µm Ultra-high-molecular-weight polyethylene cannula 
dissolution filter, BP compliant (MHRA, 2014b). Figure 3.3 below presents a schematic 
diagram of the apparatus 2 dissolution setup. To ensure the sampling cannula was 
securely connected to the various parts and is conditioned to the dissolution medium, 
a few 5 mL samples were taken up from the dissolution reservoir and then flushed out.    
Furthermore to supress light related degradation of nifedipine, the dissolution test was 
performed in a dark room where only light of long wave lengths is used. Light coming 
from the dissolution instrument was minimized but not completely eliminated as 
dissolution parameters were constantly monitored. 
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Figure ‎3.3 USP apparatus 2 dissolution setup following BP guidelines based on (MHRA, 2014b). This 
diagram was drawn using Microsoft PowerPoint.    
3.3.3.3. Method of dissolution testing 
The dissolution vessel containing the dissolution medium was allowed to reach the 
specified temperature and thus equilibrate for 5 min at 37.0 ± 0.5 oC. Next the capsule 
to be tested was removed from the amber sealed vial. A small, loose piece of non-
reactive stainless steel, wire helix with few turns, was securely attached to the test 
capsule, to act as a capsule sinker, as recommended by the BP guidelines (MHRA, 
2014b). The capsule was then dropped into the dissolution vessel, at which time 0 min 
was marked. Samples were withdrawn on 1, 2, 3, 4, 5, 6, 10, 20, 45 and 60 minutes. At 
each time interval a sample of 5 mL was withdrawn into the syringe presented in fig 
3.3 above. From the withdrawn sample, 2 mL was injected into 2 mL amber HPLC glass 
vials, and the remaining 3 mL was injected back to the dissolution medium. Once the 
dissolution testing was complete, the HPLC vials were analysed immediately using the 
HPLC assay. 
3.3.3.4. Polarized microscopic dissolution 
Dissolution testing was mimicked under polarized microscopy. Approximately 1 mg of 
sample was spread on a clear slide and monitored under polarized microscopy 
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following method described in previous chapters (2.3.5). 0.5 mL of 0.1M HCl (37.0 ± 0.5 
oC) was pipetted into the formulation and images, through 5X magnification objective, 
were captured, with 1min interval, for 60 min.     
3.3.4. Solubility measurement of nifedipine 
The thermodynamic solubility of crystalline nifedipine was measured in 0.1M HCl (37.0 
±0.5 oC) by adding excess amounts of pure crystalline nifedipine to 25 mL of solvent. 
Samples were continually shaken by a shaking board and maintained in 37.0 ± 0.5 oC 
water bath in a dark room to equilibrate for 5 days. Solutions above excess solid 
nifedipine were filtered following the same filtering setup used in the dissolution 
instrument. The concentration of NIF was then determined using the stability indicting 
HPLC assay described above.       
3.3.5. Stability studies 
A stability study was performed by storing in-situ capsule FD formulations in nitrogen 
sealed amber vials under two conditions; The first condition 25 ± 2 oC and 57 ± 0.4% 
RH, was achieved by storage at a 25 ± 2 oC controlled room temperature, where by the 
samples were stored in a sealed box containing saturated solutions of sodium Bromide 
salt (Greenspan, 1977). The second condition 37 ± 2 oC and 74 ± 0.13% RH was 
achieved using the same method while a saturated sodium chloride salt solution was 
used to maintain the % RH (Greenspan, 1977). Both conditions were monitored 
periodically to ensure temperature and humidity values are within in specified limits. 
Samples were withdrawn and tested for physical stability: % w/w of crystalline 
nifedipine, chemical stability: presence of chemical degradation products, and 
performance: unit dosage weight uniformity, drug content and dissolution profile.   
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3.4. Results 
3.4.1. HPLC assay method validation 
3.4.1.1. Specificity 
By separately injecting nifedipine and bupivacaine HCl (internal standard) into the 
column, it was determined that the RT’s of nifedipine and internal standard, under 
fixed flow rate of 1.0 mL min-1, isocratic mobile phase of 68% v/v methanol in 0.1M 
ammonium acetate (pH = 5.8-5.5) and a constant column temperature of 37 oC ± 1, are 
3.30 ± 0.005 min and 4.81 ± 0.007 min respectively (n = 10). A standard solution 
containing nifedipine and internal standard shows both peaks to appear with a 
separation factor of 1.94 and a resolution of 2.5 (Figure 3.4-A). Both peaks show ICH 
acceptable peak symmetry values 0.9-1.4 (Deepti and Pawan, 2013, ICH, 1996, FDA, 
2008).   
Nifedipine is known to degrade when exposed to light or high temperatures (Ali, 1989), 
resulting in the production of nitroderivatives of nifedipine: nitrophenylpyridine (NIFII) 
and nitrosophenylpyridine (NIFIII). These compounds are similar in structure to 
nifedipine and act as impurities (chapter 2 Fig 2.4). Following ICH guidelines (ICH, 
1996) it was important to ensure that the HPLC assay developed allows discrimination 
and partial identification of impurities that may interfere with measurements of the 
drug (ICH, 1996). Figures 3.4 B and C, show chromatograms of standard nifedipine 
solutions after photo and thermal degradations respectively, photo degradation has 
shown to develop degradation products NIF II and III, which elute at, 2.8 and 3.1 min 
respectively. The molecular identity of each of the peaks was confirmed using liquid-
chromatography-mass-spec (LC/MS), where the same chromatographic conditions 
were used, while the UV detector was replaced with a mass spec instrument. The mass 
charge of parent ion molecule was used to confirm the identity of the degradation 
products and the drug (Deepti and Pawan, 2013). Both HPLC-UV and LC-MS were also 
performed on placebo samples containing nifedipine, PVP and the internal standard. 
The average RT of the drug and internal standard in the presence of PVP did not 
change significantly 3.26 ± 0.010 min and 4.80 ± 0.008 min respectively (ICH, 1996).  
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Figure ‎3.4 HPLC-UV chromatograms of nifedipine solutions: A) Standard NIF solution spiked with internal 
standard. The solvent front peak indicate T0, otherwise known as the time taken for the sample solvent 
to reach the detector. Dotted lines show examples of measuring peak width at half height (W1/2), peak 
width at 10% height (W10%) and peak width (W). B) HPLC chromatogram of NIF solution degraded by 
light while in amber HPLC vial, indicating that amber vials do not fully ensure protection against photo 
degradation. The identity of NIF-II (RT: 3.1) and NIF-III (RT: 2.8) where further confirmed using LC/MS C) 
HPLC of thermally degraded nifedipine using DSC cycle heating and cooling between 25 and 200 
o
C. The 
observed solvent peak is due to the difference in UV absorbance between the sample solvent and the 
mobile phase used. 
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3.4.1.2. Robustness 
Following ICH guidelines (ICH, 1996), the HPLC assay was validated for analytical 
conditions that may influence measurement of nifedipine concentrations. As described 
above, subjecting nifedipine solutions to either light or high temperatures was shown 
to induce degradation of NIF (Fig 3.4 and 3.5), and therefore cause a reduction in the 
content of nifedipine. Repetitive measurements, over the course of 9 hours, were 
performed on a standard nifedipine solution placed in a clear vial at room temperature 
(18-25 oC). The sample was placed in a HPLC sample-stand and was subjected to 
ambient laboratory light. Figure 3.5 shows the PA (HPLC-UV absorbance) for NIF (RT 
3.3 min) to follow zero order kinetics where the PA decreases at a rate constant of 
0.042min-1, While peak area of degradation product NIF II (RT 3.1 min) was shown to 
increase at a rate constant of 0.023 min-1 after approximately 2h of subjecting the 
sample to ambient light. PA values were not converted to concentrations for 
degradation products, as no calibration graph was constructed for degradation product 
as part of this study, nevertheless converting the PA values of NIF to concentration 
values has shown the concentration of NIF to follow the equation (NIF conc. µg/mL = -
8.22x10-4 x time + 5.439, R2 = 0.97) when subjected to ambient light, while -8.22x10-4 ± 
1.5x10-5 min-1 was the determined rate constant of NIF degradation in clear vials. 
Performing the same experiment using amber glass vials has shown to decrease the 
rate of nifedipine degradation by approximately a factor of 5 times as was observed by 
(Ali, 1989). Fig3.4-B shows the presence of degradation products after 3 weeks of 
exposure to ambient light at room temperature (18-25 oC). In the effort to prevent 
light induced degradation, HPLC vials containing nifedipine solutions were covered 
with foil where possible, the HPLC sample stand was also covered with foil to further 
protect vials waiting to be analysed, and were maintained at room temperature (18-25 
oC). Following this method has shown to protect nifedipine solutions from any light 
degradation for at least 10 hours at the HPLC stand, which is more than the usual 
needed time for HPLC analysis (3 hours).      
The effect of temperature on nifedipine degradation was investigated by heating 
nifedipine powder to 200 oC using the heat-cool-heat-cool DSC cycle described in 
chapter 2. The sample was protected from light at all times to avoid light induced 
degradation. NIF powder exposed to high temperatures was then used to make 
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standard solutions with concentrations of 5 µgmL-1, which were then analysed using 
HPLC assay. Results show a recovery of 79.1 ± 6.4% (n=3) while a peak at 2.8min, 
corresponding to NIFIII, was detected (Figure ‎3.4-B). In a separate experiment, the 
thermal stability of nifedipine solution were tested by storing light protected NIF 
solutions at moderately high temperatures (40 ± 5 oC) for >10h. Results show the PA of 
NIF before and after storage to be < 0.2% RSD (n = 10). Similarly thermal stability at 
room temperature (18-25 oC) for > 10h showed < 0.2% RSD between PA of NIF before 
and after storage.  
Fluctuations in RT, flow rate and injection volume have shown to cause irregularity in 
measurements, especially for low concentrations of nifedipine solutions ≤ 3 µgmL-1 
(RSD ≥ 20.5% of n=3). As a result the internal standard (bupivacaine HCl) was 
introduced to the HPLC assay. Using the PA ratio of drug to internal standard has 
reduced the effect of occasional fluctuations in injection volume on the determined 
concentration of nifedipine to RSD ≤ 0.5%.   
 
Figure ‎3.5 PA of NIF, NIF II and NIF III was repeatedly measured from a standard solution held in a clear 
vial. The vial was subjected to ambient laboratory light and a temperature of 18-25 
o
C. Degradation of 
NIF follows the equation PA=0.042 x time + 301.03. PA of NIF-II = 0.023 x time – 0.517, and finally PA of 
NIF-III = 0.0183 x time (min) + 2.505.  
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3.4.1.3. Linearity, range and precision 
The linearity of the HPLC assay was validated for drug content uniformity in the 
developed pharmaceutical product, 10 mg in-situ capsule FD NIF in PVP, following the 
ICH guidelines, with a range that covers at least 70-130% (Fig 3.6) of the test 
concentration (5 µgmL-1). Furthermore, the assay was also validated for dissolution 
testing use, where the final expected test concentration is 10 µg ±10%. Following the 
ICH guidelines, a range of 0-12 µgmL-1 was validated for linearity (Fig 3.6). R2 = 0.9998, 
slope = 0.138 and the y-intercept = -0.015. The calibration curve presented in figure 
3.6 was derived from 3 separate calibration curves, to ensure repeatability (ICH, 1996), 
performed in 3 different days, from 3 different nifedipine stock solutions, to ensure 
intermediate precision (ICH, 1996), Error bars represent standard error of n=3. The 
relationship between PA ratio and concentration of nifedipine was further tested by 
another analyst, using a different internal standard stock solution, to ensure 
reproducibility (ICH, 1996). A similar, but different linear equation was determined, 
where the y-intercept was equal to -0.0077 and a slope of 0.130 (R2=0.998). The small 
difference in relationship observed was thought to be due to a small difference in the 
concentration of internal standard stock solution. To eliminate variance going forward, 
a new calibration curve was prepared for every new internal standard stock solution 
prepared, as the concentration of internal standard in the calibration standard and 
samples must be constant to facilitate quantification of drug following the FDA 
guidelines (FDA, 2001).           
3.4.1.4. Limit of detection and quantification  
Using the calibration curve below (Fig 3.6), the limit of detection and quantification 
were calculated using the standard deviation of intercept. This was calculated using 
the same method used in section ‎2.4.3.1.   
Table ‎3.2 Detection and quantification limits of the HPLC assay for NIF.  
Equation y = 0.13881x - 0.0151 
R2 0.999 
SD of Intercept 0.00465 
LOD 0.11 µg/mL 
LOQ 0.33 µg/mL 
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Figure ‎3.6 Calibration graph of nifedipine using stability indicating HPLC assay. The Y axis represents the 
PA ratio of nifedipine to bupivacaine HCl. Error bars represent the standard error of three different stock 
solutions prepared in 3 different days (n=3). R
2 
equals 0.9998 indicating that the line of best fit shows a 
good representation of the data points.  
3.4.1.5. System suitability  
Prior to starting the analysis of any sample, a standard sample was injected at least 6 
times to ensure the system was functioning well. The suitability of the system was 
assessed by calculating the RSD% of RT for drug and internal standard as well as the 
PA’s. The system was evaluated as suitable to use when RSD values ≤ 2% (Deepti and 
Pawan, 2013). The low RSD value indicated system suitability following ICH guidelines. 
In cases where the RSD value was > than 2%, the system was checked and assessed 
following manufacturer guidelines (Technologies, 1999).    
3.4.1.6. Detection of NIF degradation products 
As no calibration graph was constructed for the degradation products of NIF (NIFII and 
NIFIII), percentage PA was used as a method of detection for the presence of these 
products. Percentage PA is equal to the PA of 1 or both degradation products divided 
by the total sum PA of NIF, NIF II and NIF III (if present). This method of detection was 
validated using LC/MS (Figure ‎3.4).      
    





















Conc. of NIF (ug/mL)
PA ratio = 0.139x (Conc. of NIF) - 0.015
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3.4.2. Dissolution method validation  
3.4.2.1. Interference of apparatus 
Dissolution test was performed using a placebo capsule, containing only PVP, to ensure 
no interference was introduced by any of the used parts. All samples showed no peaks 
at the RT of nifedipine, indicating system suitability for testing the dissolution of 
nifedipine.   
3.4.2.2. Evaluation of filters  
Following USP and BP dissolution monographs, samples were filtered in-line while 
withdrawn from the dissolution bath to ensure removal of any particulates or 
undissolved drug that may interfere with further analytical procedures. If undissolved 
drug passes through the filter it may dissolve in collected samples and thus lead to a 
higher concentrated and more variable results. The method of filtration was developed 
and validated as described below. USP dissolution paddle apparatus are usually fitted 
with cannula filters 0.45µm. These filters were tested using marketed nifedipine soft 
gel formulations (Adalat nifedipine 10 mg). Results showed the percentage dosage 
released, at ≥ 20 min, to equal 120% ± 5% of the expected drug content (i.e. 12 mg of 
NIF released), while, in a separate experiment, the drug content of the same 
formulation and same batch (Adalat nifedipine 10 mg) showed each capsule to contain 
an average of 10 ± 0.5 mg of NIF. This therefore indicates that the cannula filters are 
insufficient in filtering undissolved nifedipine particles. To ensure efficient filtration of 
collected samples, an additional, polyvinylidene fluoride (PVDF) membrane syringe, 
filter was added between the cannula and sample syringe. This has improved filtration 
efficiency as the concentrations of collected samples were found to be ± 5% of the 
expected concentration.       
3.4.2.3. Drug degradation 
Based on previous findings on the degradation of NIF when NIF solutions are exposed 
to ambient light, precautions were taken to protect dissolution medium from ambient 
light. This was achieved by performing all dissolution studies in dark rooms with red 
light and minimal stray light, coming from instrument’s digital screens. This method 
has not shown to completely prevent light degradation during dissolution studies, but 
has limited the growth of % accumulative PA of degradation products to a maximum of 
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12% within the 60 min dissolution test. (% accumulative PA of degradation products is 
the sum of the PA’s for NIF II and NIF III divided by the sum of PA’s of NIF, NIFII and 
NIFIII). It was assumed by the author that the conditions of the dissolution medium; 37 
± 0.5 oC and continuously stirring by paddle, at 50 rotations min-1, increased the 
chance of NIF degradation.        
3.4.2.4. Calculating dosage percentage dissolved  
Using the validated stability indicating HPLC assay, the concentration of NIF in the 
dissolution medium at each time point was determined. This was then converted into 
a total amount of NIF released from the formulation, taking into account the small 
volume of media withdrawn at each time interval. To obtain a percentage value, the 
amount of drug released was divided by the mean drug content of the specific 
formulation tested.  
3.4.3. Quality control of in-situ freeze-dried capsule formulations 
3.4.3.1. Successful freeze-drying  
The effect of in-situ capsule freeze-drying on the structure of freeze-dried cake was 
investigated. Figure 3.7 below, presents the in-situ capsule FD formulations (10-100% 
w/w NIF in PVP) in clear capsule, allowing visual examination of the FD cakes. FD cakes 
of formulations containing ≤ 70% w/w NIF in PVP show no shrinkage, indicating 
successful freeze-drying, while > 70% w/w NIF in PVP FD cakes have shown to loose 
structural integrity. This is similar to the pattern observed in previous chapters 
(Chapter 2), where by reducing PVP content was seen to reduce the strength of FD 
cakes. 
 
Figure ‎3.7 Images of the in-situ capsule freeze-dried formulation. The percentages illustrated are the 
w/w % of NIF in PVP.  In-situ clear capsule freeze-drying was performed for the purpose of 
demonstration. This figure is in agreement with the finding of chapter 1, as low content of PVP (100% 
NIF) shows fragile FD cakes that loose structural integrity.  
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3.4.3.2. Quality control of hard gelatin capsule shells 
The effect of the freeze-drying process on the quality of gelatin hard capsules was also 
investigated following the World Health Organization (WHO) general monograph for 
quality control of capsules. 
3.4.3.2.1 Visual inspection 
Hard gelatin capsules that have been involved in the in-situ capsule freeze-drying 
process (otherwise refered to here as treated capsules) were visually examined and 
inspected, results show > 20 treated capsules to be smooth and undamaged. The 
physical appearance of treated capsules did not suggest a change in the hardness, 
softness, swelling or mottling of capsule shells. In addition, treated and untreated 
parts of the capsule were compared using scanning electron microscope (SEM) 
techniques. Figure 3.8 (B, C & D) below presents a capsule bottom (treated) and top 
(untreated) under various magnification levels where no significant difference was 
observed in the treated parts.  
3.4.3.2.2 Effect of liquid TBA 
The effect of liquid TBA on the physical stability of hard gelatin capsules was further 
investigated to determine if any colouring additives are released from capsules while 
adding 0.5 mL of liquid TBA (40 ± 0.5 oC)  to the inside of a hard red gelatin capsule. 
Figure 3.8-A present’s the corresponding experiment performed using clear gelatin 
capsules, for presentational purposes. Added TBA was maintained liquid for 60 min by 
maintaining the temperature of the liquid filling at (40 ± 0.5 oC). This was achieved by 
placing the test capsule in a vial which then was transferred into a (40 ± 0.5 oC) water 
bath. By visual inspection, of which protocol is described above, the capsules remained 
intact and no leaching of the dye into TBA was observed (n=3). In order to confirm this 
observation, HPLC method, described below, was run on the TBA contained within the 
capsule. 
In order to validate this approach and check whether the HPLC method, described 
below, was able to detect the dyes and additive that may leach out from the red 
capsules, the following control experiment was performed; Red gelatin capsules were 
filled with 0.5 mL of 0.1M HCl, (n=3), which resulted in the whole capsule dissolving 
within 60 min, releasing its colouring and food additives (0.19% w/w E123 Amaranth, 
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0.76% w/w E124 Ponceau-4R and 0.66% w/w E171 Titanium dioxide as described by 
the manufacturers: The-Alchemists Apothecary). 
The generated solutions from the controlled experiment, were examined using UV/Vis 
instrument, dye absorbance was found to peak at 510nm (Fig 3.9-A); thus using the 
HPLC method described in section ‎3.3.2.2.2, with a modified mobile phase (20%v/v 
methanol, 80%v/v 0.1M ammonium acetate) and monitoring the wavelength 510nm, 
the generated solutions of both experiments (i.e. liquid TBA from inside the gelatin 
capsule and the resulted solution from dissolving red capsule in 0.1M HCl) were tested 
by the modified HPLC method. Results show that the chromatogram of the controlled 
experiment solutions showed a peak retained at 6.3 ± 0.01 min with absorbance at 
510nm (n=3). The parallel experiment, where by liquid TBA was used, no absorbance 
at 6.3 min was detected (n=3). Chromatograms of pure TBA was also compared to that 
withdrawn from inside the red gelatin capsule only to find no differences (n=3). This 
indicated that using liquid TBA has not resulted in detectable leaching of capsule 
colure additives. 
3.4.3.2.3 Chemical degradation of hard gelatin capsules shell   
FT-IR analysis of treated and untreated capsules were compared to determine if the 
process of freeze-drying has caused chemical changes. Treated capsules in this 
experiment, are capsule shells used in the manufacture of in-situ capsule FD 10% w/w 
NIF in PVP. Figure 3.9-B below contains an example FT-IR spectrum of both capsules. 
The correlation between 2 capsules for the range 4000-400 cm-1 is > 97%, therefore 
indicating no chemical changes to the gelatin capsule shell induced by freeze-drying.  
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Figure ‎3.8 (A) Clear gelatin capsules filled with 0.5 mL of liquid TBA (40 ± 0.5 
o
C). (B, C, & D) SEM of In-
situ red capsule FD formulation. The capsule bottom part was involved in the freeze-drying process, 
while the top part was not. The structure of both looks identical under SEM.  
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Figure ‎3.9 (A) UV-Vis absrobance spectra of red gelatin capsule disolved in 0.1M HCl. (B) FT-IR 
transmittance spectra of untreated (i.e. not FD) red gelatin capsule (
___
) and treated (FD) capsule (
___
), 
showing > 97% correlation. No chemical differences are observed between the two capsules.  
3.4.3.2.4  Uniformity of mass 
Following the WHO guidelines, the uniformity of mass of the treated gelatin hard 
capsules was determined by weighing 20 indicted capsules individually and 
determining the deviation of each of the treated intact capsules from the average 
mass. Table 3.3 below presents the weights of 20 intact capsules used in the 
production of in-situ capsule FD 10% w/w NIF in PVP formulation. All capsules show ≤ 
2% deviation from the average weight, therefore complying with the WHO limit of 10% 
deviation from the average weight.    
Treated red hard gelatin capsule shell
Untreated red hard gelatine capsule shell
Name
Sample479 By Administrator Date 08 09 2015
Sample474 By Administrator Date 03 09 2015
Description
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3.4.3.2.5 Disintegration test 
Following the international pharmacopeia guidelines (WHO, 2015) on disintegration 
test of hard capsules, 6 FD capsules were tested using the basket-rack apparatus as 
described in section 5.3 of the international pharmacopeia (WHO, 2015). The 
disintegration medium consisted of 1000 mL of water maintained at (35 – 39 oC). 
Results show all 6 FD capsules have disintegrated in 5.10 min, while performing the 
same test on un-FD red hard gelatin capsules showed to disintegrate in 5.5 min. 
Therefore indicating that the freeze-drying process has not significantly affected the 
disintegration performance of hard gelatin capsule shells. Both FD and un-FD capsules 
showed to comply with the international pharmacopeia limits for hard gelatin capsule 
disintegration time of < 30 min (WHO, 2015).   
Table ‎3.3 Average weight of intact treated capsules. (These capsules were used in the manufacture of in-
situ capsule FD 10% w/w NIF in PVP formulation) All capsules were within the WHO % deviation limit of 
10% from the average weight.   












1 195.76 2% Pass 11 203.34 -2% Pass 
2 197.09 1% Pass 12 203.53 -2% Pass 
3 197.37 1% Pass 13 201.14 -1% Pass 
4 197.33 1% Pass 14 198.65 1% Pass 
5 201.67 -1% Pass 15 198.59 1% Pass 
6 202.40 -1% Pass 16 201.36 -1% Pass 
7 201.51 -1% Pass 17 200.52 0% Pass 
8 200.02 0% Pass 18 199.29 0% Pass 
9 195.32 2% Pass 19 202.75 -1% Pass 
10 200.81 0% Pass 20 201.68 -1% Pass 
Average weight of intact capsule 200.01 ± 2.34 mg 
   
3.4.3.3. Physical state of nifedipine  
Thermal analysis output of FD cakes formed by in-situ capsule freeze-drying, following 
the same methods described in previous chapters (Section 2.3.3), was compared to the 
thermal analysis findings of ampule FD formulations. Table 3.4 below presents a 
summary output of the average thermal analysis (n=3) for formulations developed by 
both techniques (In-situ capsule and ampule FD). The average % w/w residual solvent 
in capsule formulations was shown to follow a similar trend to that of the ampule FD 
formulations. Similarly both techniques have shown to produce predominantly 
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amorphous formulations in compositions containing <70% w/w NIF in PVP. 
Nevertheless, a difference of 5% was observed in the % w/w crystalline NIF between 
the in-situ capsule FD and the ampule FD formulation containing 70% w/w NIF in PVP 
(Table 3.4). With the exception of 30% w/w NIF in PVP, Tg values of in-situ capsule FD 
formulations follow the same trend presented by ampule FD formulations, where by 
the Tg increases as the content of PVP increases in the formulation (section ‎2.4.3.1). 
However, the Tg values of in-situ capsule FD formulations were shown to generally be 
lower than Tg values of ampule FD formulations (with the exception of 70 and 100% 
w/w NIF in PVP). Figure 3.10 below presents an example second heat thermogram 
comparing the FD 10% w/w NIF in PVP formulation produced in both techniques. 
Observed differences in Tg of second heat thermograms may indicate changes in the 
amount of PVP available in the freeze-dried cake. A hypothesis addressing this 
difference will be purposed in the discussion, but it is reported in the next section the 
overall nifedipine content for the formulation that will be taken forward is within BP 
acceptable limits, so non has been lost form the capsule for this formulation. 
Table ‎3.4 Average thermal analysis of the in-situ capsule FD formulations. The percentage of crystalline 
material is dependent on the average enthalpy value. Crystalline nifedipine was undetected in ≤ 50% 
w/w NIF in PVP of the in-situ capsule FD formulations, which is in agreement with the data generated 
from ampule FD formulations in chapter 2 (section 2.4.3.).  
In-situ capsule FD formulations 














100% 3.0% 1.2% 106.93 1.10 - 49.22 0.27 
70% 9.0% 0.5% 10.13 2.20 18% 80.12 7.59 
50% 10.0% 0.5% 0.00 0.00 0% 96.23 0.25 
30% 9.7% 0.3% 0.00 0.00 0% 91.96 0.58 
10% 10.8% 0.2% 0.00 0.00 0% 130.26 3.56 
Ampule FD formulation 














100% 1.8% 0.6% 101.96 3.07 - 46.72 0.44 
70% 10.1% 0.9% 4.73 0.58 13% 77.80 0.58 
50% 12.6% 1.5% 0.00 0.00 0% 99.87 3.84 
30% 13.2% 1.2% 0.00 0.00 0% 124.49 1.52 
10% 11.8% 0.2% 0.00 0.00 0% 142.87 0.61 
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Figure ‎3.10 Thermogram of the second heat of in-situ capsule FD and Ampoule FD 10% w/w NIF in PVP 
formulation using DSC. (All DSC thermograms in this thesis unless stated will have exothermic transitions 
upwards).   
 Despite the absence of a melting peak in DSC thermograms of FD 50% w/w NIF in PVP 
formulations, scanning electron micrograph (figure 3.11) shows the presence of crystal 
like structures on top of larger amorphous particles. Such small NIF crystals may be 
undetected using thermal methods as they may simply dissolve in PVP once heated to 
temperatures above Tg of the product. Scanning electron micrograph of the FD 10% 
w/w NIF in PVP shows a much lower number of crystals.      
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Figure ‎3.11 Scanning electron micrograph of FD cakes of in-situ capsule FD formulations (10 and 50% 
w/w NIF in PVP). The 50% w/w formulation (lower image) is showing small crystal like particles on top of 
what appears to be broken amorphous sheets.  
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3.4.3.4. Uniformity of weight and drug content 
The FD capsules of NIF in PVP were tested for uniformity of weight following BP 
guidelines. As would be expected, the average weight of individual unit dosage form 
was seen to increase as the content of PVP in the formulation increased, FD 10% w/w 
(i.e. 10 mg NIF in 90 mg PVP) is approximately 90 mg heavier than the average weight 
of FD 100% w/w (i.e. 10 mg NIF and 0 mg of PVP). Weight uniformity is presented as 
relative standard deviation (RSD%). With the exception of 30% w/w NIF in PVP, the 
weight of formulation was seen to be less uniform as the % w/w of NIF increases (table 
3.5). This may be related to the effect of NIF content on the structural strength of FD 
cakes. Although all formulations have shown variations in unit dosage weight greater 
than that observed in the marketed (TEVA 10 mg nifedipine fast release soft gel 
capsule) formulation, the FD 10% w/w NIF in PVP formulation shows a an RSD <2%.     
Formulations showing large variations (RSD > 2%) in unit dosage weight (FD 100 - 30% 
w/w NIF in PVP) have also shown large variations in drug content (≥ 5% RSD). Figure 
3.12 presents the average drug content of in-situ capsule FD formulations and the 
marketed TEVA formulation. Both 50 and 70% w/w NIF in PVP formulations show an 
average drug content below the BP acceptable limit (10 ± 0.5 mg). This may be due to 
the weak nature of the produced FD cakes in such formulations. Manual process such 
as recapping of FD capsules, inside nitrogen bags, have shown the potential to cause 
loss of capsule content, which may be more effective with weakly held FD cakes. In-
situ capsule FD 10% w/w NIF in PVP has shown greater potential, in uniformity of 
weight and drug content, than other in-situ FD formulations, in addition it shows BP 
acceptable drug content (MHRA, 2014b).        
Table ‎3.5 Uniformity of weight for unit dosage (n=3). All formulations are designed to contain 10 mg NIF. 
The percentage listed under formulation column details the w/w % of NIF in PVP of the in-situ capsule 
FD formulations. Weight of empty capsule = 90 mg.  
Formulation and % 
w/w of NIF in PVP 
Expected weight of 
formulation (mg) 
Average observed weight of 
unit dosage form (mg) 
%RSD 
Marketed  - 616.39 0.2% 
FD 100% 100.00 100.37 4.4% 
FD 70% 104.29 103.95 3.0% 
FD 50% 110.00 109.72 2.3% 
FD 30% 123.30 125.41 3.2% 
FD 10% 190.00 200.01 1.2% 
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Figure ‎3.12 Average drug content in each of the tested formulations as well as the marketed 
formulation. Error bars represent standard error of n=3. The marked dashed lines indicate the BP drug 
content limits (MHRA, 2014b).  
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3.4.4. Dissolution studies 
3.4.4.1. Comparing dissolution profiles of different formulation types of NIF in 
PVP  
A multivariate approach (MANOVA) test was conducted to clarify differences in 
dissolution profiles of different formulations of NIF (Yuksel et al., 2000, Costa et al., 
2001). Whereby percentage dosage released at individual time intervals are compared 
for any statistically significant differences. Dissolution rates of different formulations of 
NIF where further compared using mathematical model dependent methods, whereby 
dissolution profile curves are fitted to the most representative kinetic model (Costa et 
al., 2001), allowing a better understanding of the dissolution kinetics and therefore the 
rate constant of dissolution (Costa et al., 2001). For all dissolution studies in this 
chapter, a good linear relationship was found when plotting the natural logarithm, ln, 
of percentage undissolved drug versus time (Figure ‎3.13-B & Figure ‎3.14-B), therefore 
indicating a first-order dissolution process (Chutimaworapan et al., 2000, Costa et al., 
2001). The slope of the first order linear relationship is known as the rate constant (k), 
which may be related to the half-life (t1/2) of undissolved drug (i.e. the time taken for 
the content of undissolved drug to half), using the equation [t1/2  = ln2 / k] (Zeuzem et 
al., 1996).          
The average dissolution profile of nifedipine as received (NIF-AR), 10 ± 0.5 mg of drug 
placed in empty red gelatin capsules, in 0.1M HCL (37.0 ± 0.5 oC), was found to release 
approximately 9% of drug content in 60 min of dissolution testing. The addition of PVP 
to the dissolution medium, in concentrations equivalent to the amount of PVP in 30% 
w/w NIF in PVP (labelled NIF-AR* in figure 3.13-A), did not show a great effect on the 
dissolution profile of nifedipine as received (Figure ‎3.13-A). Applying MANOVA analysis 
shows to be no significant difference, in the percentage drug released at all time-
points, between NIF-AR and NIF-AR*(p > 0.05). The average dissolution rate constants 
of NIF-AR and NIF-AR* are 0.00162 ±7.7x10-5 min-1 and 0.00175 ± 1.0x10-4 min-1 with 
no significant difference. Treating NIF-AR as control, a MANOVA analysis was applied 
to determine if there is a significant difference in dissolution profiles between freeze-
dried formulations, physical mix, NIF-AR and NIF-AR*. Using the Wilks’ Lambda test of 
the MANOVA analysis, the 4 dissolution profiles have shown to be significantly 
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different (P <0.001). Additionally Post hoc analysis was performed using Dunnett (2-
sided) test to identify where the significant difference lay between the 4 dissolution 
profiles (Table 3.13 Appendix 1). Results of the FD formulations show significant 
difference (P < 0.001) to the control NIF-AR starting from 2 min into the dissolution 
profile, while the PM formulation starts to show significant difference from 10 min into 
the dissolution profile (P < 0.05). Repeated measures were applied separately to each 
drug product to allow comparison of percent dissolved at the sequential times. 30% 
w/w FD and 30% w/w PM started to show significant differences in the average 
percentage dissolved at 2 min of the dissolution profile (P < 0.001). Significant 
differences were observed in all remaining sequential times (P < 0.05).  
As MANOVA analysis is based on the assumption that the population of data follows a 
normal distribution, a Levene’s test was applied to compare the variances of 
percentage dissolved at each time point separately, thus treating each time point as a 
single population. Results, from the Leven’s test, show the variances of percentage 
dissolved of time points ≤ 10min to be significantly different (i.e. does not follow a 
normal distribution). Therefore MANOVA results for time points at 10min and below 
are rendered irrelevant. A data suitable non-parametric test (Kruskal-Wallis test which 
assumes monotonic relation-ship between the two variables) was applied to 
determine any significant differences between the percentages dissolved of the 
different test formulations at each time point 1-10min (Table 3.14 Appendix 1). Results 
show significant differences in percentage dissolved to arise between the different 
formulations at ≥6 min table 3.14 (Appendix 1) includes the P values.   
A model dependent method was adopted to further study the dissolution kinetics for 
the fastest segment of each of the dissolution profiles. By plotting the ln of the 
percentage undissolved drug against time (Figure ‎3.13-B), a linear relation confirms the 
reaction follows a first order kinetics (Yuksel et al., 2000, Costa et al., 2001). While 
dissolution profiles for NIF-AR and NIF-AR* show a lag time, for drug release, of 
approximately 20 min, drug content below the detection limit are assumed to be 
released but undetected in this phase. Therefore, no data points were plotted 
between 0 and 20 min, in figure 3.13-B, for NIF-AR and NIF-AR,* as this may interfere 
with the slope of the line, which is also defined as the rate constant (k). Figure 3.13-C 
compares the average k value (n=3) for each of the 4 test formulations. No significant 
difference was found between the dissolution rate constant of NIF-AR* and NIF-AR 
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(even at P = 0.1). The k value for the PM formulation shows a significant difference 
from NIF-AR (P < 0.001 Student’s T-test) with approximately 20 times. The FD 
formulation shows a rate constant, approximately, ten times greater than that of the 
equivalent PM formulation (P < 0.001 Student’s T-test).  
The outcome of the above performed statistical compression and analysis on the four 
test formulations indicates that the dissolution profile of NIF-AR and NIF-AR* show no 
significant difference in rate or percentage dissolved at individual time points. This 
concludes that the presence of PVP in dissolution medium, at levels equivalent to 30% 
w/w NIF in PVP, does not improve the dissolution profile of nifedipine. Nevertheless, 
grinding PVP with NIF to formulate a physical-mix has shown to improve the 
percentage dissolved values of nifedipine at ≥ 10 min, and has increased k by 
approximately 20 times. Presenting NIF in a freeze-dried formulation with an 
equivalent concentration of PVP has shown to further enhance the dissolution rate 
constant, from the PM formulations, by approximately 10 times.  
For a better grasp on the differences in dissolution rates between the 4 dissolution 
profiles, t1/2 for each of the profiles was determined using the presented average rate 
constant in figure 3.13-C. Table 3.6 below shows that the t1/2 of undissolved NIF in in-
situ capsule FD formulation of 30% w/w NIF in PVP is shorter than the equivalent 
physical-mix formulations by approximately 10 time and lower than NIF as received by 
approximately 100 time.    
Table ‎3.6 A summary of t ½ of undissolved NIF in dissolution profiles of different formulations of NIF  
Formulation k (min-1) t1/2 (min) 
Freeze-dried 0.20 3.43 
Physical mix 0.02 34.08 
NIF AR* 0.18 x10-2 396.08 
NIF AR 0.16 x10-2 435.94 
*NIF as received in a PVP containing dissolution medium 2.59x10
-3
% w/v PVP in 0.1M HCl  
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Figure ‎3.13 Comparing (A) dissolution profile, (B) dissolution kinetics and (C) rate constant of nifedipine in different dosage types. The dissolution medium is 0.1M HCL unless 
otherwise stated. Temperature of dissolution medium is 37.0 ± 0.5oC and dissolution volume 900mL. Test was performed following USP paddle apparatus 2. Error bars represent 
standard error of n=3   



































































* Using altered dissolution medium used: 2.59 x 10
-3

















Chapter 3. In-situ freeze-dried solid solution 
154 | P a g e  
 
3.4.4.2. Effect of NIF:PVP ratio on dissolution profile in FD formulations 
Dissolution profiles of FD formulations containing different NIF:PVP ratios are 
presented in figure 3.14-A. Table 3.15 (Appendix 1) presents full descriptive data of 
percentages dissolved at  individual time points. In order to assign the correct 
statistical test (i.e. parametric or non-parametric), the data was subjected to Levene’s 
test (Table 3.16 Appendix 1). Results show percentages dissolved prior to 5 min of the 
dissolution profile, for all compared formulations, to have significantly different 
variances, thus indicating a non-normally distributed data. Therefore, a non-
parametric test (Kruskal-Wallis) was used to compare the percentages dissolved for 
each formulation at time points 1-3 min (Table 3.18 Appendix 1). Results from the 
Levene’s test also show dissolved percentages at 5 and 60 min to follow a normal 
distribution; therefore a MANOVA analysis was performed following the same method 
described in the previous sub-section. Results from the Kruskal Wallis test (table 3.18 
Appendix 1) indicate that a significant difference was observed between percentages 
dissolved of different FD formulations and FD-100% at time-points ≥ 2 min (p < 0.05). 
Similarly, MANOVA analysis shows a significant difference at time-points ≥ 45 min (p < 
0.01). The Dunnett t-test further illustrates these significant differences arise from 
differences in percentages dissolved between FD-10% and FD-100% at 45 and 60 min 
(p <0.001), and FD-30% and FD-100% at 45 and 60 min (p <0.001) both with a positive 
mean difference (table 3.17 Appendix 1). On the other hand a significant difference 
was observed between FD-70% and FD-100% at 45 and 60 min (p = 0.001 and p < 0.001 
respectively). No significant difference was observed between FD-50% and NIF-AS in 
percentages dissolved at individual time points. 
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Figure ‎3.14 Comparing (A) dissolution profile, (B) dissolution kinetics and (C) rate constant of In situ FD nifedipine capsules with varying NIF:PVP ratios. The dissolution medium is 
0.1M HCL unless otherwise stated. Temperature of dissolution medium is 37.0 ± 0.5
o
C and dissolution volume 900mL. Test was performed following USP paddle apparatus 2. Error 
bars represent standard error of n=3  























































 FD 10% w/w NIF in PVP  FD 30% w/w NIF in PVP  FD 50% w/w NIF in PVP




































(w/w % NIF in PVP)
C
Chapter 3. In-situ freeze-dried solid solution 
156 | P a g e  
 
Figure 3.14-B shows all dissolution profiles to follow a first order kinetics. Using 
student t-test, a significant difference in average k value was observed between FD 
10% w/w and FD-100% (p < 0.001), with k of FD-10% greater by approximately 86 
times. The k value of FD-30% was shown to be approximately 56 times greater than 
FD-100% with the significant difference observed at (p < 0.001). The average k values 
of FD-50% showed to be approximately 8 times greater than FD-100% with the 
significant difference observed at (p < 0.05). The k value for FD-70% was shown to 
equal 7.91 x 10-4 min-1 (table 3.7).  
Table ‎3.7 A Summary of t ½ of undissolved NIF in dissolution profiles of different FD formulations of NIF. 
Percentages presented in the FD formulations refer to the % w/w NIF in PVP.  
FD Formulation k (min-1) t1/2 (min
-1) 
10% 0.37 1.88 
30% 0.22 3.12 
50% 0.03 21.49 
70% 7.91 x10-4 879.00 
100% 3.91 x10-3 177.28 
 
3.4.4.3. Effect of PVP and physical state of nifedipine on the kinetic and 
thermodynamic solubility of nifedipine 
Although the presence of PVP in dissolution medium did not show a significant effect 
on the dissolution profile of nifedipine (Fig 3.14), a further investigation on the effect 
of PVP on the kinetic or intrinsic solubility of nifedipine is presented in figure 3.15-A 
and B. The concentration of NIF in dissolution medium at 5 min (Fig 3.16-A) and the 
maximum concentration of NIF, in dissolution medium, reached within 60min (Fig 
3.16-B) are plotted for NIF-AR* against the equivalent % w/w composition. For 
example, the data mark for NIF-AR* 10% w/w NIF in PVP in figure 3.15-A indicates the 
concentration of NIF in dissolution medium, at 5 min, whereby the dissolution medium 
contained a dissolved mass of PVP equivalent to that present in a 10% w/w NIF in PVP. 
As the content of NIF per unit dosage form, for all formulations, was 10 mg, the 
equivalent PVP weight was 90 mg in 900 mL, otherwise expressed as 1x10-2 w/v%.   
Both of figure 3.15-A and B show that the presence of PVP in dissolution medium has 
no significant effect on the kinetic solubility of as received nifedipine. On the other 
hand, the content of PVP in FD formulation showed to correlate to an increase in the 
concentration of NIF in dissolution medium, of 0.1M HCl following [NIFconc.5min = 19.3 
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x C + 11.04] for the concentration of NIF at 5 min of dissolution, and [NIFconc.Max = 
19.6 x C + 11.96], where C is the % w/w NIF in PVP composition, for the maximum 
concentration of NIF reached within the 60 min dissolution test, otherwise defined as 
the kenitic solubility. Both linear correlations were found significant (p < 0.05) when 
tested with linear regression analysis. Although the content of PVP in FD formulation 
showed to correlate to the kinetic solubility of NIF, it is important to refer back to the 
phase diagram described in previous chapters (Chapter 2.4.2.3) where the relation 
between the content of PVP in FD formulations and the % w/w crystalline NIF showed 
a linear relationship with a negative slope, therefore suggesting that the enhancement 
in kinetic solubility is a result of increasing the amorphous NIF content.   
Although the presence of PVP in dissolution medium has shown not to affect the 
kinetic solubility of NIF, results in figure 3.15-C show that the thermodynamic solubility 
of NIF as received, determined over 5 days of equilibrium at (37.0 ± 0.5 oC), to 
correlate with the concentration of PVP in dissolution medium following the equation 
[NIF solubility (thermodynamic) = 134.62X + 7.11] where X is the concentration of PVP in 
dissolution medium in % w/v. An outlier point, thought to be a result of artefact error, 
presented in figure 3.15-C, was excluded from the regression analysis.  
The average kinetic solubility of predominantly amorphous NIF FD-10% (10.16 ± 0.04 
µg/mL) was determined to be 20% greater than the thermodynamic solubility of the 
equivalent NIF-AR* (8.33 ± 1.5 µg/mL), therefore presenting evidence of the positive 
effect on the kinetic solubility of NIF, induced by its amorphous state.  
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Figure ‎3.15 Comparing the concentration of nifedipine (A) after 5 min of dissolution (B) after 60 min of dissolution and (C) after 5 days of equilibrium (thermodynamic solubility). 
The dissolution medium is 0.1M HCL, with the exception to NIF as received* in (A) & (B). 
#
 Only when testing nifedipine as recived*, the dissolution medium also contained PVP at 
concnetrations equal to thoes resulted by the full dissolution of PVP from equevelent FD formulations in 900 mL 0.1M HCl (e.g: NIF as received* with an x-axis (composition w/w % 
NIF in PVP) of 50%, indicates that the dissolution medium for this perticlar test contained a predisolved 10 mg of PVP). Error bars represent standard error (n=3). Circuled data 
point in (C) was considered an outliyer casued by an artefact, and therfore was not included in linear regression analysis.   
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3.4.4.4. Comparing FD 10% w/w NIF in PVP to marketed formulation 
A currenlty markted fast release formulation of nifedipine has been compared to the 
performance of the in-situ capsule FD formulaiton (10% w/w NIF in PVP). Both 
formulations contained 10 mg of NIF. The dissolution profile of both formulations is 
presented in figure 3.16 below. Table 3.8 shows that the predominantly amorphous in-
situ FD capsule formulation, 10% w/w NIF in PVP, reached a dosage percentage 
dissolved of 80% in an avage of 4.8 ± 0.2 min (also referd to as T80), thus compatabil 
with the T80 BP guidelines of fast release tablets and capsule (MHRA, 2014b). The 
marketted formulation on the other hand shows a T80 aproximatly 3 times longer than 
the in-situ FD formulation.  
 
Figure ‎3.16 Comparing the dissolution profile of the in-situ capsule FD formulation 10% w/w NIF in PVP 
against the TEVA 10 mg NIF marketed formulation consisting of a soft gel capsule. Average T80 for the 
marketed formulation is approximately 3 times longer than that of the in-situ capsule FD formulation 
(10% w/w NIF in PVP). Error bars represent slandered error of n=3.     
Table ‎3.8 A summary table comparing key parameters of in-situ capsule FD 10% w/w NIF in PVP with the 
marketed formulation soft gel 10 mg NIF TEVA fast release capsule. Variations are shown as SE. 
Parameters In-situ capsule FD Marketed (soft gel) 
Drug content (10 mg) 9.61 ± 0.09 9.62 ± 0.16 
T80 (min) 4.8 ± 0.2 13.40 ± 2.40 
Dissolution rate constant (k) 0.37 ± 0.05 0.10 ± 0.02 
Maximum reached dosage % dissolved 95% ±0.35% 89% ±0.99% 
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3.4.5. Polarized microscopic dissolution          
The observed reduction in the concentration of NIF in dissolution medium after 20 min 
of the FD-10 dissolution test (Figure ‎3.14-A), may indicate that recrystallization and 
precipitation of drug was taking place in dissolution medium. This concept was 
qualitatively examined as part of this study. The dissolution experiments of FD 
formulations FD-10% and FD-50% were simulated under a polarized microscopy, 
whereby a mass of 1 ± 0.2 mg of material was placed on a clear microscopic slide, and 
a volume of 0.5 mL of 0.1M HCl (37.0 ± 0.5 oC) dissolution medium was pipetted on 
top. The dispersion in dissolution media was monitored through polarized light 
microscopy, where a photo was taken every min over 1 hour. Table 3.9 shows images 
of polarized microscopy at subsequent time points for both FD formulations and a 
control PM-50%. As described in previous chapters, crystals are identified by 
birefringence. Results show that initial recrystallization signs of FD-10% appear at 15 
min, where 3 crystals were observed. The number of crystals was shown to stop 
increasing at 30 min where 6 crystals was the final observed number. FD-50% on the 
other hand appears to take, approximately 5 min more for recrystallization to initiate. 
Image at 20 min of the FD-50% dissolution shows weak birefringence of 3 crystals. The 
number of crystals in FD-50% was shown to sharply increases between 20 and 30 min, 
reaching approximately 100 crystals, at which point the number of crystals was 
maintained approximately the same between 40 and 60 min. Figure ‎3.17-A shows a 
summary of the number of crystals observed, in FD-10% and FD-50%, over the 
duration of the experiment. In an attempt to further quantify the outcome of the 
experiment, individual images were analysed using the software ImageJ, where the 
mean grey value (MGV) of each image was measured. MGV of polarized images 
containing no birefringence is equal to 0.00 arbitrary units (AU). The presence of 
crystals and therefore birefringence causes the measured MGV to increase.  The 
controlled sample, PM-50%, was shown to give a constant MGV of 6.0 ± 0.5 AU (Figure 
3.17-B). The MGV of FD-50% showed to continuously increase after a lag time of 
approximately 25 min and only reaches a plateau at approximately 50 min. Despite the 
small difference in the number of crystals observed between 40 and 50 min in the 
dissolution of FD-50%, the MGV was seen to almost double in value between these 2 
time points. A closer examination of individual crystals (Fig 3.18) shows individual 
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crystals to grow in size, therefore increasing the amount of birefringence observed, 
which was detected through MGV measurements.   
Table ‎3.9 Dissolution of FD-10%, FD-50% and PM50% under polarized light microscopy. Presence of 
birefringence indicates the presence of crystal materials. This may be due to their presence in a sample 
prior to dissolution, such as the controlled sample, or due to recrystallization of amorphous materials.  
Time 
min-1 
FD-10% FD-50% PM-50% 
0 
   
5 
   
10 
   
15 
   
20 
   
30 
   
Chapter 3. In-situ freeze-dried solid solution 




FD-10% FD-50% PM-50% 
40 
   
50 
   
60 
   
  
 
Chapter 3. In-situ freeze-dried solid solution 
163 | P a g e  
 
 
Figure ‎3.17 Analysis of polarized microscopic dissolution: (A) Number of crystals observed under polarized microscopy of FD-10% and FD-50% formulations in a simulated 
dissolution experiment. (B) Mean grey value of polarized microscopy images of simulated dissolution of FD-10% and FD-50% and PM-50%. Although the number of crystals in FD-
50% stops increasing at approximately 40 min, the MGV (correlated to birefringence) continues to increase, therefore indicating crystal growth as presented in figure 3.17. (C) 
Relative crystallinity (θt) versus time fitted with the Avrami equation to determine the rate constant of NIF crystallisation during microscopic simulated dissolution of FD-10% and 
FD-50% (table 3.9).   
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Figure ‎3.18 Crystal growth observed in the FD 50% NIF in PVP formulation. This image was constructed 
from individual light polarized microscopic images using ImageJ software.     
It is important to note that the FD-50% has the potential of presenting more crystals 
than the FD-10% in a single image, simply due to the difference in dilution factor of 
NIF, as NIF in FD-10% is 5 times more diluted than NIF in FD-50%. Therefore, taking the 
dilution factor into account, the final estimated number of crystals formed by FD-10%, 
if the same amount of NIF was observed in a single image, is equal to 30 crystals. This 
was calculated as shown below: 
[Observed number of crystals X Dilution factor = Estimated number of crystals] 
Taking the dilution factor into account, the number of crystals generated from the 
dissolution of FD-50% was still greater than that generated by the FD-10% dissolution 
by approximately 3 times. 
To determine the rate of recrystallization, in order to further compare the two FD 
formulations, the relative crystallinity (θt) was plotted as a function of time 
(Figure ‎3.17-C). Where θt was determined by dividing MGV at interval time points by 
final MGV determined at the end of the experiment. This gives a relative crystallinity 
between 0 (no crystallinity) and 1 (maximum crystallinity reached at end point) for 
both formulations. It is important to note that a relative crystallinity of 1 does not 
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imply that all nifedipine within a formulation has crystalized, but only nifedipine 
susceptible to crystallisation with the time frame and the conditions of the 
experiment. The plots of relative crystallinity (Figure ‎3.17-C) may subsequently be 
analysed with a mathematical model, to determine the rate constant (k). One of the 
commonly used models is the Avrami model (Gaisford et al., 2009): 
 
𝜃𝑡 = 1 − exp [−(𝑘𝑎𝑡)
𝑛𝑎] 
Equation ‎3.1  
(Also presented in  section  1.1.3) 
Where ka is the Avrami rate constant and na is the Avrami exponent (Gaisford et al., 
2009). Figure ‎3.17-C shows both sets of data points, FD-10% and FD-50%, fitted to the 
Avrami equation, where the rate constant and Avrami exponential were determined 
from the equation of the fitted curve (table 3.10). The rate constant of the FD-10% 
showed to be approximately double that of the rate constant of the FD-50% 
formulation. With FD-10% showing a half-life of 1.8 min, while FD-50% showing a half-
life of 1.9 min.  
Table ‎3.10 Avrami rate constant of crystallization (ka) and the Avrami exponent (na) determined for 
both formulations (FD-10% and FD-50%) when in dissolution medium. This was achieved by fitting the 
Avrami equation to the MGV data points as presented in Figure ‎3.17-C. The half-life (t1/2) was 
determined from ka and na using the following equation: √0.693 𝑘⁄
𝑛𝑎
 (Mazzobre et al., 2003).  
Formulation ka (min
-1) na t1/2 
FD-10%  0.04688 4.63767 1.8 
FD-50%  0.02285 5.31117 1.9 
3.4.6. Stability and shelf life of FD formulation 
A stability study was performed on the in-situ capsule FD 10% w/w NIF in PVP 
formulation to allow the estimation of shelf life in storage temperatures ranging from 
25-37 oC and relative humidity ranging from 57-74% RH. The product was packaged in 
FD amber vials as presented in figure 3.7 and sealed under nitrogen. Quality control 
tests were performed on the product at time point 0, 1 and 3 months to test for the 
physical and chemical stability as well as the performance of the product. Table 3.11 
below presents a summary output of the stability study showing average 
measurements before and after storage. The table also includes BP based 
specifications for nifedipine fast release capsules (MHRA, 2014b).  
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Table ‎3.11 Summary of stability study output of the in-situ capsule FD formulation (10% w/w NIF in PVP) 





0 months 3 months 25 oC 
57% RH 










form (mg) 201 ± 20 
201.57 ± 0.30 200.40 ± 0.31 201.06 ± 0.65 
Tg (oC) 2nd 
heat 
- 130.26 ± 3.56 125.04 ± 2.19 125.16 ± 0.76 
Crystalline 
NIF % w/w  


























- 0.37 ± 0.05 - - 0.39 ± 0.04 
T80 (min) < 20 min 4.8 ± 0.2 -   - 5.27 ± 0.1 
*based on peak area % 
Although the average weight of unit dosage form does not show a great change over 
the storage period, Tg shows a decrease by approximately 5 
oC over the course of 3 
months of storage at both temperatures.  
Both, chemical stability and performance have shown to be constant throughout the 3 
month storage at both temperatures. Figure 3.19 below shows the dissolution profiles 
of the in-situ capsule FD 10% w/w NIF in PVP formulation before and after 3 months 
storage at 37 oC. No significant difference was observed between the 2 profiles.      
To further teste the effect of FD on dissolution performance of red gelatin capsules, 
empty capsule bottoms were filled with 0.5 mL of pure TBA, which was then FD 
following the same FD cycle. The empty FD capsules were then loaded with 10 mg of 
NIF as received and put under a USP apparatus 2 dissolution tests (n=3). Results were 
compared to the dissolution of 10 mg NIF as received from untreated red gelatin 
capsules. No difference was observed between the two dissolution profiles (P > 0.05).      
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Figure ‎3.19  Average dissolution profile (n=3) of the FD 10% w/w NIF in PVP at time point 0 months and 
3 months of stability storage at 37 ± 2
 o
C and 75% RH while sealed under nitrogen. No significant 
difference was found between the two profiles. (P>0.05). Error bars represent standard error.   
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3.5. Discussion 
A novel in-situ FD capsule platform was successfully developed for the rapid 
dissolution of PWSD’s in their amorphous form. The novel in-situ capsule FD 
formulation containing 10% w/w NIF in PVP met the BP guidelines with regards to drug 
content and dissolution rate (MHRA, 2014b). Additionally the dissolution rate of the 
novel formulation was observed to be approximately 3 times faster than that of the 
marketed, liquid-filled capsule formulation (TEVA). The in-situ FD-10% formulation 
complied with ICH oriented stability testing (ICH, 2006), where the formulation’s 
performance was maintained with in BP specifications after an accelerated stability 
study.  
Nifedipine was chosen as a model drug because of its poor solubility and high 
permeability (Ali, 1989), thus, this API is an excellent test material as it would greatly 
benefit from the enhancement of its dissolution rate (Chapter 2.1.4). Red opaque 
capsules were chosen to protect nifedipine from light degradation, and therefore 
ensure its chemical stability over storage period.   
The platform developed in this study allowed a simple manufacturing process, 
whereby recrystallization inducing stress was avoided by directly freeze-drying 
formulations inside capsule shells. The use of TBA was essential for this process, as it 
was shown not to cause hard gelatin capsules to dissolve (Fig 3.8-A). Residual TBA after 
the freeze-drying process, for the FD-10%, showed to equal a w/w % of 10.8 ± 0.2%. 
This is equivalent to 10.8 ± 0.2 mg of TBA per capsule. While this value may be reduced 
through improving the efficiency of the freeze-drying cycle, the content of TBA per 
capsule a day is still below the limit of human consumption by the NSF, 1.0 mg/kg-day 
(NSF-Toxicology-Services., 2003), for those above 15 Kg of weight. For example in the 
case of a 75 Kg patient, currently without extra measures for the removal of TBA, a 
maximum of 6 capsules per day maybe consumed following NSF guidelines (NSF-
Toxicology-Services., 2003). However, employing this platform in the treatment of 
chronic conditions may raise concerns due to accumulation of TBA in the body (NSF-
Toxicology-Services., 2003, McGregor, 2010); therefore, this platform is more suited 
for the delivery of emergency medicines.  
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FD capsules were shown to comply with the guidelines for hard gelatin capsule 
monograph of the international pharmacopeia; where by individual capsules were 
visually examined, and tested for uniformity of weight (table 3.3) and disintegration 
performance. FT-IR spectrum of FD capsules were also examined and compared to 
untreated capsules, where no significant difference was observed, therefore indicating 
that FD capsules have not chemically degraded. Scanning electron micrograph 
presented in figure 3.8 showed the physical appearance of FD capsule shells, at various 
magnifications, to be identical to that of the untreated capsule shells. HPLC results 
have also confirmed that the red dye, of the red hard gelatin capsule shells, does not 
leach into liquid TBA (40.0 ± 0.5 oC) based solutions. Therefore, confirming the use of 
hard gelatin capsules fit for the manufacture of in-situ capsule FD formulations.             
Results from this study, show similar crystalline/amorphous patterns to those 
observed in chapter 2, where by, using DSC methods, freeze-dried formulations < 60% 
w/w NIF in PVP showed to be predominantly amorphous. Therefore, indicating that 
the change from freeze-drying in amber vials to opaque size 0 capsules has not 
affected the content of amorphous drug in FD formulations. However a significant 
deviation in the Tg was observed, specifically for FD-10% and FD30%, in the second 
heat of in-situ capsule FD formulation cakes, when compared to the ampule FD cakes 
(table 3.4). As the deviation, in Tg, is observed in the second heat, this may indicate 
that it is due to a small change in the amount of PVP available in the freeze-dried cake 
(as described in section 2.4.2). The overall amount of drug and therefore PVP is as 
expected, so no loss from the capsule was observed. However it can be hypothesized 
that due to PVP’s adhesive property (Lee, 2005), the polymer may adhere to capsule 
walls while in solution or during freeze-drying. The loss of small amounts, of PVP from 
the drug-polymer dispersion can lower the glass transition temperature of the freeze-
dried cake by as much as 20 oC based on the Gordon Taylor theory (Brostow et al., 
2008). 
Although capsule shells were confirmed not to leach red dye into TBA liquid based 
solutions, gelatin leaching, from the capsule shells into feed solutions, may still be a 
possibility. As a result, the diffusion of gelatin to the formulation can affect the Tg of 
the final product. The glass transition of gelatin can vary from 50-90 oC (Gugulothu et 
al., 2015, Sudhakar et al., 2006), therefore if fully dispersed in FD cakes, can contribute 
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to a minor increase or decrease in the overall Tg following the Gordon-Taylor equation 
(Lu and Weiss, 1992), assuming no intermolecular interactions are present between 
gelatin and the other components (Lu and Weiss, 1992).       
Using the novel in-situ capsule FD platform to manufacture 10 mg NIF fast release 
capsules, has shown to better comply with BP regulations, when the % w/w of NIF in 
PVP was maintained at 10%. Higher NIF:PVP ratios (≥ 30% w/w NIF in PVP) were shown 
to have high variations (RSD% > 2%) in unit dosage weight. While formulations 
containing ≤ 50% w/w PVP showed to contain drug contents below the BP (MHRA, 
2014b) acceptable range of 10 ± 0.5 mg (Table 3.3, Fig 3.12). As discussed in previous 
chapters (2.4.2.1), low PVP content can reduce the strength of the FD cake, leaving 
such formulations susceptible to yield loss when handling in processes such as manual 
recapping under nitrogen, leading to variations in weight and the loss of drug content. 
This problem may be overcome in larger manufacturing units, where automated 
recapping processes may be installed in a nitrogen only environment.  
Although the recommended BP method of determining the concentration of nifedipine 
is to use an ultraviolet instrument (MHRA, 2014b), it was found, through preliminary 
studies of this project, to be unequipped to protect nifedipine from light degradation 
(Ali, 1989). Repeated readings of the same sample cannot be performed using the UV 
instrument, as the measurement process leads to the degradation of the sample itself 
(Ali, 1989).  Preliminary experiments using UV showed un-explained fluctuations in 
absorbance, which later were determined, using ICH validated (ICH, 1996) stability 
indicating HPLC assay, as absorbance of degradation products (Ali, 1989). In other 
words, the analytical tool used for assessing stability of NIF, was a factor in 
accelerating the degradation of NIF. To ensure better photo protection of nifedipine 
samples, for drug content uniformity and dissolution tests, a stability indicating HPLC-
UV assay was tested and validated, according to ICH guidelines (ICH, 1996, Potter and 
Hulm, 1988, Kuminek et al., 2010), to ensure nifedipine samples are protected from 
degradation for the duration of analysis. Similar steps were taken towards sample 
preparation methods and dissolution tests, nevertheless, degradation of nifedipine 
during dissolution tests proved to be very difficult to eliminate due to its long duration. 
The maximum accumulative % PA of degradation products observed in the dissolution 
tests of FD 10% w/w NIF in PVP, an average % PA of 11.3 ± 0.4% (i.e. of the total PA 
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occupied by nifedipine and degradation products) at 60 min. (concept of percentage 
PA is explained in section 3.4.1.3). This was clearly observed as a decay in the dosage 
percentage dissolved, after 20 min, of the FD 10% w/w NIF in PVP dissolution (Fig 3.14-
A). Other FD formulations have shown lower accumulative % peak are of degradation 
products, which may be due to the much lower concentrations of NIF observed in 
solution. As dissolved NIF degrades at a much faster rate than solid NIF (Ali, 1989).      
Method of dissolution testing was further optimised, to specifically account for the 
extreme hydrophobic properties of nifedipine (Ali, 1989), following previously 
performed studies (Mehta et al., 1995, Huang et al., 2006, Garbacz et al., 2009, Heller 
et al., 1999a, Crum et al., 2013). Plasticizer containing tubing and syringes where 
replaced by polypropylene products, as preliminary results showed variations (RSD > 
2%) in nifedipine concentration of repeat sampling (n = 3). In addition, the usually 
fitted 0.45 µm cannula filters were found inefficient in filtering nifedipine particles as 
observed in dissolution of soft gel capsules of NIF (described in section 3.4.2.2). Listed 
information from manufacturer detailed that the pore size value listed was an average 
value, indicating that particles above 0.45µm may pass through. As a result, a 
membrane non-adsorptive millipore polyvinylidene fluoride syringe filter was added to 
further enhance the filtration of nifedipine particles. Non-sink conditions were 
implemented in dissolution studies, by not adding additional or external surfactant 
agents such as Sodium dodecyl sulfate (SDS) to enhance the solubility of NIF and 
therefore create a sink condition in dissolution medium (Schug et al., 2002). Non-sink 
conditions in dissolution tests have enabled the kinetic solubility of amorphous 
nifedipine to be determined, a value that may not be obtained if the thermodynamic 
solubility of NIF was measured. In addition, as the solubility of drug is a factor that 
influences dissolution rate, as demonstrated by Noyes and Whitney (1897), tests with 
non-sink conditions, unlike sink conditions, allow better discrimination between 
dissolution profiles of different formulations where the kinetic solubility of drug is 
predicted to be different (Liu et al., 2013).        
Dissolution studies have shown that the presence of PVP in dissolution medium, with 
concentrations ≤ 0.024% w/v (equivalent to NIF:PVP ratios of 90-0% w/w PVP in NIF), 
does not enhance the dissolution rate or the kinetic solubility of pure crystalline 
nifedipine (Fig 3.13 and 3.15 respectively). Alternatively, using the same amount of 
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PVP in physical-mix formulations, where the drug and polymer were simply mixed 
together, has shown to enhance the dissolution rate by a factor of 20 times. This may 
be due to the dual effect of decreasing the particle size of nifedipine where by 
increasing the surface are of dissolution, thus enhancing the rate of dissolution (Noyes 
and Whitney, 1897), and increasing the surface are between the drug and polymer, 
and therefore allowing more efficient wetting This effect was also observed by 
(Broman et al., 2001), where enhancing the contact time between polymer and drug 
was described as key factor in enhancing the wetting of drug, therefore providing 
access of the dissolution medium to the drug surface and preventing aggregation of 
particles and subsequent decrease in surface area. In addition Broman et al. (2001) 
suggests that drug-polymer interactions may occur between drug and polymer, when 
in dissolution medium. Dissolution of NIF as received in PVP containing dissolution 
medium is thought not to have encouraged drug-polymer interaction in dissolution 
medium due to the low concentration of PVP, while in dissolution of physical mix 
formulations, the drug and polymer were mixed prior to dispensing into the dissolution 
medium. This has increased the concentration of PVP in the vicinity of nifedipine 
particles and therefore enhanced drug-polymer interactions while in dissolution 
medium.     
Formulating PVP in an amorphous solid dispersion with NIF has shown to further 
enhance the dissolution rate by a factor of 10 times from the equivalent PM 
formulation (Fig 3.13). The enhancement in dissolution rate is due to presenting NIF in 
its amorphous state (in FD formulations) rather than its crystalline state (PM 
formulations). This was further supported by the pattern observed between the effect 
of content of crystalline NIF in FD formulation and the rate of dissolution; figure 3.14 
shows a sharp increase in the rate constant of FD formulations as the % w/w of NIF in 
PVP decreases, which, as described as a phase diagram in previous chapters (chapter 
2.4.2.3), indicating a decrease in the content of crystalline NIF. Similar patterns were 
observed by Najib et al. (1986) using ibuprofen and PVP solid dispersion and Torrado et 
al. (1996) using albendazole in PVP solid dispersions. Kaushal et al. (2004) described 
high drug content solid solutions to contain small crystals within the dispersion, this 
was observed in >50% w/w FD NIF in PVP formulations in previous chapters (2.4.2.3.2). 
The formation of small crystals within solid dispersion showed to limit molecular 
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dispersion of drug and polymer and as a result has limited the dissolution 
enhancement usually observed in amorphous materials (Kaushal et al., 2004). A more 
recent study by Verma and Rudraraju (2015), investigating the wetting kinetics of 
amorphous solid dispersions of PWSD’s, found that the type and content of polymer 
used in solid dispersion has a great influence over the lowering of the contact angle of 
drug, a measure of wettability, where the limit of contact angle is 0o, indicating 
complete wetting, and 180o for no wetting (Verma and Rudraraju, 2015). PVP, with a 
wetting angle of 27 ± 0.5o (Verma and Rudraraju, 2015) was described to be much 
more efficient than other polymers (HPMC and Copovidone) in lowering contact angles 
of PWSD’s, such as crystalline cilostazol (68 ± 0.6o). Higher amounts of PVP were also 
found to generate higher supersaturated solution from the dissolution of amorphous 
cilostazol solid dispersion, and were maintained for longer as the recrystallization of 
super saturated drug was inhibited at higher concentration of PVP (Verma and 
Rudraraju, 2015). Similar results were observed in this study, where recrystallization of 
nifedipine supersaturated solution from FD-10% generated less crystals than the FD-
50% formulation, taking the dilution factor of NIF in PVP into account as described in 
section 3.4.5 of this chapter (Table 3.9 and Fig 3.19-A). In addition, the MGV of FD-50% 
(Fig 3.18-B) showed to continue increasing after 40 min despite reaching a constant 
number of crystals after 40 min, indicating crystal growth in size (Fig 3.17). FD-10% on 
the other hand, showed a constant MGV value once the number of crystals reached a 
plateau, indicating that high content of PVP can also inhibit crystal growth. This may be 
due to the higher drug-polymer hydrogen bonding interactions, observed at lower % 
w/w NIF in PVP of the amorphous FD formulations  as described in previous chapters 
(chapter 2.4.3), therefore stabilizing dissolved NIF more efficiently. 
To further compare the two formulations in terms of physical stability in dissolution 
medium, the rate of crystallization was determined using the Avrami model (Gaisford 
et al., 2009). The Avrami rate constant of crystallization for FD-10% was found higher 
than that of FD-50% by approximately 2 times. This may be due to the fact that the 
dissolution rate constant of NIF in FD-10% is approximately 10 times higher than NIF in 
FD-50%, thus dissolved NIF is more readily available to crystallise in the dissolution of 
FD-10%.        
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Verma and Rudraraju (2015) also investigated the effect of polymeric carrier on drug 
solubility when present in solvent medium. By measuring the thermodynamic solubility 
of cilostazol in 0, 0.1 and 0.2% w/v PVP solutions, which were allowed to equilibrate 
over 24h (Verma and Rudraraju, 2015), concluded that the inclusion of PVP in 
dissolution medium has no significant effect on the solubility of cilostazol. Such 
polymer concentrations were chosen as they represent concentration of polymer in 
dissolution medium following the dissolution of formulations. Previous studies of the 
effect of polymeric carriers (e.g. PVP and polyethylen glycol) in solvent on the solubility 
of PWSD’s (e.g. pofecoxib and ibuproxam) show contradicting results, where the 
concentration of polymer (0-20% w/v) in solvent, compared to the 0-0.022% w/v 
polymer in solvent tested in this study, was found to enhance the thermodynamic 
solubility of PWSD’s, which were allowed to equilibrate over 2 days (Cirri et al., 2004). 
In both studies by Verma and Rudraraju (2015) and Cirri et al. (2004), the determined 
effect of polymeric carrier on solubility was performed in purified water, rather than 
the dissolution medium used by both studies: 0.1M HCl, pH=1.2 (Hwisa et al., 2013). 
The difference in pH of solution is known to have an impact on solubility (Ali, 1989), 
therefore comparing the thermodynamic solubility of crystalline drug in water to the 
kinetic solubility of amorphous drug in 0.1M HCl may be biased.  
Results from this study, investigated the effect of increasing the concentration of PVP 
in dissolution medium, on the thermodynamic solubility of crystalline nifedipine, which 
was allowed to equilibrate for 5 days. The concentration range of PVP in dissolution 
medium 0-0.022% w/v (Fig 3.15-C) was chosen in order to cover the range of PVP 
concentrations resulted after full dissolution of 10%-100% w/w NIF in PVP in 900 mL of 
dissolution medium. As presented by figure 3.15-C, a strong correlation between the 
concentration of PVP in dissolution medium and the thermodynamic solubility of 
crystalline NIF was observed, where the thermodynamic solubility of NIF in 0% w/v 
PVP in dissolution medium (0.1M HCl pH = 1.2 and 37.0 ± 0.5 oC,) was found to equal 
6.8 ± 0.1 µg/mL. Literature reference for the thermodynamic solubility of nifedipine in 
0.1M HCl was not found, however, solubility of NIF in water at pH 4 was published by 
(Ali, 1989) to equal 5.8 µg/mL. Evidence of the effect of pH (4-9) on the solubility of NIF 
can be found elsewhere (Ali, 1989, Schug et al., 2002). On the other hand, no 
correlation was found between the concentration of PVP in dissolution medium and 
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the kinetic solubility (Kaushal et al., 2004) of NIF in dissolution medium (Fig 3.15). The 
kinetic solubility of amorphous nifedipine, from FD formulations (≤ 50% w/w NIF in 
PVP) showed significant enhancement when compared to equivalent NIF-AR*. Results 
show that at 20 min of dissolution, the FD-10% has reached higher concentrations of 
NIF than the equivalent NIF-AR*, by approximately 26 times (Fig 3.15-B), which also 
exceeds the thermodynamic solubility of crystalline NIF in dissolution medium by 
approximately 1.5 times.  
ICH derived stability studies of in situ FD-10% w/w NIF in PVP, in nitrogen filled sealed 
amber glass vials, showed physical and chemical stability of amorphous nifedipine, for 
at least 3 months, in temperatures ranging between 25-37 oC and 57-74%RH. Product 
quality and performance was tested before and after stability study (fig 3.19) in 
accordance to BP and ICH guidelines and regulations (MHRA, 2014b, ICH, 2006). This 
platform therefore showed great potential in solving fundamental barriers in 
formulating amorphous drugs into stable formulations (Kaushal et al., 2004, Trasi et 
al., 2014, Craig et al., 1999, Vasconcelos et al., 2007, Verma and Rudraraju, 2015). 
Making it an ideal platform to use for early stages of testing novel water insoluble 
drugs in animal trials and early stage clinical trials, where amounts of drug 
manufactured are in short supplies. 
A novel polarized light microscopy dissolution method was developed to allow visual 
qualitative analysis of the recrystallization process during dissolution (Kaushal et al., 
2004, Verma and Rudraraju, 2015). The method, very quickly, started showing 
potential in generating quantitative date to allow accurate comparison between the 
degree and onset of drug recrystallization during dissolution simulated tests; 
therefore, this is worth developing in the future. The Avrami model was used to 
determine the crystallisation rate constant for both FD-10% and FD-50%, as it is based 
on the assumption that there is no crystal impingement within the system (Gaisford et 
al., 2009). As the amount of nifedipine in the freeze-dried cakes of both formulations is 
equal to or less than the amount of PVP, it was assumed that crystals of nifedipine 
have the potential to grow, during the dissolution simulated test, without being 
inhibited by their neighbours, thus the Avrami model was found to be fit for use. 
However, approaching maximum relative crystallinity with the examined freeze-dried 
systems does not imply that all present nifedipine has crystallised. In fact figure 3.18-B 
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shows the physical mix (PM-50%) to have an MGV value approximately 3 times greater 
than the maximum value reached by FD-50%.   
In this study, the dissolution profile of FD-10% was compared to that of the marketed 
soft capsule formulation, TEVA, which consists of a liquid filled soft capsule in which 
nifedipine was pre-dissolved (Cole et al., 2008). The dissolution profile of the marketed 
soft gel shows a lag period of approximately 5 min, where by the slow dissolving soft 
capsule shell (Cole et al., 2008) allowed the release of the liquid formulation at about 6 
min. On the other hand, the predominantly amorphous solid FD-10% formulation was 
dispensed in a conventional fast dissolving, hard gelatin capsule shell (Cole et al., 2008) 
and thus showed a lag period of only 1 min. Once the FD amorphous formulation was 
released from the hard gelatin capsule, it only required an additional 4 min for 80% of 
the drug to dissolve. While the liquid formulation required an additional 11 min 
(approximately 3 times longer). This clearly shows the dissolution enhancement gained 
by rendering a drug into its amorphous form (Verma and Rudraraju, 2015).   
3.6. Conclusion  
A novel platform of in-situ capsule FD formulation was successfully developed, and 
allowed the stable manufacture of solid solution of predominantly amorphous 
nifedipine formulation. Dissolution studies showed FD-10% to have the highest 
dissolution rate constant (0.37 min-1) and lowest t1/2 (1.88 min) of all FD formulations, 
reaching T80 in less than 5 min, which is more than 3 times faster than the marketed 
soft gel formulation of NIF (TEVA). In-situ capsule FD-10% showed physical and 
chemical stability over 3 month accelerated stability study at 37 oC and 75%RH.   
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Chapter 4. Instant disintegrating buccal tablets for 
emergency delivery of naloxone 
4.1. Introduction 
Opioid overdose causes an estimated 69,000 deaths per annum and is a major 
contributor to the global burden of disease (Degenhardt et al., 2011). Naloxone is a 
highly effective opioid antagonist but must be delivered rapidly to the systemic 
circulation of overdose victims, who may be unconscious, so as to prevent fatal 
outcome from respiratory depression (Strang et al., 2013). Existing published 
pharmacokinetic–pharmacodynamics studies of naloxone do not enable simple 
determination of the appropriate dose required to achieve a target concentration or 
concentration–time profile to maximize its antidote efficacy (Dowling et al., 2008). 
Speed of onset is critical to reverse the life-threatening respiratory depression which 
characterizes the opioid overdose (Dowling et al., 2008). Naloxone injection is 
currently licensed for intravenous (IV) and intramuscular (IM) administration and is 
available in two concentrations, 0.4 mg/mL and 1 mg/mL injectable solution.  Licensing 
of naloxone has recently changed in the UK to expand access to naloxone as a 
medicine which is available in emergency situations (MHRA, 2013).  Making naloxone 
available as an emergency medicine is in accordance with the position statements of 
the American Academy of Clinical Toxicology, the American College of Medical 
Toxicology, the American Association of Poison Control Centres (Doyon et al., 2014), 
the American Medical Association (AMA, 2015) and the World Health Organization 
(WHO, 2014).  However, the use of injections in emergency situations is limited by the 
training required to administer these, ideally using aseptic technique, and syringes are 
not readily portable (McDermott and Collins, 2012, Weber et al., 2012). Orally ingested 
dosage forms are unsuitable as they are not easily administered to an unconscious 
patient and naloxone undergoes extensive first pass metabolism and has low 
bioavailability (< 1%) after oral administration (Hussain et al., 1987). 
Prototype improvised kits for nasal administration have been introduced in ambulance 
services and clinical trials, but the use of nasal naloxone remains off-licence as 
Chapter4. Instant dissolving buccal tablets for emergency delivery of naloxone 
Page | 178  
 
supporting pharmacokinetic data is lacking (Strang et al., submitted). There are 
reasons for caution about reliance on nasal naloxone, and concerns about the clinical 
adaptation of untested unlicensed formulations have been expressed (Strang et al., 
submitted). Other non-injectable options need to be considered. 
Buccal delivery provides an attractive alternative route of administration for the 
emergency delivery of drugs (Sudhakar et al., 2006, Lam et al., 2014, Sankar et al., 
2011). The application of a tablet to the inner cheeks of the oral cavity is simple and 
easily accessible to a non-specialist bystanders or healthcare professionals in 
emergency situations (Sudhakar et al., 2006). Following naloxone liberation from the 
dosage form, the buccal mucosa, a 40-50 cell (500-600 µm) thick stratified epithelium, 
provides the principal absorption barrier (Kulkarni et al., 2009).  The vasculature of the 
buccal mucosa drains into the retromandibular, lingual and facial veins, which in turn 
drain directly into the internal jugular vein and, via the superior vena cava, into the 
systemic circulation (Sudhakar et al., 2006, Sattar et al., 2014, Pather et al., 2008).  The 
absorption of naloxone from the human buccal cavity is unknown, but the 
bioavailability of naloxone from the buccal administration in rats has been reported to 
be 70%, compared to 0.3% via the oral route due to the extensive first pass 
metabolism (Hussain et al., 1987), with maximum plasma levels obtained within 15 
min (Hussain et al., 1987).  Sublingual administration of 2-8 mg of naloxone solution 
has been reported to precipitate opiate withdrawal in humans within 30 min (Preston 
et al., 1990). 
Dosage forms for buccal delivery include (i) tablets and lozenges, (ii) films, wafers and 
patches, (iii) liquids, creams, gels, ointments, (iv) sprays, lozenges, chewing gum and 
mucoadhesive film (Patel et al., 2011). Of these options, tablets provide the simplest, 
most portable and easily applied formulation as an emergency medicine, but for 
efficacy will be required to disintegrate immediately on application.  Orally 
disintegrating tablets have recently become widely accepted dosage forms, especially 
for pediatric and geriatric patients and there are more than 55 products having 
marketing authorization in the United States, European Union and Japan.  However, 
despite their rapid disintegration, dissolution times for drugs from these formulations 
is often in minutes rather than seconds (Kraemer et al., 2012).  Development of 
formulations with ‘instant’ disintegration rates (e.g. ≤ 10 s) is required for emergency 
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medicines; one strategy to achieve this is to exploit the physicochemical advantages of 
amorphous materials, which enhance disintegration rate and bioavailability due to 
their increased molecular mobility compared to corresponding crystalline material 
(Allesø et al., 2009, Craig et al., 1999). However, a major problem with producing and 
maintaining amorphous form in a product is physical and chemical instability, i.e. 
reversion to crystalline structure (Alonzo et al., 2010, Jawad et al., 2012). Production of 
solid amorphous medicines is typically complex because the quality attributes of the 
final product are difficult to control, which has proved a limitation for many early 
phase amorphous formulations entering clinical trials (Kawakami, 2009). 
The aim of this study was to develop a safe, easily administered and quick-to-act 
buccal tablet containing naloxone.  A novel instant disintegrating tablet formulation 
was designed by modifying the ratio of gelatin, sodium bicarbonate and mannitol to 
produce an amorphous, but stable tablet by freeze-drying.  Although freeze-drying is 
frequently used as a manufacturing technique for pharmaceuticals, its application to 
instant disintegrating tablets (also referred to as freeze-dried wafer), a technology 
known as Zydis ®, was commercialized in 1993 (Green and Kearney, 1999). However, as 
the expiration of Zydis® related patents is near, (Gugulothu et al., 2015 there has been 
an increase in the research activity associated with this dosage form, therefore 
creating the need for evaluating the performance of similar freeze-dried systems. Such 
evaluation should include measurements of solid state behaviour and disintegration 
times. 
 The principles of molecular and material science (Sun, 2009) were used to design a 
formulation and manufacturing process that confers structural and physicochemical 
properties for optimal stability and performance.  Speed of drug liberation is the 
critical performance or quality attribute for a solid dosage form designed to deliver 
drug in an emergency.  At present there is not a pharmacopoeial method for 
quantifying disintegration for instant disintegrating tablets (Sattar et al., 2014, 
Kraemer et al., 2012, Patel et al., 2012). Therefore a buccal disintegration test was 
developed which proved to be: (i) discriminatory for quality control purposes, and (ii) 
bio-relevant with potential for future development as an assay to predict in vivo 
performance. 
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To achieve the aims of this chapter, the following objectives have been set: 
1- Utilizing freeze-drying to develop, solid dispersion, instant disintegrating tablet 
containing 0.8 mg of naloxone HCl with a pharmaceutical manufacture 
convenient and transferable method.  
2- Developing quality control specifications of the novel pharmaceutical 
formulation for quality assurance and stability measures.  
3- Adapting the manufacture and quality control methods to good manufacturing 
practice to allow for MHRA application for the use of the novel formulation in 
human clinical trials.   
4- Developing novel discriminative disintegration assay with potential for use as a 
quality control test for the novel instant disintegrating tablet of naloxone. 
Table ‎4.1 Target properties of an ideal fast disintegrating tablet 
Property and 
description 
Target properties Limits 
Solid state Predominantly amorphous 
matrix 
Absence of peaks associated 




< 10 seconds Based on BP limits for fast 
disintegrating tablets < 3min 
Drug content 0.8 mg Based on BP limits for naloxone 
injections 0.76-0.84 mg 











12 months , not less than a 5% 
change of the following: 
 
Size: Length: 26-30mm 
Width: 14-18mm 
90%Disintegration time < 10 s 
6 months , not less than a 5% 
change of the following: 
 
Size: Length: 26-30mm 
Width: 14-18mm 
90%Disintegration time < 10 s 
Chemical stability; 
Drug content 
12 months , not less than a 5% 
change of the following: 
 
Based on BP limits for 
naloxone injection  0.76-0.84 
mg 
6 months , not less than a 5% 
change of the following: 
 
Based on BP limits  for naloxone 
injection 0.76-0.84 mg 
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Table ‎4.2 Details of the physical and chemical characteristics of Naloxone. Naloxone structure was 
constructed using ACD/ChemSketch.  
Molecular  Formula  C19H21NO4 (Zhurkovich et al., 2015)  
Structure of Naloxone 
 (Zhurkovich et al., 2015) 
Melting Range 200-205°C (PubChem, 2005) 




( C octanol / C water) 
2.09 (Kaliszan et al., 2002) 
pKa 7.9 (Kaliszan et al., 2002) 
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4.2. Equipment & Materials  
4.2.1. Equipment 
Aluminium blister: Zhejang Xinfei Machinery Ltd China, specification: custom made; 
Digital Caliper: DURATOOL distributors- CPC Preston UK, model: DC150, specification: 
0-150mm; Freeze-drying vials: Packed and provided by Guy’s hospital pharmacy 
manufacturing unit London UK, Catalogue Code (CC): CON/056, specification: 1oz Clear 
Glass Universal Type 1; Freezer: Fisher scientific Ltd Leicestershire UK, Product Number 
(PN): 1204-8281, specification: -20 oC laboratory Freezer (Liebherr GGU1500) under 
bench; Gel imager box: Syngene Europe office Cambridge UK, model: G:BOX HR; Micro 
thermocouple: TC Ltd Uxbridge UK, CC: 401-324 specification: Welded Tip PFA with 
Plug; Rubber Bung: Packed and provided by Guy’s hospital pharmacy manufacturing 
unit London UK, CC: CON063/13, specification: Grey 25mm; Screw cap: Packed and 
provided by Guy’s hospital pharmacy manufacturing unit London UK, CC: CON/058, 
specification: 28 mm silver lacquer; Temperature logger: TC Ltd Uxbridge UK, CC: 753-
671, model: YC-747U, specification: Hand Held Dual Input Multi Thermocouple Type 
Indicator.  
Other equipment used in this chapter, have been listed under the equipment section 
of previous chapters.  
All instruments used in this study were calibrated following manufacturer 
recommendation unless otherwise stated in the method section of this chapter.  
4.2.2. Materials 
Gelatin powder: Fagron UK Ltd Newcastle, Chemical Abstracts Service (CAS): 9000-70-
8, Product Code (PC): Gelatina pulv, Batch Number (BN): 12E30-B02, specification: 
Pharma grade 110 g bloom strength; Mannitol 10% intravenous infusion: Fresenius 
Kabi Manor UK, CC: 2275341, specification: BP grade; Mucin: Sigma-Aldrich Gillingham 
UK, CAS: 84082-64-4, CC: M2378-100G, specification: from porcine stomach; Naloxone 
HCl dihydrate: Fagron UK Ltd Newcastle, CAS: 51481-60-8, PN: D603739, BN: 13D22-
N07, specification: Pharma grade; Potassium phosphate monobasic: Sigma-Aldrich 
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Gillingham UK, CAS: 7778-77-0, CC: P9791-100G; Sodium bicarbonate: Fagron UK Ltd 
Newcastle, PC: NF100075, specification: Pharma grade; Sodium phosphate: Sigma-
Aldrich Gillingham UK, CAS: 7558-79-4, CC: S7907-100G; Water for Injection (WFI): 
Guy’s Hospital London UK specification: internally manufactured.  
4.2.3. Software  
GeneSnap version 6.07.03: Syngene Europe office Cambridge UK; ImageJ: Image 
processing and analysis Java, developed by Wayne Rasband at the national institute of 
mental health; Temp monitor_S2: TC Ltd Uxbridge UK.  
4.3. Methods 
4.3.1. Manufacture of instant disintegrating tablets of naloxone HCl 
Instant disintegrating tablets were produced in the Pharmacy Manufacturing Unit of 
Guy’s Hospital of the Guy’s and St Thomas’ NHS Foundation Trust, London UK.  All 
equipment and instruments were calibrated, tested and maintained in accordance 
with ICH guidelines (ICH, 2000). Feed solution for tablet was prepared by dissolving 
0.780 g of pre-weighed gelatin powder (Fagron Ltd), 0.132 g of sodium bicarbonate 
powder (Fagron Ltd) and 2.931 g of mannitol 10% w/v (Fresenius Kabi) in 40 mL of 
water for injection (WFI) held at 70 oC. Once all excipients were fully dissolved, a 
further 40 mL WFI (room temperature) was added and the solution was allowed to 
cool to room temperature. Naloxone hydrochloride dihydrate (pharm-grade; Fagron 
Ltd) 0.0586 g was dissolved in the feed solution, which was made up to 100 mL. The 
same method was used in preparing feed solutions with varying mannitol:gelatin 
ratios, where the added weights of each of the excipients were adjusted accordingly. 
Empty wells of an aluminium blister (Zhejang Xinfei Machinery Ltd), made and 
designed specifically for this study, were filled with 1.500 g of naloxone HCl feed 
solution. Filled blister wells were cooled down to -20 oC to allow feed solutions to 
freeze, and then were maintained at -20 oC for 2 h as an annealing step. After 
annealing, the blisters were cooled down to -80 oC. Frozen tablets where removed 
from the wells and placed into pre-cooled freeze-drying vials (1 oz Clear Glass 
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Universal Type 1) packed inside a temperature controlled freeze-drying chamber, -40 
oC (Lyotrap freeze dryer; LTE Scientific Ltd). The drying chamber was sealed and a 5 day 
freeze-drying cycle was initiated to ensure all ice within the tablets was sublimed 
under ≤ 0.1 mbar and ≤ -40 oC (Tang and Pikal, 2004). At the end of the freeze-drying 
cycle, the drying chamber was backfilled with nitrogen, allowing it to reach 
atmospheric pressure with the cooling unit on. The drying chamber was opened and 
the freeze-drying vials were immediately sealed with rubber stoppers and screw lids 
while inside the drying chamber. The finished products were removed from inside the 
drying chamber and inspected for breakage or shrinkage. Detailed methodology of the 
preparation and usage of the freeze-dryer was described in previous chapters (chapter 
2). Following GMP requirements, the manufacturing method was documented 
following ICH and MHRA guidelines (Appendix 2). 
Quality control tests were performed on each of three batches of manufactured 
tablets to ensure that they matched specifications.  Two tablets from each batch were 
tested for the uniformity of weight and dimensions (using a digital calliper) and 
disintegration time using an adapted USP method, where by the time taken for 2 
tablets to disintegrate in a non-shaking 100 mL beaker containing 25 mL of water, thus 
making a total of 6 tablets used for each test.  
4.3.2. Naloxone HCl HPLC assay 
A stability indicating, reverse phase, HPLC assay for naloxone HCl was adapted from a 
published method (Mostafavi et al., 2009). This assay was based on comparing 
response, PA, of finished product sample to a standard solution with a known 
concentration of drug, which is the approach commonly used in the pharmaceutical 
industry. The concentration of drug in the standard solution is equal to the ideal 
concentration of finished product sample assuming no drug loss was encountered. 
Equations used to calculate the concentration of naloxone HCl in finished product 
samples, and the content of naloxone HCL per instant disintegrating tablet, are 
described in later sections of this study (Equation 4.1-4.3).  
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As the drug used in this study was available as naloxone HCl dihydrate, the mass of this 
sample was used to convert concentrations and amounts from naloxone HCl dihydrate 
to naloxone HCl.   
4.3.2.1. HPLC system and conditions 
The method utilizes C-18 Gemini-NX 5 µm reverse phase column, mobile phase of 32% 
v/v methanol HPLC grade and 68% 0.1 ammonium acetate (pH 5.8), isocratic flow rate 
of 1 mL/min, column temp of 37 oC and an injection volume of 20 µL. Absorbance was 
measured at 229 nm.  
4.3.2.2. Preparation of mobile phase 
This was performed following the same method described in previous chapters 
(chapter 3.3.2.2). 
4.3.2.3. Preparation of external standard solution  
Pre-weighed 88.0 mg of Naloxone HCL dihydrate (the equivalent mass of 80.0 mg of 
Naloxone HCl) was added into a 100 mL volumetric flask and diluted to the 100 mL 
mark with distilled water. The developed solution was gently mixed by inverting 3 
times. 10 mL of the generated solution was pipetted into a 250 mL volumetric flask and 
further diluted to the 250 mL mark using distilled water. Therefore, developing a 
standard naloxone hydrochloride dihydrate solution with the concentration 35.2 
µg/mL. 
4.3.2.4. Preparation of finished product HPLC sample from a BP adapted 
disintegration method  
Two naloxone instant disintegrating tablets were disintegrated in 25 mL of distilled 
water as part of a BP adapted disintegration test. This solution was transferred into a 
50 mL volumetric flask and diluted to the 50 mL mark using distilled water. 
4.3.2.5. HPLC method validation 
The HPLC method was validated and tested for specificity, linearity, limits of detection 
and quantification, accuracy and precision and robustness according to ICH and MHRA 
guidelines following methods described in previous chapters (chapter 3.3.2.2). As an 
additional requirement for GMP based analytical assay, the HPLC method was also 
validated for reproducibility where by the relationship between response and 
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concentration of naloxone HCl dihydrate determined by two different analysts was 
compared.       
Table ‎4.3 below presents the dilutions used in validation of linearity in the relationship 
between PA and concentration of naloxone HCl dihydrate. The tested range covered 
approximately 50-150% of the target concentration of Naloxone HCl dihydrate in 
finished product (35.2 µg/mL as described above) as recommended by MHRA 
guidelines.  
Table ‎4.3 Preparation of naloxone hydrochloride serial dilutions for a HPLC-UV calibration graph, using 
ultra-purified water as a solvent.   
Dilution 
number 
Volume of stock solution pipetted into individual 
dilutions / mL 
Make up to total 
volume of: / mL 
Final conc. 
µg / mL 
1 0.4 25 20 
2 0.76 25 38 
3 0.8 25 40 
4 0.84 25 42 
5 1.2 25 60 
4.3.3. Differential scanning calorimetry 
Differential scanning calorimetry studies were performed over a temperature range of 
25–200°C following the same sample preparation methodology described in previous 
chapters (Chapter 2). Experimental conditions followed an equilibration at 25 oC for 5 
min, ramp to 200 oC (10 oC/min), followed by a ramp to 25 oC (10 oC/min) and a ramp 
to 200 oC (10 oC/min). All experiments were repeated three times. The sample size 
used was approximately 5 mg, with the mass for each experiment recorded accurately 
on a six-figure balance. 
4.3.4. Environmental scanning electron microscopy 
Samples were adhered to a conventional SEM stub and imaged using a FEI Quanta 
200F microscope. The operating conditions were: vacuum pressure 200 Pa, HV 20kV, a 
gaseous secondary detector and a typical magnification of ×1000. 
4.3.5. Powder X-ray diffraction (PXRD) 
PXRD analyses were performed on Rigaku MiniFlex 600 diffractometer (Rigaku, Tokyo, 
Japan). The samples were spread on a zero background holder and placed on a spinner 
stage. The instrument produces Cu Kα radiation (1.5418 Å) operated at a voltage of 40 
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kV and a current of 15 mA over a scan range 3-40° 2θ with a step size of 0.01° 2θ at a 
speed of 5°/min. 
4.3.6. Digital image disintegration assay 
A digital image or photographic disintegration assay was developed to measure tablet 
disintegration in small volumes of medium in temperature controlled blisters.  
Disintegration was quantified using a gel imager to follow tablet disappearance.  The 
disintegration vessel was a thermal-jacketed aluminium blister sheet with black-
painted wells of the same dimension as those used for manufacturing the tablets (Fig 
4.1).  Disintegration medium was phosphate buffered distilled water (pH 7.3 ± 0.2) or a 
synthetic saliva adapted from the SS5 USP recipe for artificial saliva (Quilaqueo and 
Aguilera, 2015), which consisted of distilled water, salts (NaCl = 8 g/L, KH2PO4 = 0.19 
g/L and Na2HPO4 = 2.38 g/L) and mucin 2.16 g/L (from porcine stomach). 
Assay temperature was adjusted by placing the whole apparatus in a temperature 
controlled water bath at the target temperature. Disintegration medium, 0.7 mL, was 
pipetted into the blister wells adjacent to the test well and micro probe thermocouples 
connected to a data logger thermometer were used to monitor the temperature of the 
disintegration medium. Once the temperature of the disintegration medium in blister 
wells reached the target temperature, the apparatus was placed inside a heat-insulting 
box of polystyrene, and transferred into a closed box gel imager for the disintegration 
assay. This apparatus allowed accurate temperature logging throughout the 
disintegration assay to ensure the temperature of the disintegration medium was 
maintained ± 1 oC of the target temperature.   
Disintegration was measured using a GeneSnap version 6.07.03 gel imager, with the 
camera located above test blister well. A reference image was then taken of test blister 
well containing disintegration medium, after which the well was dried and an instant 
disintegrating tablet was placed in the blister. An image of test well was then taken (t = 
0 s) and the assay initiated by adding the required volume of temperature-conditioned 
disintegration medium onto the tablet, (e.g., 0.7 mL at 35 oC) after which 100 
consecutive images were taken at 0.4 s intervals. Image J analysis software, was used 
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to analyse the images by determining the mean grey value (MGV), corrected for 
baseline at each time point and normalized to the assay range. 
 
 
Figure ‎4.1 Schematic for the digital image disintegration assay, constructed from an aluminium blister 
sheet with a painted black background to provide contrast for the tablet. Disintegration of the tablet 
was monitored as the mean grey value using an image analyser.  
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4.4.   Results 
4.4.1. HPLC method validation 
Following the same steps for, validating analytical methods, described in previous 
chapters, the stability indicating HPLC assay for naloxone HCl was validated. 
4.4.1.1. Naloxone HPLC Assay  
The HPLC assay developed in this study was based directly on the relationship between 
PA ratio of sample to external standard and the concentration of drug in µg/mL. Unlike 
previous chapters, internal standard was replaced here by using standard solutions of 
naloxone HCl as an external standard solution. This method was more convenient for 
GMP dedicated laboratories, where the aim was to avoid introducing foreign 
compounds to samples of manufactured products and or HPLC instruments which have 
been dedicated for particular formulations. The concentration of drug in unknown 
samples was determined by comparing the PA’s, at the RT of the drug, of unknown 
samples to an average PA of standard solution generated by 2 separate HPLC injections 
before and after the unknown sample, one each, assuming a linear relationship 
between drug PA and concentration in the range of analysis (this is confirmed in later 
sections of this study Table ‎4.5). The following equation was used to convert PA at 2.6 
min, for finished product sample, to a concentration of naloxone hydrochloride 
dihydrate µg/mL:   
 
[NLX HCl dihydrate] µg/mL =  
PAFPS ×  Mass of standard (mg)
PASTD ×  88.0
 × 35.2    Equation ‎4.1 
To determine the content of naloxone HCl dihydrate per tablet, the following equation 
is then used: 
Content of NLX HCl dihydrate (mg) =  
Conc.  of naloxone HCl dihydrate (FPS)
40
  Equation ‎4.2 
Finally to determine the content of naloxone HCl per tablet the following equation was 
used: 
Content of NLX HCl  (mg) =  
Content of naloxone HCl dihydrate pert tablet x 363.83
399.87
 Equation ‎4.3 
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4.4.1.2. Specificity  
4.4.1.2.6 Separation adequacy 
Table ‎4.4 HPLC System suitability criteria (FDA, 1994) for the naloxone HPLC assay. Despite not meeting 
the FDA recommended capacity factor, other aspects of the assay, such as repeatability and 
reproducibility, were found to meet the required needs. Therefore making the naloxone HPLC assay fit 
for purpose. 
Parameters Naloxone FDA recommended criteria 
Column efficiency 4020.46 >2000 
Capacity factor 0.81 >2 
Peak Symmetry 0.88 0.9-1.4 
Resolution from noroxymorphone 4.0 >1.5 
 
4.4.1.2.7 Selectivity 
Selectivity was investigated through the analysis of 10 different placebo samples. The 
placebo samples were prepared by disintegrating placebo IDT (Naloxone free IDT) in 
100 mL volumetric flask. The resulting solution was tested using the Naloxone stability 
indicating-HPLC assay. 
No interference was detected at the expected RT of Naloxone.     
4.4.1.3. Linearity and limitations in quantification and detection   
Table ‎4.5 below shows a summary of the linear relationship between PA of Naloxone 
HCl dihydrate and the PA response at 2.66 min. the target concentration to be 
measured is much higher than the limit of detection and quantifications detailed 
below:  
Table ‎4.5 Calibration curve details for the NLX HPLC assay. LOD and LOQ were calculated following the 
same steps taken in previous chapters. All values listed below are related to the concentration of 
naloxone HCl dihydrate.  
Linear range 20.0 to 60.0 µg/mL (naloxone HCL dihydrate in distilled water) 
HPLC assay NLX conc. (µg/mL) = (13.5 X PA) – 4.77 
R2 ≥ 0.9999 
LOD 0.36 µg/mL 
LOQ 1.83 µg/mL 
Equation to 
determine 
content of NLX 
per tablet 
Content of NLX per tablet in mg  =  [(PA (RT 2.6 min) +4.7696) / 13.505] x 0.025 
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4.4.1.4. Accuracy and Precision 
The calibration graph was tested for accuracy and precision through the analysis of 
three standard solutions of Naloxone with known concentrations. Results for accuracy 
are reported as % bias between the estimated and the actual concentration values. All 
of which are less than 1.5%. Precision of the HPLC assay is described via the inter and 
intra percentage coefficient variance.  All of which is below 0.5%. 
Table ‎4.6 Accuracy of the naloxone HPLC assay; Three standard naloxone solutions were tested on 
different times of the day. Each sample was injected twice and the average estimated concentration was 
compared to the actual concentration. Note; the conc. of A, B & C is slightly different (32-33 µg/mL) 
Sample 
analysed 
Average*  Accuracy %bias from 
actual concentration 
Inter %CV Intra %CV 
A 32.25 -0.9% 0.1% 
0.40% B 32.09 -1.4% 0.1% 
C 32.40 -0.4% 0.0% 
* Estimated concentration (number of repeat injections = 2) 
4.4.1.5. Robustness 
4.4.1.5.8 Repeatability of response 
The variation in repeatability of RT for 10 different injections of the same standard 
solution is presented by the percentage coefficient variance (%CV) as 0.0%, while the 
variation in PA is determined to be 0.1%. 
Table ‎4.7 Summary for repeatability of response, RT and PA, for 10 different HPLC injections of the same 




1 2.66 432.8 
2 2.66 432.9 
3 2.66 432.4 
4 2.66 432.7 
5 2.66 432.5 
6 2.66 432.4 
7 2.66 432.9 
8 2.66 432.9 
9 2.66 432.7 
10 2.66 433.0 
Average 2.66 432.7 
STD 0.00 0.2 
%RSD 0.00% 0.10% 
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4.4.1.5.9 Stress study 
Standard solutions of naloxone were subjected to varies stress factors to determine 
the ones that can contribute to degradation of naloxone. Degradation of naloxone was 
detectable using the HPLC assay described above by showing a peak at 2.22 min for 
Noroxymorphone. It is not necessary to identify or quantify this impurity for 
demonstration of compliance (BP). 
Table ‎4.8 Summary of stress study: Presenting the different stress tests that were performed on 














% of naloxone 
hydrochloride 
concentration* 
None 2.6 NLX - 701.05 31.15 100% 
No stress stored 
for 16 h 
2.6 NLX - 698.55 31.04 100% 
Light, solution 
was subjected 
to light for 16 h 
2.6 NLX - 698.55 31.04 100% 
Heat to 70 o C 





2.2 NOX 16.40 
Heat to 70 o C 





2.2 NOX 70.85 
*In relation to solution prior to the stress 
4.4.1.6. Reproducibility 
4.4.1.6.10 Confirming linearity 
A linear relation between the concentration of naloxone (20 – 60 µg/mL) and the PA 
was confirmed by an additional analyst. 
Table ‎4.9 Validation of linearity by a second analyst 
Linear range 20.0 60.0 µg/mL (naloxone I distilled water) 
HPLC assay NLX conc. (µg/mL) = (13.2 X PA) – 11.67 
R2  >0.999 
 
4.4.1.6.11 Variation in drug content analysis by different analysts  
 Standard sample solution of finished product were analysed by 2 different analysts 
using the same HPLC method described above. The determined concentrations were 
compared to one another to show <2% variation from one another.     
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Table ‎4.10 Variation in determined drug concentration, between the 2 analysts as a measure of 
reproducibility.  
 
PA at 2.6 min Calculated conc. of NLX using  µg/mL Intra % variation 
Analyst 1 302.5 22.75 
-0.4% 
Analyst 2 301.3 22.66 
 
4.4.1.7. Summary of HPLC method validation 
The method for the assay of naloxone hydrochloride by HPLC has been assessed for 
specificity, repeatability, linearity, accuracy and precision and was found to be 
satisfactory. The method is considered fit for purpose and is suitable for use within the 
13th Floor Pharmacy QC Lab for routine and stability testing. 
Table ‎4.11 Acceptance criteria (FDA, 1994) and results summary for the validation of HPLC assay for 
naloxone hydrochloride. 
Parameter Observed values FDA recommended criteria 
Resolution 4.0 >2.0 between additional peaks 
Linearity R2> 0.999 R2>0.9992 
Precision <0.4% RSD <2.0% 
Precision between 
analysts 
<0.4% RSD <2.0% 
LOD 0.36 µg/mL 
Internal acceptance criteria LOQ ≤ 5% 
of the target concentration. Thus it 
must not exceed 1.6 µg/mL 
LOQ 1.83 µg/mL 
Internal acceptance criteria LOQ ≤ 
10% of the target concentration. Thus 
it must not exceed 3.2 µg/mL 
 
4.4.2. Temperature control validation for DIDA 
As temperature is believed to be a critical parameter that can influence the rate of 
table disintegration, it was critical to control the assigned temperature of the 0.1-0.7 
mL disintegration medium over the period of the disintegration test. To validate the 
method used to control the temperature of the disintegration bath, validation 
experiments were performed, where by the temperature of the disintegration bath 
was monitored and recorded with an interval of 1 sec at all investigated temperatures 
(25 oC, 33 oC, 35 oC and 37 oC-Fig 4.2) for 0.7mL, and all volumes (0.1 mL, 0.2 mL, 0.4 
mL -Figure ‎4.3) for 35 oC. Each condition was tested 3 times for at least double the 
duration of the expected disintegration. Results show that temperature, for all 
conditions, was controlled within a ±1.0 oC of the target temperature (Fig 4.2 & 4.3).      
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Figure ‎4.2 Average recorded temperatures for 4 different target temperature conditions of a 0.7 mL 
DIDA test. (starting from the top, the target temperatures were: 37, 35, 33 and 25 
o
C). Error bars 




Figure ‎4.3 Average temperature of disintegration mediums with different volumes for the duration of 
the experiment. Target temperature is 35 
o
C Error bars represent standard error of n=3.   
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4.4.3. Tablet composition  
Ratios of mannitol, gelatin and sodium bicarbonate were varied with the aim of 
identifying a tablet composition that would form an amorphous and porous freeze-
dried product. Mannitol was utilized because of its hydrophilic nature, bulking 
properties and common use as a lyoprotectant (Gugulothu et al., 2015). Gelatin was 
selected to confer the quality attributes for a successful product; i.e. gelatin typically 
forms glassy amorphous complexes with relatively high glass transition temperatures, 
Tg 50-90°C, provides structural strength and has mucoadhesive properties (Sudhakar et 
al., 2006, Gugulothu et al., 2015). 
Preliminary results showed that simply freeze-drying aqueous solutions of pure 
mannitol and pure gelatin produced tablets of very poor quality.  Freeze-dried tablets 
composed of 100% w/w mannitol possessed a distinct melting peak with an average 
onset at 163.9 ± 0.5 oC (n=3), indicative of a crystal melt (Figure 4.4). A small 
endotherm at approximately 60°C for 100% w/w freeze-dried mannitol was 
representative of the hemihydrate crystalline form of mannitol (Nunes et al., 2004), 
indicating that freeze-drying a solution of pure mannitol produced a crystalline 
product.  Comparable studies have demonstrated that freeze-dried mannitol contains 
a mixture of the hemihydrate together with the anhydrous polymorphs as mannitol 
hemihydrate is quite unstable (Nunes et al., 2004, Cavatur and Suryanarayanan, 1998). 
The melting points for the α and β polymorphs are very close together and have been 
reported to fall between 165 and 166°C (Cornel et al., 2010, Telang et al., 2003). A 
lower onset for this melting peak of approximately 164°C indicates the presence of an 
additional phase. Further inspection of the leading edge of the endothermic peak 
revealed a very small and broad inflexion overlaid on the rapidly falling heat flow 
curve. Nunes et al. have attributed this broadening of the peak onset to conversion of 
an anhydrous δ polymorph to the β form of mannitol. Dehydration of the hemihydrate 
form mannitol at 60°C initiates the formation of the δ polymorph (Nunes et al., 2004). 
The δ polymorph is enantiotropic and thus will undergo transition to the more stable β 
form over quite a wide temperature range, typically from 140 to 180°C with a 
relatively small PA when observed by DSC, thus it is often difficult to identify this 
transition (Telang et al., 2003). 
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Pure mannitol crystalline tablets were brittle and difficult to remove from their sample 
vials without collapsing into a powder. In contrast, pure gelatin tablets had a sticky 
texture and lacked porosity.  Formulations containing both mannitol and gelatin 
proved successful when freeze-dried; addition of gelatin diminished the crystalline 
melting peak in the freeze-dried product whereas mannitol conferred porosity within 
the tablets. However, even with high gelatin content, persistent peaks were observed 
in the amorphous halo of the powder x-ray diffraction results. This indicated a 
crystalline fraction within the freeze-dried tablet and the unique peak at 9.7° 2θ 
identified the presence of mannitol hemihydrate (Nunes et al., 2004), an example of 
this unambiguous peak can be seen in Figure 4.6. 
 
Figure ‎4.4 Differential scanning calorimetry to show the effect of mannitol:gelatin ratio on the thermal 
properties of the freeze-dried instant disintegrating tablets.The tablets were composed of 
mannitol:gelatin in the ratios illustrated, plus sodium bicarbonate 11% w/w, with the exception of the 
100% w/w mannitol sample.  
Since mannitol has an affinity for inorganic salts and this miscibility often leads to the 
inhibition of mannitol crystallization when present in freeze-dried solids (Telang et al., 
2003), sodium bicarbonate was introduced as a ternary agent. Physical mixtures of 
mannitol and sodium bicarbonate were investigated by heating to 200°C to melt the 
mannitol, then analysed by DSC while cooling at 10°C/min back to room temperature. 
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The addition of sodium bicarbonate reduced the size of the mannitol recrystallization 
peak in the cooling cycle.  At concentrations of sodium bicarbonate above 10% w/w, 
crystallization of mannitol could no longer be seen. The reduction in the observed 
mannitol recrystallization enthalpy was linear with increasing sodium bicarbonate 
concentration (ΔrecryH = -20.3[NaHCO3] + 220.9; r
2 = 0.9, n = 18). The extrapolated line 
crossed the enthalpy axis at a concentration of sodium bicarbonate at approximately 
10.9% w/w (supporting information; Figure 4.5), indicating that this is the 
concentration of sodium bicarbonate at which crystallization of mannitol is inhibited 
entirely. Therefore, unless otherwise stated all freeze-dried tablets were formulated to 
contain 11% w/w sodium bicarbonate. Scanning electron microscopy images revealed 
that the inclusion of sodium bicarbonate resulted in an increase in pore size but a 
reduction in the thickness of the pore walls compared to tablets prepared without 
sodium bicarbonate (data not shown). 
 
Figure ‎4.5 Peak area of the mannitol recrystallization peak measured in the cooling cycle by differential 
scanning calorimetry against the concentration of sodium bicarbonate present in the binary physical 
mixtures.  
The effect of mannitol:gelatin ratio on the crystallinity of the tablet was screened using 
differential scanning calorimetry.  As the proportion of mannitol reduced relative to 
gelatin, progressively broader peaks with a reduced area appeared at lower 
temperatures.  Peaks were entirely absent from formulations containing < 24% w/w 
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mannitol (Figure 4.4). These observations were confirmed by X-ray diffraction (Figure 
4.6) indicating that the freeze-dried product containing 24% w/w mannitol and 11% 
w/w sodium bicarbonate was fully amorphous.  Characterisation of the tablet 
excipients by PXRD showed distinct peaks for mannitol, naloxone and sodium 
bicarbonate, but no peaks for gelatin (Figure 4.7).  Thus, an optimised formulation with 
a composition of 24% w/w mannitol, 65% w/w gelatin and 11% w/w sodium 
bicarbonate was defined.  These tablets were confirmed to be predominately 
amorphous by PXRD, both with and without the incorporation of naloxone 800 µg 
(Figure 4.7). 
 
Figure ‎4.6 Powder X-ray diffraction to show the effect of mannitol:gelatin ratio on the solid state 
properties of the freeze-dried fast disintegrating tablets. The tablets were composed of mannitol:gelatin 
in the ratios specified, plus sodium bicarbonate 11% w/w.  
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Figure ‎4.7 Powder X-ray diffraction of individual tablet excipients, plus the formulated product with and 
without naloxone 800 µg. 
4.4.4. Tablet specification and stability 
The instant disintegrating buccal tablets conformed reproducibly to quality 
specifications for weight, size, speed of disintegration and drug content (Table ‎4.1).  
The white hemispherical porous tablets were 29.4 ± 0.2 mm in length, 16.1 ± 0.5 mm 
in width with a depth of 3.0 ± 0.2 mm and weighed 17.7 ± 0.4 mg (Figure 4.8).  
Scanning electron microscopy revealed the pore size in the tablet to be approximately 
100 µm (Figure 4.8).  The target drug content, 800 µg of Naloxone HCl/tablet and 
chemical stability over 9 months when stored under nitrogen at 4 oC or 25 oC were 
confirmed by HPLC assay.  The residual moisture content of the tablets was 10.4 ± 
3.2% w/w, which is relatively high, but it did not result in chemical degradation of the 
API or physical instability (Table ‎4.12). 
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Figure ‎4.8 FDT’s appearance and physical structure; The top left, photograph of the instant 
disintegrating tablet with the length displayed in mm, top right showing the tablet’s intended method of 
dispensing to an unconscious patent’s buccal cavity. Bottom main image; presenting a scanning electron 
micrograph of the instant disintegrating tablet, with a smaller image to its tope left corner; showing 
porous structure at higher magnification.  
  
Chapter4. Instant dissolving buccal tablets for emergency delivery of naloxone 
Page | 201  
 
Table ‎4.12 Summary of naloxone FDT’s stability data for 9 months, specifications listed are derived from 
related BP monographs.  
    Stability 
Parameter Specification 0 months 9 months 
      4 oC 25 oC 
Tablet weight (mg) 16.9 - 20.7 17.8 ± 0.5 17.8 ± 0.5 17.6 ± 0.5 
Dimension - length (mm) 20.0 - 30.0 29.4 ± 0.2 29.1 ± 0.3 29.1 ± 0.7 
Dimension - width (mm) 14.0 - 18.0 16.1 ± 0.5 16.1 ± 0.3 16.0 ± 0.3 
Disintegration test* (s) ≤180 14.0 ± 5.9 9.0 ± 5.0 10.0 ± 5.0 
Naloxone HCL assay (mg) 0.76 - 0.84 0.80 ± 0.01 0.81 ± 0.02 0.80 ± 0.03 
*BP adapted disintegration method. 
4.4.5. Good manufacturing practice 
For the purpose of meeting GMP requirements, thus to allow application for using 
naloxone HCl instant disintegrating tablets in clinical trials, the manufacturing method 
and quality control tests for naloxone HCl IDT were documented following ICH and 
MHRA guidelines in appendix 2 and 3 respectively. These documents allowed the 
transfer of laboratory developed methods to be implemented in a control 
pharmaceutical manufacture environment, and therefore allow for an investigational 
medicinal product dossier (IMPD) to be submitted to the MHRA for the use of the 
developed naloxone IDTs to be used in a human clinical trial (Appendix 4). 
4.4.6. Rapid Buccal Disintegration 
The novel digital imaging disintegration assay (DIDA) was used to explore the effects of 
temperature, solvent volume and composition on the disintegration of the tablets. 
Under all conditions the tablets disintegrated fully (>90%) within 30 s.  Tablets 
disintegrated in < 10 s in 0.7 mL of phosphate buffer at 35 oC (Figure 4.9-A).  
Temperature variation over the range reported to exist in the buccal cavity (Moore et 
al., 1999), 33-37 oC did not alter the disintegration rate, but the rate was 4-5 times 
slower at 25 oC.  In opiate overdose, the volume of oral fluid available in the buccal 
cavity may be reduced compared to 0.7 mL  in a typical adult human (Patel et al., 
2012). Reducing the amount of fluid available to the tablet progressively reduced the 
rate at which the tablet disintegrated, with disintegration in 0.1 mL being 4.5 times 
slower than in 0.7 mL (Figure 4.9-B). Interestingly, when phosphate buffer was 
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replaced with synthetic saliva, a slightly quicker disintegration rate was observed, a 
result of better spreading and wetting of the tablet caused by the mucin present in the 
disintegration media (Figure 4.9-C). 
Evaluating the discrimination between disintegration profiles in different temperatures 
and volumes, was performed using the similarity factor (f2) test (Shah et al., 1998) 
rather than MANOVA analysis. This is due to the high number of data points recorded 
for each disintegration profile, and therefore making the MANOVA analysis 
impractical. Equation 4.4 below present f2: 
𝑓2 = 50. log{[1 +
1
n




]−0.5. 100} Equation ‎4.4 
Where n is the number of time points in the disintegration profile, Rt and Tt represent 
the percentage of matrix reaming in the reference profile and the tested profile 
respectively. When f2 is ≥ 50, this indicates a high similarity between the 2 
disintegration profiles. Table 4.13 below presents a summary of the f2 test output for 
discrimination against temperature and volume respectively. 
Table ‎4.13 Summary of the f2 test for disintegration between profiles with different temperatures and 
volumes. f2 ≥ 50 shows high similarity between the profiles. Low similarities are only seen between 25 
o
C and other temperatures. While discrimination against volume shows low similarities between all 
volumes with the exception of 0.2 and 0.1 mL     











35 oC 57.6 High 
0.7 mL 
0.4 mL 28.36 Low 
33 oC 63.32 High 0.2 mL 19.13 Low 
25 oC 19.78 Low 0.1 mL 17.09 Low 
35 oC 
37 oC 57.6 High 
0.4 mL 
0.7 mL 28.36 Low 
33 oC 72.83 High 0.2 mL 35.26 Low 
25 oC 22.74 Low 0.1 mL 27.89 Low 
33 oC 
37 oC 63.32 High 
0.2 mL 
0.7 mL 19.13 Low 
35 oC 72.83 High 0.4 mL 35.26 Low 
25 oC 21.75 Low 0.1 mL 48.2 High 
25 oC 
37 oC 19.78 Low 
0.1 mL 
0.7 mL 17.09 Low 
35 oC 22.74 Low 0.4 mL 27.89 Low 
33 oC 21.75 Low 0.2 mL 48.2 High 
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Figure ‎4.9 Disintegration profiles of naloxone FDT: The effect of (A) temperature [volume 0.7 mL; medium – phosphate buffered saline], (B) volume of disintegration  medium 
[temperature 35 
o
C; medium – phosphate buffered saline] & (C) disintegration medium [temperature 35 
o
C; volume 0.7 mL] on the disintegration profile of the FDT; using a digital 
image disintegration assay.  Data represent mean ± standard error, n=3. 
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4.4.6.1. Comparing naloxone FDT to the Zydis® formulation 
The rate of disintegration for naloxone FDT was also compared to the Zydis® 
formulation, marketed as Imodium® for the release of loperamide HCl. DIDA 
parameters included 0.7 mL of phosphate buffer and a maintained temperature 37 oC. 
As demonstrated by figure 4.10, the disintegration of the Zydis® formulation does not 
reach a percentage of matrix remaining ≤ 20%. On the other hand, the Zydis® 
formulation showed to generate a cloudy suspension. While this may not be ideal for a 
buccal formulation, it is considered fit for purpose as the Zydis® formulation was 
designed for oral delivery rather than buccal (Green and Kearney, 1999). However the 
enhancement in matrix disintegration, and disappearance of the naloxone FDT matrix, 
is clearly emphasised in figure 4.10.    
 
Figure ‎4.10 Disintegration of the naloxone FDT compared to the Zydis® formulation, marketed as 
Imodium instants®, at 37 
o
C and 0.7 mL of phosphate buffer. The Zydis® produces a cloudy suspension 
with more than 40% of the matrix remaining, while the novel naloxone FDT generates an almost clear 
suspension with less than 90% of the matrix remaining.    
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4.5. Discussion 
An instant disintegrating tablet for rapid delivery of naloxone HCl was developed 
successfully to be tested in a clinical trial for emergency buccal delivery medicine in 
opioid overdose. The product is suitable for proof of concept clinical trials in humans 
to determine the pharmacokinetics of naloxone delivered via this route. The size and 
shape of the developed tablet were designed to ensure a high surface area contact 
with the buccal epithelium. The open pore structure and amorphous structure of the 
low density tablet, 11.8 ± 0.3 × 10-3 g/mL, were designed for rapid release of drug in 
low volumes of fluid. Additionally, the size and shape of the tablet were fashioned 
based on the recommendations of healthcare professionals experienced in treating 
overdose patients (Gugulothu et al., 2015). These dimensions contrast with smaller 
fast disintegrating buccal tablets currently under development (Gugulothu et al., 
2015). 
A tablet specification was developed for weight, dimensions, rate of disintegration and 
drug content and used to verify batch-to batch reproducibility and stability 
(Table ‎4.12). Tablets containing 24% w/w mannitol showed no shrinkage or collapse 
from their dimensions after the initial freezing step, confirming that the collapse 
temperature of the formulation was not exceeded during the drying cycle. If the Tg of 
mannitol in maximally freeze concentrated aqueous solutions (-27 oC) is exceeded 
during drying, collapse and crystallization of the amorphous cake is observed as a 
dramatic shrinkage of the product (Cavatur and Suryanarayanan, 1998). One of the 
roles of gelatin in the formulation is to raise the glass transition of both the freeze 
concentrated solution and the dried amorphous product in which gelatin maintains the 
amorphous structure.  The drying cycle reported within this paper is conservative, 
incorporating a wide safety margin; when considering scale up and increasing process 
efficiency, the drying temperature of -40 oC could be increased. 
Gelatin alone was insufficient to prevent crystallization of mannitol within the tablet 
during freeze-drying. Even at 65% w/w gelatin, sodium bicarbonate was required to 
eliminate the persistent PXRD peak, indicative of the crystalline hemihydrate form of 
mannitol. This peak disappeared when 5% sodium bicarbonate was added to the feed 
solution. However, measurement of recrystallization during the cool cycle using DSC 
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revealed that concentration of sodium bicarbonate for full suppression of 
crystallization was 11% w/w. Thermal analysis, especially DSC, is influenced less by 
particle size and density issues compared to PXRD because the whole of the crystalline 
fraction present in the sample contributes to the response observed (Kim et al., 1998). 
Thus DSC was more sensitive for determining the concentration of sodium bicarbonate 
needed to prevent mannitol crystallization. When salts are present in freeze 
concentrated solutions of mannitol, the sugar has a greater affinity for ions and water, 
than with itself and thus the formation of mannitol crystals is inhibited. However water 
is key to this mechanism; removal of a large proportion of the non-frozen water during 
secondary drying and this protective effect is lost and mannitol crystals are observed 
(Telang et al., 2003). Thus secondary drying was negated in the preparation of the 
tablets reported here and a longer primary drying cycle was applied. This resulted in 
10% w/w residual water content for the tablets that maintained their amorphous 
structure but did not adversely influence the stability of the product. 
A wide range of mannitol to gelatin concentration ratios were investigated to allow 
selection of a predominantly amorphous formulation for further investigation. Gelatin 
acts as a binder and provides structural strength, resistance to breakage and a highly 
porous spongy structure (Gugulothu et al., 2015). Too much gelatin can have a 
negative effect on the rate of disintegration and dissolution as a result of inter-
molecular interactions between the polymer chains of gelatin, through both hydrogen 
bonding and steric hindrance (Sudhakar et al., 2006). Both mannitol and salts are 
incorporated within freeze-dried materials to bridge and intercalate these tight 
polymer aggregates and thus expand the porous structure (Jones et al., 2011). Thus, 
high concentrations of gelatin in the formulation increase the likelihood of strong 
inter-polymer chain attractions, resulting in water trapping and the subsequent 
formation of gels (Gugulothu et al., 2015). Unlike in other studies, for example study 
by Gugulothu et al., where this problem was overcome by lowering the gelatin content 
and compensating with crystalline mannitol as a supporting agent (Gugulothu et al., 
2015), we have shown that it is possible to increase the ratio of gelatin to mannitol and 
form amorphous tablets (Figures 4.4, 4.6 & 4.7). 
To circumvent the issue of strong gelatin intermolecular interaction, small amounts of 
an ionic salt, i.e. sodium bicarbonate, were used to expand the gelatin network, inhibit 
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mannitol crystallization and generate an amorphous material (Jones et al., 2011). This 
resulted in a fast disintegrating, gelatin-mannitol amorphous complex.  Gelatin may 
also play an important role in the long term stability of amorphous mannitol by 
increasing the glass transition of amorphous mannitol by approximately 13 oC, as 
reported by Kim et al. (Kim et al., 1998) Mannitol in turn acts as a lyoprotectant agent 
for proteins and is thus believed to stabilize the porous structure of gelatin in freeze-
dried formulations (Telang et al., 2003). The stabilizing effect of mannitol in freeze-
drying decreases with an increase in mannitol crystallinity (Izutsu et al., 1994), which is 
avoided in the current product.  Mannitol in freeze-drying feed solutions is known to 
crystallize in temperatures close to -26 oC (Tang and Pikal, 2004). The addition of small 
amounts of salt stabilizes amorphous mannitol in freeze concentrated solutions (Tang 
and Pikal, 2004); hence sodium bicarbonate was included in the tablet matrix of this 
study (Tang and Pikal, 2004). Furthermore, the inclusion of sodium bicarbonate 
enhanced the porosity of freeze-dried material. To further prevent crystallization of 
mannitol, the freeze-drying process was performed, at -40 oC, below the glass 
transition of amorphous freeze-concentrated mannitol, determined by a previous 
study to be ~ -27 
oC (Cavatur and Suryanarayanan, 1998). 
Mannitol polymorphs were clearly detected in the DSC thermograms for tablets 
composed of non-optimal ratios of mannitol and gelatin.  For the crystalline containing 
samples, sodium bicarbonate also plays a significant role in the formation and thermal 
stability of the polymorphs observed. Telang et al. have shown that salts will depress 
the melting points of mannitol polymorphs by up to 15 oC, with additional broadening 
of the associated peaks (Telang et al., 2003). The complex thermal and PXRD results 
show that a mixture of the hemihydrate and β polymorphs are formed during freeze-
drying, and when tablets are heated, de-hydration and conversion results in the 
observation of melting profiles for the δ & α polymorphs as well as the underlying β 
form. These transitions are broadened and depressed by the presence of sodium 
bicarbonate.  
There is no standard method for in vitro disintegration tests for instant disintegrating 
tablets. Many studies use standard USP apparatus 2 disintegration methods with a 
disintegration volume of 900 mL, whereas the total volume of saliva in the mouth does 
not usually exceed 3 mL (Mueller et al., 2010). Other studies have attempted to study 
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disintegration by applying physical force to the tablet using a texture analyser (Fu et 
al., 2005), in which case disintegration profiles are therefore dependent on mechanical 
strength of the tablet rather than its disintegration properties.  We report a novel and 
reproducible digital image disintegration assay to study rapidly disintegrating buccal 
tablets. The assay allows automated data collection to monitor tablet disintegration in 
a volume and temperature controlled environment, using conditions relevant to the 
buccal mucosa.  The disintegration of the tablet as a whole is used as a surrogate for 
drug release, and was rapid, economical, discriminatory and appropriate for the 
product developed.  A factor that may limit the wider application of the assay is its 
reliance on the disappearance of white colour as a measure of tablet disintegration, 
which would exclude its use for evaluating the disintegration of tablets with insoluble 
excipients. Combining image analysis algorithms, common to particle size analysis, 
with our photographic approach to small volume disintegration is likely to remove this 
temporary limitation. 
The novel disintegration assay was optimized for temperature in the range of 33-37 oC, 
corresponding to buccal temperature range (Moore et al., 1999), and for disintegration 
medium with a volume in the range of 0.1-0.7 mL (Figure 4.9)  corresponding to saliva 
volumes range (DiSabato-Mordarski and Kleinberg, 1996). No significant differences 
were observed in the disintegration profile over the buccal temperature range, but 
profiles were significantly different when the test was conducted at 25 oC (Figure 4.9-
A). Directly correlating the disappearance of white colour to the dissolution of the 
matrix may be partially limited, as several white or off-white polymers form 
translucent masses of high viscosity within a larger body of water. These gel-like 
agglomerates cannot be said to be dissolved. However, complementing the novel 
disintegration assay with a drug quantification method, such as HPLC, performed once 
full disintegration is achieved, may give assurance of drug dissolution.  The assay has 
the potential for further development as a quality control test for instant disintegrating 
buccal tablets and, with further exploration of biorelevant test conditions, as an assay 
that is predictive of in vivo performance. 
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4.6. Conclusion 
A novel amorphous instant disintegrating tablet, containing naloxone, was successfully 
produced to good manufacturing practice standards. The composition, based on three 
excipients, mannitol, gelatin and sodium bicarbonate, was essential for fulfilling the 
design aims for a naloxone instant disintegrating buccal tablet. The tablets were both 
chemically and physically stable for 9 months and may be used as a prototype in 
clinical trials for the fast buccal delivery of emergency naloxone.  A novel disintegration 
method for the instant disintegrating buccal tablets was developed and used to 
investigate the disintegration profile of the tablet formulations manufactured in this 
study. Total disintegration of the developed tablet was achieved in less than 10 s which 
is critical for their intended application. 
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Chapter 5. General discussion and future work 
Drug solubility and dissolution rate are critical factors for delivering drugs orally, as the 
drug concentration in the intestinal luminal fluid is one of the main factor that 
determine the rate and extent of oral absorption (Augustijns et al., 2014) as described 
by Fick’s law (Flynn et al., 1974). Poor water solubility is a central problem for the 
pharmaceutical industry, as an estimated 40% of new chemical entities are identified 
as poorly water-soluble (Heimbach et al., 2007, Verma and Rudraraju, 2015). The main 
parts of this thesis look at utilising freeze-drying as a method of manufacturing solid 
dosage platforms to enhance the rate of drug release.    
Freeze-drying is one of many methods used to make solid dispersions; this is a method 
of dispersing a drug, often hydrophobic, in a water soluble excipient, most commonly a 
hydrophilic polymer, to enhance the dissolution rate of the PWSD’s (Van den Mooter, 
2012, Vasconcelos et al., 2007). Although freeze-drying is categorised as a solvent 
evaporation method (Vasconcelos et al., 2007), it removes solvent mainly by 
sublimation (Tang and Pikal, 2004). The use of relatively low temperatures in the 
process of freeze-drying has made it attractive for the manufacture of solid 
formulations with an extended shelf-life (Craig et al., 1999). The absence of high 
temperatures, such as those observed in the HME process (Patil et al., 2015), has also 
made freeze-drying an ideal method of manufacture for the many thermally sensitive 
drugs. However, freeze-drying is a time consuming method, and as a result can be very 
expensive due to its slow production and high demand of power (Fu et al., 2004). 
Nevertheless, optimizations of freeze-drying cycles and the use of industrial freeze-
driers have made it economically efficient for the pharmaceutical industry.  
One of the recently overcome limitations of using freeze-drying to formulate PWSD’s, 
is the use of alternative solvents that can allow the drug and polymer to be dissolved 
while serving to the specific needs of freeze-drying. These include relatively high 
freezing temperature (≥ -20 oC) and vapour pressure (≥ 1 mbar); to resemble those of 
water (Murphy and Koop, 2005). Therefore, allowing a high rate of sublimation to 
maintain freeze-drying economically efficient (Vessot and Andrieu, 2012). Tert-butanol 
(TBA), showed to be a successful organic solvent that may be used instead of or in 
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combination with water as a solvent for freeze-drying feed solutions (Vessot and 
Andrieu, 2012). In this research TBA was found to be a successful substitute to water in 
making freeze-drying feed solutions of, the extremely hydrophobic drug, nifedipine, 
and the water soluble polymer, PVP. Additionally, the relatively high freezing 
temperature and vapour pressure of TBA (24 oC and 35.7 mbar at 20 oC respectively) 
was vital to its success in substituting water in the freeze-drying process (Teagarden 
and Baker, 2002a).   
Despite recent updates in the utilization of freeze-drying as an industrial method of 
manufacturing oral solid dosage formulations (Al-Saadi Kumar, 2015), freeze-drying is 
not fully utilized in manufacturing predominantly amorphous formulations, which is 
known to enhance dissolution rate of PWSD’s (Kaushal et al., 2004). The low physical 
and chemical stability of amorphous materials (Kaushal et al., 2004, Yu, 2001) makes it 
difficult to process predominantly amorphous freeze-dried cakes, into conventional 
solid dosage units such as tablets, without inducing physical or chemical degradation 
(Yu, 2001, Craig et al., 1999, Vasconcelos et al., 2007, Kaushal et al., 2004). This 
research investigated the possibility of overcoming this barrier by eliminating 
intermediate steps, and freeze-drying feed solutions while in a vehicle that would 
allow the developed, predominantly amorphous freeze-dried cake to be packaged and 
dispensed with no additional manufactural process. Therefore, adapting the freeze-
drying process of TBA based feed solutions, of PWSD’s, to manufacture predominantly 
amorphous solid unit dosage forms. Hard gelatin capsules showed to fulfil this need 
elegantly, whereby accurately measured feed solutions, containing 10 mg of 
nifedipine, were added to the inside of capsule bottoms and were in-situ freeze-dried.  
Liquid TBA, and the in-situ freeze-drying process, was found to not affect the, 
international pharmacopeia based, specifications of hard gelatin capsules (WHO, 
2015), therefore giving this system great potential to be used in early clinical studies.  
Nevertheless, simply freeze-drying TBA based solutions of nifedipine did not produce 
amorphous nifedipine. While formulating high ratios of PVP:NIF generated freeze-
dried solid solutions with enhanced dissolution rate. To understand the mechanism 
behind the enhancement of dissolution rate, physicochemical properties of freeze-
dried formulations, containing a range of NIF:PVP ratios, were examined via thermal 
analysis, infrared analysis and polarized microscopy. Results indicated that formulating 
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NIF with PVP (at w/w percentages ≤ 50% NIF in PVP), via freeze-dying, has resulted in a 
miscible binary molecular dispersion, with a single Tg, where by signs of crystalline 
nifedipine were undetectable using thermal and microscopic techniques. The 
miscibility of nifedipine and PVP has also contributed to an increase in the overall Tg, 
upon the addition of PVP, which is critical for the physical stability of amorphous 
nifedipine. This has enhanced the stability of amorphous nifedipine during and after 
manufacture of the solid solution.  
When comparing FT-IR analysis of freeze-dried ≥60% w/w NIF in PVP, produced in this 
study, to equivalent solid dispersions produced by hot-melt extrusion (HME) processes 
in similar studies, performed by Chan and Iqbal, a clear difference is observed in the IR 
crystalline NIF characteristics. Where freeze-dried samples do not show the 
characteristic peaks of crystalline NIF, at 762 cm-1 and 793 cm-1, observed in equivalent 
HME solid dispersions (Iqbal and Chan, 2015, Chan et al., 2004). This may be an 
indication that crystals detected in freeze-dried formulations may consist only of 
fragments, such as nifedipine dimers. The mixing of NIF and PVP in feed solutions may 
have therefore, generated a more dispersed solid solution, leading to a more effective 
inhibition of NIF crystal growth. However, another reported factor that may affect the 
tendency of amorphous materials to crystalize is the thermal history (Bhugra and Pikal, 
2008). Tsukushi et al. (1994) found that amorphous tri-omethyl-b-cyclodextrin 
generated by melt quenching, has much lower enthalpy relaxation than that generated 
by milling, and therefore a lower tendency to crystalize. Although the temperature 
range used in the freeze-drying methods of this project are relatively low, the normal 
temperature range used in secondary drying can vary from 40 oC to 50 oC, therefore 
creating a thermal history that would lead to higher recrystallization tendency (Bhugra 
and Pikal, 2008). Surana et al. (2004) compared the physical stability of amorphous 
trehalose manufactured by freeze-drying, melt quenching, spray drying and 
dehydration. The authors concluded, from crystallisation studies during water 
sorption, that amorphous trehalose prepared by quench melting has the least 
tendency to crystallise, followed by freeze-drying and spray drying, showing equal 
tendencies, and finally amorphous trehalose prepared by dehydration, showing the 
highest tendency to crystallise.  
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In this project, the in-situ capsule formulation of NIF in PVP was only subjected to a 
secondary drying temperature range of (18-25 oC), and was sealed and stored under 
nitrogen gas. Therefore, it is concluded by the author, in light of the above described 
FT-IR analysis, that the developed in-situ freeze-dried formulation shows potential for 
higher physical stability than that produced by HME. Further FT-IR analysis has shown 
strong indications of hydrogen bonding between the nifedipine and PVP (NH and 
carbonyl group respectively). Such drug-polymer interactions are believed to further 
discourage molecular mobility of amorphous nifedipine, and therefore enhance its 
physical stability. Similar observations were published by Aso and Yoshioka (2006) 
using 13C- NMR analysis. The enhancement of physical stability of amorphous 
nifedipine in the novel in-situ freeze-dried platform has led to a significant increase in 
the dissolution rate of nifedipine. However, although no signs of nifedipine crystals 
were detected in the 30% w/w NIF in PVP, a reduction in the % w/w NIF in PVP, 
showed to further enhance the dissolution rate by approximately 1.7 times and the 
kinetic solubility by approximately 1.3 times. This enhancement was observed despite 
that both formulations did not show any detectable nifedipine crystals using thermal, 
spectral and microscopic methods.  
A closer look at the dissolution of freeze-dried formulations, using a novel polarized 
microscopic dissolution test, showed crystallization and precipitation of drug after 
dissolution to be a possibility. Based on the assumption, that observed birefringence is 
directly proportional to the amount of recrystallized and precipitated nifedipine, FD-
10% generated less birefringence, measured in MGV, than FD-50% by almost 20 times 
(taking a dilution factor of 5 times into account). This may indicate that the role of PVP 
to stabilize amorphous nifedipine is not limited to the physical stability of amorphous 
nifedipine during manufacture and shelf life, but also in solution. This may be achieved 
via drug-polymer interactions while in dissolution medium (Broman et al., 2001), thus 
an increase in concentration of PVP in the vicinity of nifedipine in dissolution medium, 
may result in the formation of a highly viscous boundary layer (Kaushal et al., 2004) 
around nifedipine molecules. This can inhibit the recrystallisation and precipitation of 
nifedipine, which as a result increases the kinetic solubility of nifedipine in dissolution 
medium. Additionally, as presented by the Noyes and Whitney equation, enhancement 
in solubility results in dissolution rate enhancement (Noyes and Whitney, 1897).   
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The novel in-situ capsule freeze-dried platform developed as part of this project was 
recently proposed by Crum et al. (2013) before there was an opportunity to publish 
the work presented in this thesis. However, Crum et al. (2013) failed to meet the 
dissolution rate requirements of the BP  (MHRA, 2014b), as all formulations described 
by the authors only showed ≤ 50% dosage released at 20 min, while the minimum BP 
acceptance criteria is ≥ 80% dosage released at 20 min. The FD-10% formulation 
developed in this thesis has shown to supersede the dissolution rate of the 10 mg 
nifedipine marketed fast release soft gel formulations TEVA® by more than 3 times. 
The developed FD-10% formulation has also showed to conform to fast release 
nifedipine capsule specification of the BP (MHRA, 2014b), making it fit for use, as a 
formulation platform, in early stages of a clinical trial.  
The in-situ FD platform described in this project has shown great potential for a much 
needed enhancement in the dissolution and kinetic solubility of PWSD’s (Verma and 
Rudraraju, 2015, Heimbach et al., 2007). This as a result, is expected to improve the 
oral bioavailability of class II drugs of the BCS (Vasconcelos et al., 2007, Leuner and 
Dressman, 2000). However, drug potency may act as a limiting factor, as the amount of 
drug needed must be molecularly dispersed in a high w/w % of polymer. This puts the 
estimated maximum amount of drug to be approximately 15 mg per capsule. 
Therefore drugs with low potency, such as Ibuprofen, my not be suitable candidates 
for this platform. However, relatively higher dose size, such as 30 mg, may still be 
achieved by administering multiple dose units at each time point. The miscibility of 
drug in polymer as well as the solubility of drug and polymer in TBA, or TBA and water 
co-solvent (Vessot and Andrieu, 2012), is another crucial factor for the success of the 
platform design. Table 5.1 below presents a number of drugs which may potentially be 
delivered using the in-situ FD platform for dissolution rate enhancement.  
Freeze-drying was also utilized to develop a predominantly amorphous buccal tablet 
with enhanced release of the antagonist naloxone. This was performed as part of a 
project, aiming to support wider availability of non-injectable emergency naloxone in 
community settings, to overcome fatal outcomes from opioid overdose in the absence 
of medically trained personal (Alqurshi et al., submitted, Strang et al., submitted, 
Degenhardt et al., 2011). The designed buccal platform was optimised to contain a 
predominantly amorphous matrix, for enhanced dissolution rate. This was confirmed 
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by the absence of peaks, indicative of crystalline structure, in powder X-ray diffraction 
and differential scanning calorimetry analysis. The tablet was also made to have an 
oval shape and a large size to allow ease of applying in emergency situations 
(Gugulothu et al., 2015).  
Using principles of molecular and material science (Sun, 2009), the porous freeze-dried 
instant disintegrating tablet was designed by modifying the ratios of mannitol, gelatin 
and sodium bicarbonate to develop a stable predominantly amorphous freeze-dried 
solid dispersion. Varying the ratios of individual excipients relied on understanding the 
role of each excipient and its effect on the physical stability of the amorphous matrix. 
While mannitol was used as a fast disintegrating agent, gelatin, acting as a high Tg 
polymer, was critical to stabilise its amorphous form during and after freeze-drying. 
Nevertheless, gelatin was not sufficient to stabilise amorphous mannitol even at high 
ratios, and therefore the addition of sodium bicarbonate determined to be essential 
for the physical stability of predominantly amorphous matrix. In addition to the 
analytical methods used in development of the NIF-PVP in-situ FD capsule 
formulations, PXRD analysis was also used in the development of the predominantly 
amorphous instant disintegrating tablet. This allowed comparison of analysis between 
DSC and PXRD. 
The rate of disintegration for the instant dissolving tablet is the most critical quality to 
control for the success of fast dissolving buccal tablets. Nevertheless, to the best of my 
knowledge, there was no discriminative disintegration method found in regulatory 
recourses or in the literature. The use of conventional USP apparatus I, with high 
disintegration volumes, such as 900 mL, is a common approach in current published 
studies, investigating fast release buccal formulations (Hirani et al., 2009, Ray et al., 
2011, Malik et al., 2012a, Kraemer et al., 2012). In this thesis, a novel digital image 
disintegration assay was developed, where biologically relevant volumes and 
temperatures are implemented. The novel assay showed great potential of being used 
as a quality control assay for fast disintegrating tablets. In general, the use of sequence 
imaging as a monitoring technique, in this thesis, has shown to be quite useful in both 
monitoring the stability of amorphous nifedipine, in dissolution medium, and the rate 
of disintegration by the naloxone amorphous matrix. Such technique may also be 
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extended to monitor accelerated stability studies of amorphous formulations, where 
samples are stored under high temperatures and humidity levels.  
The buccal platform design developed in this project was intended for a clinical trial in 
humans to determine the pharmacokinetics of naloxone delivered via the buccal route, 
and therefore evaluate the potential of emergency buccal naloxone through rapid 
releasing tablets (See appendix 2-4 for the manufacturing and quality control of 
naloxone buccal IDT, and a copy of the investigational medicinal product dossier 
respectively). Table 5.1 below lists a number of potential candidates for emergency 
rapid delivery, via the fast disintegrating buccal tablets.    
Conclusion 
The aims of the research reported in this thesis were successfully fulfilled, where two 
novel freeze-dried platform designs, for formulations with enhanced drug release, 
were developed. The first platform design, the in-situ freeze-dried capsule formulation, 
showed to significantly enhance the release of, the poorly water-soluble drug, 
nifedipine. The second platform design: instant disintegrating tablet, showed rapid 
matrix disintegration in biorelevant conditions to the buccal cavity, including limited 
disintegration volumes of 0.1mL. Both novel formulations were compared to 
equivalent marketed formulations, and showed a superior enhancement in the rate of 
drug release, for the in-situ freeze-dried platform, and a superior matrix disintegration 
for the IDT platform. The underpinning science behind the success of both 
formulations was investigated using various analytical tools and techniques, including 
characterisation of physical state and intermolecular forces. Additionally, the 
development of novel techniques, described in this thesis, such as polarized 
microscopy dissolution and the digital image disintegration assay (DIDA), allowed 
better understanding of the mechanism behind the enhancement in formulation 
performance. Additionally, the novel DIDA test successfully demonstrated great 
potential in the quality control of rapid disintegration by FDT’s.         
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Table ‎5.1 A list of potential drugs for both or either of the developed platforms designed in this thesis.  
Drug Indication Molecular 
weight 
BCS class Solubility Permeability Recommended 
















494 II Low High 1.25, 2.5 & 5.0 







 Phenytoin Antiepileptic 252.3 II Low High 25.0 
In-situ freeze-
dried capsules 
(Lindenberg et al., 
2004) 




284.7 I High High 5.0 FDT 
(Lindenberg et al., 









347.92 III High Low 2.0 FDT 
Chlorpheniramine 
hydrogen maleate 
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